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Alternative splicing occurs in more than 90% of human genes and is particularly 
abundant in the nervous system. It has been recognized that toxicity can be caused at 
the level of pre-mRNA processing and potentially lead to age-dependent 
neurodegeneration upon low-dose chronic exposure.  
ELAV (Embryonic Lethal Abnormal Visual system)/Hu family proteins are prototype 
RNA binding protein and gene specific regulators of alternative mRNA splicing in 
the nervous system. Analysis of mutants in ELAV family proteins shows overlapping 
and distinct functions during development and age-dependent neurodegeneration. 
Overexpression of ELAV family proteins further revealed that cytoplasmic 
localization of ELAV family proteins in associated with enhanced neurotoxicity. 
Intriguingly all Drosophila ELAV family proteins and mammalian Hu proteins can 
regulate neuron-specific alternative splicing of Drosophila neuroglian gene- a known 
ELAV target.      
The blood brain barrier (BBB) and efficient excretion are protective mechanisms 
making delivery of many drugs to the brain difficult in vivo. Therefore, I analyzed 
the roles of a number of key Organic Anion Transporter Protein (OATP) and Multi-
Drug Resistance (MDR) proteins and established a sensitized genetic background for 
CNS drug delivery. 
To assess if xenobiotics can interfere with ELAV function leading to 
neurodevelopmental/neurodegenerative defects, I assessed ELAV regulation of its 
major target erect wing (ewg) using an ewg fluorescent reporter, which recapitulates 
endogenous ELAV-mediated splicing and allows rapid visualization of potential 
modulators. From a compound screen in a sensitized genetic background, I identified 
a number of xenobiotics that cause changes in ewg splicing, indicating interference 
with ELAV function. Importantly, these compounds also phenocopy specific 
characteristics of ELAV mutants. My approach demonstrates the potential for using 
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Chapter 1: Introduction 
 
Exposure to substances has been linked to the development of cancer and neurodegeneration. 
In many instances the mechanisms of action of such carcinogens and neurotoxins, however, 
is poorly understood.  
Despite pre-mRNA splicing being described more than 30 years ago, it is only recently that 
its misregulation has been linked to the occurrence of cancer and neurodegeneration 
(Darnell, 2011). Splicing has been shown to be susceptible to modulation by many 
substances such as antineoplastic drugs, commonly used pharmaceuticals and food additives 
which lead to a variety of effects ranging from inhibition of general splicing to specific 
modifications in alternative splicing regulation causing misexpression of disease-related 
genes (Zaharieva et al., 2012). Since the splicing process can be targeted by xenobiotics, 
chemical compounds foreign to living organisms, the development of novel compound 
screening approaches that can assess splicing-mediated toxicity is imperative. 
With the advancement of toxicology, a tendency for replacing in vivo mammalian testing 
with alternative models was acquired.  Drosophila melanogaster is a well-established animal 
model for neurodegeneration studies and holds a potential of becoming a valuable system to 
study neurotoxicity. However, implementing the fly as a successful toxicology model 
requires profound understanding of a drug’s absorption, distribution, metabolism and 
excretion (ADME) in this animal. The possibility of combining the power of Drosophila 
genetics and established neurological fly models with toxicity testing opens exciting 
opportunities for discovery of novel toxicological mechanisms. As the splicing machinery is 
highly conserved between flies and man, studying neurotoxic events derived from 
misregulation of splicing in Drosophila could have direct implications to humans. 
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A highly conserved family of RNA binding proteins between Drosophila and mammals is 
the ELAV/Hu family. Hu proteins have been implicated in various functions along the RNA 
processing pipeline. Furthermore, Hu proteins have been shown to be involved in the 
progression and metastasis of a number of cancers and their misexpression has been linked to 
the development of Alzheimer’s disease (Pascale et al., 2008). The founding member of this 
family is Drosophila ELAV, which has been shown to promote neuron-specific splicing 
(Soller and White, 2004). Studying ELAV’s roles in nervous system development and 
maintenance in flies would help better understand human Hu proteins. Identifying 
xenobiotics that interfere with ELAV-mediated splicing would potentially reveal substances 
that could also act on mammalian Hu proteins and therefore be associated with their 
misregulation in cancer and neurodegeneration. 
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1.1. Mechanisms of general and alternative splicing  
The majority of the content of pages 3-21 has been published as ‘Interference of 
xenobiotics with alternative splicing’ in the Journal of Toxicology with myself as first 
author, Prof. Kevin Chipman as second author and Dr. Matthias Soller as 
corresponding author. All three authors planned the topics and layout of the 
manuscript. I researched the literature, wrote the manuscript text and drew the figures. 
Prof. Chipman and Dr. Soller proofread and made minor changes to the manuscript 
prior to submission. For the full article please see (Zaharieva et al., 2012)  
 
Sequencing of a number of genomes from higher eukaryotes revealed approximately 20,000 
protein-coding genes per genome. Some species such as chicken (Gallus gallus) have less 
(~17,000) and some, such as grapevine (Vitis vinifera) have more (~30,000) (Pertea and 
Salzberg, 2010). Humans have about 22,000 genes illustrating that it is not gene number, but 
the complex mode of gene regulation (post-transcriptional and post-translational), which 
determines organismal complexity.  
A unique feature of eukaryotic genes is the interruption of protein-coding sequences (exons) 
with non-coding regions (introns).  On average, a human gene extends over about 30 kb of 
chromosomal DNA which is transcribed into a pre-messenger RNA (pre-mRNA). After 
excision of introns by the spliceosome, mature mRNA of approximately 3 kb is generated, 
which is then exported to the cytoplasm and serves as a template for protein synthesis 
(Orphanides and Reinberg, 2002, Soller, 2006). 
Often, several mRNAs can be generated from a single gene by varying inclusion of certain 
parts of the coding sequence (alternative splicing, Figure 1.1) giving rise to functionally 
diverse proteins. In humans, as much as, 94% of genes are alternatively spliced (Wang et al., 










Figure 1.1. Types of alternative splicing illustrated by an artificial gene model  
Constitutive exons present in all mRNAs are shown as dark grey boxes and alternative mRNA 
sequences that may or may not be included are shown as light grey boxes. Mutually exclusive exons 
are indicated in black and white boxes. From the model gene shown a total of 32 different isoforms 
can be generated. This figure and it legend is incorporated from Zaharieva et al, 2012. 
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Caenorhabditis elegans, around 60% and 10% of genes are alternatively spliced, respectively 
(Kim et al., 2007, Graveley et al., 2011). Hence, alternative splicing is a major mechanism to 
generate molecular variability from a limited number of genes. A relevant example to 
toxicology is the functionally diverse repertoire of human constitutive androstane receptor 
(CAR) isoforms, generated by alternative splicing, which together with the pregnane X 
receptor provide a pathway for innate defense against widely found environmental 
xenobiotics, such as phthalates (DeKeyser et al., 2011). 
 
1.1.1. General splicing and its regulation 
Splicing is accomplished by the spliceosome, a mega-Dalton structure formed of small 
nuclear ribonucleoprotein (snRNP) particles, which consist of five core structural RNAs 
(designated as U1, U2, U4, U5 and U6, because of their high content of uridylic acid (Busch 
et al., 1982) and over 150 auxiliary proteins (Jurica and Moore, 2003, Luhrmann and Stark, 
2009). The spliceosome is formed through sequential assembly of U snRNPs together with 
auxiliary proteins on the nascent pre-mRNA and introns are excised by joining of the exons 
in two transesterification steps (Staley and Guthrie, 1998) (Figure 1.2). Spliceosome 
assembly is mediated by specific sequences at the exon/intron junctions called splice sites 
(ss). Both the 5! ss consensus (AG/GURAGU) and the 3! ss consensus (YAG/N) are loosely 
defined, whereby, only the first G of the 5! ss and the AG of the 3! ss are strictly conserved 
(Smith et al., 1989, Hertel, 2008). Additional elements required for splicing are the branch 
point (BP) sequence (YNYURAC) close to the 3! ss that forms a lariat with the conserved A 
and the G of the 5! ss during splicing, and a polypyrimidine tract (Py(n))  present in most 
genes before the 3! ss. The splicing reaction is initiated upon recruitment of U1 snRNP to the 
5! ss after which the mammalian branch point binding protein (mBBP/SF1) binds to the 







Figure 1.2. Stepwise assembly of the spliceosome and intron excision 
Schematic representation of step-wise assembly of U1 and U2 snRNP’s, auxiliary factors mBBP/SF1 
and U2AF, and U4/U6.U5 tri-snRNP into a functional spliceosome resulting in intron excision. 
Biochemically distinguishable complexes and point of interference of general splicing inhibitors are 
indicated. This figure and its legend are adapted from Zaharieva et al, 2012. 
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binds both the polypyrimidine tract ((Py)n) via its larger subunit and the 3! ss via its smaller 
subunit which facilitates U2 snRNP recruitment to the BP and formation of the A complex. 
The U4/U6.U5 tri-snRNP is then recruited to yield complex B. Upon release of U4 and U1 
snRNPs, catalytic activation occurs followed by a conformational change to form the C 
complex, which facilitates intron excision and joining of the two exons.  Complex C 
disassembles and the free components are used for the de novo formation of other 
spliceosomes. Although splice sites are generally highly degenerate, pre-mRNA processing 
occurs with high fidelity and accuracy, which is assured by the combinatorial interaction of 
splicing factors that bind additional sequence elements in the exon or nearby intron parts 
(Smith and Valcarcel, 2000, Soller, 2006).  
The splicing machinery and many regulatory proteins are highly conserved across eukaryotes 
(Kaufer and Potashkin, 2000, Venables et al., 2012). Interestingly, evolutionary conservation 
is particularly high in protein-protein and protein-RNA interfaces (Qian et al., 2011), 
indicating great potential for the use of model organisms to test for modulation of splicing in 
humans. Although termed general or constitutive splicing, there is evidence for tissue-
specific regulation of the process. Several copies of U2 snRNA are present in the mouse 
genome and their brain-enriched expression is required to prevent neurodegeneration (Jia et 
al., 2012) Susceptibility of general splicing to small molecules has been demonstrated in 
budding yeast. Alternative splicing is not present in yeast, however, regulation of general 
splicing is used to adapt gene expression programs to environmental stresses, e.g. amino acid 
depravation and alcohol tolerance (Pleiss et al., 2007, Bergkessel et al., 2011). Small 
molecule screens identified a number of compounds, such as, kinase inhibitors and oxaspiro 
derivatives as novel inhibitors of spliceosome assembly in S. cerevisiae (Aukema et al., 
2009). To study alternative splicing, other genetic model organisms like C. elegans and 
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Drosophila hold great potential in deciphering splicing interference on a multicellular level 
where tissue-dependent, age-dependent and even behavior changes can be assessed.  
 
1.1.2. Alternative splicing regulation  
The major mechanisms of alternative splicing regulation include: (1) definition of a stronger 
ss over a weaker one; (2) positive and/or negative regulation of splicing factors, e.g. by 
alterations of their concentration or of their activity through cellular signaling; (3) regulation 
by tissue-specific factors and (4) regulation mediated by mRNA secondary structure (for 
general reviews see (Soller, 2006, Chen and Manley, 2009, Black, 2003, Smith and 
Valcarcel, 2000, Stamm et al., 2005). 
The sequence complementarity of 5! and 3! ss to their respective consensus sequences 
determines the strength of the ss. Accordingly, introns with stronger ss are spliced more 
frequently than introns with weaker ss resulting e.g. in increased inclusion of an alternative 
cassette exon with flanking strong ss (Hertel, 2008). This phenomenon has been termed as 
the proximity rule (Reed, 1989).  
Binding of splicing factors can either promote or inhibit inclusion of an alternative exon. 
Sequences termed exonic splicing enhancers (ESE) positively regulate exon recognition and 
are preferentially bound by serine/arginine-rich splicing factors (SRSFs) (Shepard and 
Hertel, 2009, Manley and Tacke, 1996, Nilsen and Graveley, 2010, Manley and Krainer, 
2010). Sequences that negatively regulate exon recognition are termed exonic splicing 
silencers (ESS) and are bound by splicing inhibitors such as heterogeneous nuclear 
ribonucleoproteins (hnRNP) (Martinez-Contreras et al., 2007, Konig et al.). Often 
antagonistic splicing factors are in balance and alteration of the intracellular concentration 
and/or the activity of one factor will affect the outcome of the splicing process (Caceres et 
al., 1994, Long and Caceres, 2009).  
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Splicing regulation is also affected by cellular signaling triggered by external stimuli. A 
prominent example of splicing regulation by reversible phosphorylation is the shut down of 
splicing during mitosis or upon heat-shock. Here, dephosphorylation of SRSF10 (also 
known as SRp38, SRrp40, TASR) results in potent splicing repression by binding U1 snRNP 
and prevention of 5! ss recognition and subsequent spliceosome assembly (Shin et al., 2004, 
Shin and Manley, 2002).  
Tissue specific regulatory proteins bring further complexity to the regulation of alternative 
splicing. Alternative splicing is particularly abundant in the brain where it promotes 
molecular variability to establish connectivity and to diversify cellular functions (Yeo et al., 
2004, Nilsen and Graveley, 2010, Grabowski and Black, 2001). Examples of neuronal 
splicing factors are members of the ELAV (Embryonic lethal abnormal visual system)/Hu, 
Fox (Feminizing gene on X) and PTB (polypyrimidine tract binding protein) families of RNA 
binding proteins. A prominent feature of ELAV/Hu family proteins is their ability to 
multimerize to bind target pre-mRNA (Toba and White, 2008, Soller et al., 2010, Soller and 
White, 2005, Kasashima et al., 2002). Detailed explanation of ELAV-mediated alternative 
splicing is in section 1.5.1. Fox proteins have been shown to promote neuronal homeostasis. 
Upon increased membrane depolarization, Fox-1 autoregulates inclusion of an alternatively 
spliced cassette exon to produce a nuclear isoform that confines neuronal alternative splicing, 
in particular that of ion channels, to adapt the cell’s physiology and metabolism and prevent 
hyperexcitation (Damianov and Black, 2010, Lee et al., 2009, Kuroyanagi, 2009) 
Further complexity to alternative splicing is brought about by cross-talk among splicing 
factors and also their regulation by miRNAs. Neuronal differentiation involves a switch from 
the widely expressed PTB to its paralog neural PTB (nPTB) protein from broadly expressed 
transcripts. In non-neuronal cells PTB acts as a splicing repressor on nPTB, resulting in exon 
skipping and introduction of a pre-mature stop codon in the mRNA, which is then targeted 
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for Nonsense-Mediated Decay (NMD) (Shultz et al., 2010, Boutz et al., 2007). Similarly, 
PTB also autoregulates its own expression levels in non-neuronal cells. In neurons, however, 
PTB is down-regulated by miR-124 to permit execution of a neuron-specific splicing 
program mediated by nPTB (Makeyev et al., 2007).   
Nova (Neuro-oncological ventral antigen) proteins have pivotal roles in the establishment of 
the neuron-specific splicing patterns involved in synaptic plasticity (Ule et al., 2003, Ule et 
al., 2005). Genome-wide analysis of Nova binding sites revealed that the outcome of 
alternative splicing of cassette exons is dependent on where Nova binds relative to splice 
sites and the alternative exon. Exon inclusion is associated with preferential binding to the 
vicinity of the ss of the alternative exon and U1 snRNP recruitment to the 5! ss, while exon 
exclusion is associated with preferential binding to the 5! end of the regulated intron and the 
alternative exon likely blocking recognition of the 5! ss (Ule et al., 2006).  
In conclusion, the high complexity of the splicing process suggests susceptibility to various 
modifiers spanning from endogenous regulation of gene expression to exogenous impact by 
environmental factors. So far, development of novel compounds only marginally considered 
splicing to be affected either for therapeutical potential or as a source of toxicity.  
 
1.2. Alternative splicing regulation in human disease 
Disruption of alternative splicing has been associated with numerous disease conditions. 
Many cases of cancer and neurodegeneration are a result of either inhibited or excessive cell 
death due to altered gene expression programs for programmed cell death (apoptosis) 
(Garcia-Blanco et al., 2004, Darnell, 2010, Tazi et al., 2009, Cooper et al., 2009). A large 
number of apoptotic genes are alternatively spliced to produce transcripts with opposing 
functions which if misregulated could result in switching the expression of a pro-apoptotic 
isoform to that of an anti-apoptotic one, and vice versa (Schwerk and Schulze-Osthoff, 2005, 
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Jiang and Wu, 1999, Pajares et al., 2007).  Furthermore, with the advancements in high-
throughput sequencing technologies, it is increasingly evident that alterations of alternative 
splicing patterns exceeds apoptosis-only-related genes and could account for as much as 
50% of all active alternative splicing events as seen in ovarian and breast cancer tissues 
(Venables et al., 2009). 
Apoptosis can be triggered by two pathways: extrinsic and intrinsic (Adams, 2003) (Figure 
1.3). The extrinsic pathway is initiated upon extracellular binding of members of the tumor 
necrosis factor family (e.g. FasL) to their death-domain (DD) receptors (e.g. FasR). Via 
alternative splicing, soluble forms of the death receptors are also produced and their binding 
inhibits apoptosis possibly as a deliberate mechanism for receptor engagement to prevent 
further ligand binding. This regulatory mechanism has been implicated in the development of 
resistance to apoptosis in a number of cancers. In Hela cells, RNA-binding protein HuR acts 
as an anti-apoptotic regulator in promoting skipping of the trasmembrane domain (encoded 
by exon 6) of the Fas receptor gene. HuR binds to an exonic splicing silencer and inhibits U2 
snRNP binding and subsequent complex formation on the 3! ss. This leads to the production 
of a soluble isoform that prevents cell death (Izquierdo, 2008). In the cases of lymphoma and 
large granular lymphocyte leukemia, resistance to Fas-mediated apoptosis has been attributed 
to expression of soluble isoforms, where either the transmembrane (FasExo6Del) or the DD 
(FasEx8Del) are spliced out by exon skipping (Papoff et al., 1996, Liu et al., 2002).  
Adaptor proteins, which link the extracellular to the intracellular death machinery, also 
undergo alternative splicing. In the LNCaP human prostate cancer cell line an isoform of the 
apoptotic protease activation factor 1 (APAF-1, termed APAF-1-ALT) inhibits apoptosis via 
a yet unidentified mechanism (Ogawa et al., 2003). Apaf-1 is evolutionary conserved and is 
the human homologue of the C. elegans CED-4, which is expressed as two isoforms 





Figure 1.3. Schematics of the apoptotic pathways and factors regulated by alternative splicing 
Through alternative splicing cell death proteins are regulated to produce dominant negative and 
functionally antagonistic isoforms that inhibit the extrinsic (death receptor) or intrinsic 
(mitochondrial) apoptotic pathway. The two pathways are linked through the Bcl-2 family member 
Bid. Detailed overview of the mechanism of splicing is available in the text. 
 10 
long, CED-4L, isoform inhibits apoptosis and the short, CED-4S, isoform is proapoptotic in 
worms C.elegans (Shaham and Horvitz, 1996). Recently, in a screen for genes that prevented 
programmed cell death, SPK-1 was identified as the SR protein kinase responsible for the 
switch between CED-4S and CED-4L. Here, a loss of function allele of SPK-1 was linked to 
a decrease in CED-4L expression and subsequent increase in apoptotic cells (Galvin et al., 
2011).  
The intrinsic apoptotic pathway involves permeabilization of the outer mitochondrial 
membrane and release of cytochrome c into the cytoplasm, which in turn induces a series of 
biochemical reactions that result in caspase activation and subsequent cell death (Jiang and 
Wang, 2004). Several members of the Bcl-2 family (Bcl-x, Bim, Bak and Bid) are 
alternatively spliced with isoforms having opposing roles during apoptosis. In the bcl-x gene, 
alternative splice site selection at the downstream 5! splice site of exon 2 produces a long 
isoform Bcl-xL, which inhibits cell death, whereas splicing at the upstream 5! splice site 
results in a shorter, apoptosis promoting Bcl-xS isoform (Boise et al., 1993, Akgul et al., 
2004). The RNA binding proteins Sam68 and hnRNP A1 promote splicing of the shorter 
isoform by activating a proximal 5! ss. Upon phosphorylation of Sam68 by Src-like kinases, 
which are up-regulated in a number of cancers, Sam68 and hnRNP A1 no longer bind the 
proximal splice site and the long anti-apoptotic isoform of Bcl-xL is made (Paronetto et al., 
2004, Lukong et al., 2005, Paronetto et al., 2007). In addition, RBM11 binding switches 
splicing to the short Bcl-xS isoform by antagonizing SRSF1-mediated exon definition 
(Pedrotti et al., 2012).  
Several members of the caspase family (Caspase 2, 9 and 10, and FLIP) are alternatively 
spliced and produce isoforms, which display antagonistic function during cell death. The 
short isoform of caspase-9 and the long isoform of caspase-2 can inhibit apoptosis, whereas, 
their reciprocal isoforms have been implicated in promoting cell death (Kitevska et al., 2009, 
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Johnson and Jarvis, 2004). In the case of Caspase 9, the inclusion of exon 3,4,5,6 cassette 
results in a long pro-apoptotic isoform, whereas the exclusion of the same cassette results in 
a short anti-apoptotic isoform (Johnson and Jarvis, 2004). Phosphorylation of splicing 
enhancer SRSF1 mediates cassette exclusion of Casp9 and skipping of these exons has been 
implicated in the resistance of non-small cell lung cancer to chemotherapeutics (Shultz et al., 
2010, Shultz et al., 2011).  
The p53 family of transcriptional regulators consists of three highly related genes (p53, p63 
and p73), which generate 44 isoforms in total by usage of alternative promoters and ss 
selection (Khoury and Bourdon, 2010, Murray-Zmijewski et al., 2006). Knockout mice for 
each individual gene are viable, but null mutants for p63 and p73 die of developmental 
defects (Mills et al., 1999, Yang et al., 2000), whereas null mutants for p53 die of cancer 
(Donehower et al., 1992). Despite their seemingly independent roles based on the phenotypes 
of knockout mice, p53-family isoforms form an interconnected pathway involved in the 
response to oncogenic stress mediated by overlapping sets of target genes and dimerization 
of isoforms from the three genes (Collavin et al., 2010).The usage of alternative promoters 
among p53 family members generates amino terminally truncated isoforms, which lack the 
transactivation domain and can act as dominant negative inhibitors of p53 and other 
proapoptotic isoforms of the family (DeYoung and Ellisen, 2007). Alternative splicing, 
however, brings further molecular diversity and can generate additional isoforms that fail to 
induce cell cycle arrest and apoptosis, e.g. N-terminally truncated splice variants of p53 
(p47), p63 (ΔNp63α) and p73 (ΔN'p73, Ex2Delp73 and Ex2/3Delp73) (Ghosh et al., 2004, 
Rocco et al., 2006, Concin et al., 2004, Tuve et al., 2004, Courtois et al., 2002). Furthermore, 
ΔNp63α, ΔN'p73 and Ex2Delp73 were shown to promote resistance of certain cancers to 
conventional chemotherapy (Meier et al., 2006, Leong et al., 2007, Concin et al., 2005)  
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A common feature of cancer cells is the switch from aerobic to anaerobic glycolysis resulting 
in the production of lactate. This switch is achieved through mutually exclusive splicing of 
pyruvate kinase pre-mRNA from the exon 9-containing isoform (M1 isozyme) to the exon 
10-containing isoform (M2 isozyme). In human gliomas, the oncogenic transcription factor 
c-Myc is upregulated resulting in increased expression of PTB, hnRNP A1 and A2 and 
preferential inclusion of the exon 10-containing isoform and anaerobic glycolysis (David et 
al., 2010). Accordingly, knockdown of splicing repressors PTB, hnRNP A1 and A2 in 
glioblastoma cell lines results in preferential expression of the exon 9-containing isoform and 
aerobic glycolysis (Clower et al., 2010). 
In a number of neurodegenerative diseases accumulation of cytoplasmic protein aggregates 
promotes neurotoxicity. In frontotemporal dementia with parkinsonism on chromosome 17 
(FTDP-17) excessive inclusion of exon 10 of the microtubule-associated protein tau (MAPT) 
gene is associated with the development of Alzheimer’s disease (Kar et al., 2005). Exon 10 
encodes the fourth microtubule-binding domain of tau, resulting in a protein with higher 
affinity to bind microtubules leading to the formation of neurofibrilary tangles and further 
cytotoxicity.  
Recently, genome wide association studies comparing healthy individuals with 
frontotemporal lobar degeneration (FTLD) and Alzheimer's disease (AD) patients revealed 
age and disease-dependent changes in neuron-specific alternative splicing programs that can 
be affected during aging and disease of the CNS. In particular age-related changes correlate 
with increased PTB activity and disease-specific effects reflect decreased Nova activity in 
alternative splicing regulation (Tollervey et al., 2011b). Furthermore, in most cases of FTLD 
and amylotrophic lateral sclerosis (ALS), ubiquitinated and hyperphosphorylated C-terminal 
fragments of the nucleic acid binding protein TDP-43 are deposited in cytoplasmic inclusion 
bodies. A genome wide analysis of TDP-43 mRNA targets revealed differential splicing 
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patterns between healthy and FTLD cortical postmortem human samples (Tollervey et al., 
2011a, Polymenidou et al., 2011). In the mouse brain, TDP-43 binds to more than a 1000 
genes including a number of neurodegeneration-related genes such as fus/tls and progranulin 
which are implicated in the development of ALS and FTLD, respectively (Polymenidou et 
al., 2011).  
Cytotoxicity derived from protein aggregation is a major aspect of Alzheimer’s, Parkinson’s 
and Huntington’s disease pathology (Wilhelmus et al., 2008). Tau, Amyloid-beta, Alpha-
synuclein and Huntingtin are substrates of tissue transglutaminase (tTG), which catalyses the 
formation of isopeptide bonds (cross-links). Elevated mRNA levels of tTG have been 
reported in AD and PD brain samples (Citron et al., 2001, Citron et al., 2002). Furthermore, 
in AD samples, alternative splicing of tTG results in a short truncated isoform lacking a 
domain necessary for cross-linking inhibition, therefore resulting in an enzyme with higher 
cross-linking activity in neurons containing neurofibrilary tangles (Citron et al., 2002).  
Spinal muscular atrophy (SMA) is characterized by degeneration of motor neurons due to the 
absence of, or mutations in, the Survival Motor Neuron 1 (SMN1) gene, which encodes an 
essential protein involved in RNA metabolism (Kolb et al., 2007). SMN2 is a second, almost 
exact copy of the gene and differs only by a few bases. However, this difference results in 
skipping of exon 7 in the SMN2 pre-mRNA resulting in the production of a truncated protein 
that cannot substitute for the function of SMN1. Identification of substances that inhibit 
skipping of exon 7 is a key therapeutic strategy to substitute for the lack of SMN1 (reviewed 
in (Nlend Nlend et al., Sumner, 2007, Lorson et al., 2010, Bebee et al., 2010).  
Further to neurodegeneration, alternative splicing also plays a role in maintaining neuronal 
homeostasis illustrated by the Fox-1-mediated alternative splicing program for the prevention 
of hyperexcitability and subsequent seizures (Gehman et al., 2011). Fox-1 knockout mice 
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show increased neuronal excitability as a result of splicing changes in proteins implicated in 
synaptic transmission and membrane excitation (Gehman et al., 2011).  
 
1.3. Experimental approaches to reveal interference of xenobiotics with splicing 
regulation 
Given the delicate balance of positive and negative signals that confine tissue specific pre-
mRNA splicing, xenobiotics are likely to interfere with various aspects of the process. 
Cancerous and neuronal cells have been shown to have elevated levels of certain components 
of the splicing machinery (like splicing factors SRSF1 in tumors and PRPF3 in 
photoreceptors) in order to comply with their higher metabolic needs (Karni et al., 2007, Cao 
et al., 2011), therefore, these cell types are likely to be susceptible to interference by various 
compounds. In the brain, such interference could include neurological side effects and/or 
neurodegeneration. An understanding of how xenobiotics can affect neuronal alternative 
splicing is particularly important in cases of unexplained acute neurotoxicity and of low dose 
chronic exposure resulting in accelerated age-dependent neurodegeneration. Following, we 
describe current approaches used to test for xenobiotic interference with splicing regulation.  
Human intron size ranges between 100 and 100,000 bp. Due to their large size, incorporating 
full length intron-containing genes into reporter constructs is not feasible. Instead, mini-
genes (a minimal genomic sequence that recapitulates endogenous alternative splicing 
regulation) fused to Green or Red Fluorescent Proteins (GFP or RFP), are widely used 
reporters in the study of splicing. Using such a reporter, Stoilov et al (2008) assessed the 
inclusion of cassette exon 10 of the MAPT gene in response to a library of FDA approved 
drugs. Whenever the exon is included, GFP is produced, and when the exon is excluded RFP 
is produced (Figure 1.4) and the ratio between the two determines the rate of exon inclusion 






Figure 1.4. A representation of GFP and RFP reporter constructs for assessing exon exclusion 
 (A) Reporter gene developed by Stoilov et al (2008), which assesses rate of inclusion of human 
MAPT exon 10. Exclusion of exon 10 results in GFP expression by incorporation of a split ATG start 
codon, which is reconstituted after splicing. Inclusion of exon 10 results in RFP expression from an 
ATG further distal in the transcript. (B) Gene model of the C. elegance Let-2 gene illustrating 
mutually exclusive splicing of exons 9 and 10 between embryonic (top) and adult (bottom) splicing 
patterns. (C) Analysis of mutually exclusive splicing regulation in the Let-2 gene by two reporter 
constructs: one for exon 9 inclusion resulting in GFP expression (top); and a second for exon 10 
inclusion resulting in RFP expression (bottom) (Ohno, Hagiwara et al. 2008).  Constitutive sequences 
present in mature RNAs are indicated in dark grey boxes. Alternative exons and are indicated in light 
grey, and mutually exclusive exons and proteins made are either shown in black or white. Stop 








elements in flanking exonic sequences and generation of an unusually long 5! UTR when 
exon 10 is included. 
In another example of a cell-based reporter system an increase of luciferase or GFP readings 
from SMN2 reporter mini gene constructs was used to identify chemical enhancers of exon 7 
inclusion (Zhang et al., 2001).  
 To validate the specificity of compounds for interference with a test exon, ideally, additional 
reporter systems with other test exons from different genes should be available. A caveat of 
mini-gene reporters can be the lack of additional control elements relevant in the endogenous 
context, and therefore, further validation needs to include analysis of the endogenous gene 
by quantitative RT-PCR. Changes in expression of reporter proteins can also result from 
altered splicing of constitutive exons or interference with translation. RT-PCR and intronless 
reporters can be used to assess splicing of constitutive exons and changes in translation, 
respectively. Follow up studies using chromatin immunoprecipitation (ChIP) experiments 
are then required to distinguish changes in alternative splicing resulting either from altered 
mRNA stability or transcription elongation (Kornblihtt et al., 2004).  
Reporter constructs for alternative splicing have also been used to study splicing regulation 
in a whole organism to identify regulatory factors in forward genetic screens (Ohno et al., 
2008). A further exploitation of such reporter systems is to use compound libraries to 
interrogate splicing regulation with small molecules in forward chemical genetic approaches. 
With regards to splicing, protein-protein and RNA-protein interfaces are of particular 
interest as they are highly conserved throughout evolution (Qian et al., 2011). Since 
alternative splicing is particularly abundant in the brain, invertebrate animal models have 
shown to overcome limitations derived from cell culture systems. Firstly, drug effects can be 
tested in an intact nervous system; secondly, toxicity can be identified on a multi-
organ/system level; lastly, the effect of a compound can be directed towards a transgenic 
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disease animal model. However, such in vivo approaches are limited to the simultaneous use 
of only a few reporter constructs, due to the number of fluorescent proteins available. 
Alternative to the use of reporter constructs, changes in gene expression from exposure to 
single compounds have been extensively analyzed on microarrays (Afshari et al., 2011, 
Lettieri, 2006, Gant, 2007). Ecotoxicologists have utilized this approach in understanding 
how environmental pollutants can change gene expression in aquatic organisms (Williams et 
al., 2008). 
A limitation of microarrays, however, is that they are not suited for high throughput studies 
and often lack the sequences to probe for differential regulation of alternative splicing. 
Future applications for gene expression analysis will likely replace microarrays with high 
throughput sequencing techniques addressing the effect of one or a few compounds on the 
entire transcriptome. Since high throughput sequencing of cDNA libraries is not compatible 
with screening changes to genome-wide expression from large chemical libraries, selecting 
for a few key alternatively spliced genes, e.g. apoptosis-related and other oncogenes, might 
provide signatures for toxic insults that result in cell death or tumor development. In this 
case, gene-specific primers incorporating compound-specific bar-coding can be used for RT-
PCR amplification, followed by massive parallel amplicon sequencing (Wiseman et al., 
2009). More recently, techniques to directly sequence single RNA molecules have been 
developed and potentially could provide a high throughput platform for assessing effects 
from compound libraries on the entire transcriptome, including alternative splicing 
misregulation (Ozsolak and Milos, 2011). Certainly, these approaches have the potential for 
automation and future integration into standardized protocols for risk assessment. 
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1.4. Xenobiotics interfering with splicing regulation 
There are several modes of action described for xenobiotics to interfere with the splicing 
reaction (Sumanasekera et al., 2008). In principle, they can be subdivided into 
inhibitors/modulators of either general or alternative splicing. General inhibitors interfere 
with spliceosome assembly but can also modulate the kinetics of the splicing reaction. In 
contrast, alternative splicing modulators interfere with recognition of alternative exons 
and/or alter the binding of gene specific splicing factors. Anticancer drugs, heart 
medications, naturally occurring compounds and food supplements, as well as synthetic 
substances that can interfere with general or alternative splicing. A comprehensive list of 
compounds and information on their mode of action is shown in Table 1.1. Remarkably, 
these compounds belong to structurally very different classes implying multiple mechanisms 
of interference, which to date are mostly elusive. 
 
1.4.1 General splicing inhibitors 
Spliceostatin A and pladienolide, commonly used anticancer drugs were the first compounds 
identified among microbial natural products to inhibit general splicing (Figure 1.2). Both 
bind to the SF3b subcomplex of the U2 snRNP and prevent spliceosome assembly by 
inhibiting recognition of the branchpoint by U2 snRNP and transition from the A to B 
spliceosomal complex (Kaida et al., 2007, Kotake et al., 2007, Roybal and Jurica, 2010). 
Isoginkgetin, a naturally occurring component of the Ginko biloba tree, was identified as the 
third general splicing inhibitor and was shown to prevent the stable recruitment of the 




Table 1.1 Compounds modulating constitutive and alternative splicing categorized according to genes tested in various assays (I- in vitro splicing assay 
from nuclear extracts, II- reporter gene assay in cell culture, III- analysis of endogenous genes in cell culture). Note that there are several compounds 
affecting the splicing patterns of single genes.n.d.: not defined 
 
 Compound Characteristics Assay Mode of action Citation 
General splicing inhibitors 
 Isoginkgetin Anticancer drug II Prevents U4/U6.U5 recruitment (O'Brien et al. 2008) 
 Pladienolide derivatives Anticancer drug II Inhibits SF3b complex formation (Kotake et al. 2007) 
 
Spliceostatin A Anticancer drug I 
Inhibits U2 snRNP binding and 
blocks A to B spliceosome complex transition 
(Kaida et al. 2007) 
(Roybal and Jurica 2010) 
 Dihydrocoumarin Food additive I 
HDAC inhibitors which block spliceosome 
complex assembly (Kuhn et al. 2009) 
 Splitomicin Synthetic inhibitor of Sirt2 in yeast I 
 SAHA Anticancer drug I 
 Anacardic acid Antibacterial I HAT inhibitors which block spliceosome 
complex assembly 
(Kuhn et al. 2009)  Garcinol Antioxidant I 
 Butirolactone Synthetic inhibitor of Gen5 I 
 FR901464  Anticancer drug  II Inhibition of spliceosome assembly through 
binding to SF3b and SC35 
(Lagisetti et al. 2009) 
 Meayamycin Anticancer drug  I (Albert et al. 2009) 
Alternative splicing modulators  
Neuronal genes  
SMN2 Sodium butyrate Dietary supplement III 
Inhibition of HDACs to promote inclusion of 
exon 7 
(Chang et al. 2001) 
 Valporic acid Anticonvulsant III (Brichta et al. 2003) 
 Sodium 4-phenylbutyrate Anti-inflammatory action III (Andreassi et al. 2004) 
 M344 Synthetic benzamide III (Riessland et al. 2006) 
 Aclarubicin Anticancer drug II/III (Andreassi et al. 2001) 
 SAHA Anticancer drug III (Hahnen et al. 2006) 
 Tautomycin Antifungal/Antibiotic III Inhibition of PP1 to promote exon 7 inclusion 
via Tra2-beta1 dephosphorylation 
(Novoyatleva et al. 2008) 
 Cantharidin Terpenoid III 
  Salbutamol Asthma medication III beta2-adrenoreceptor agonist (Angelozzi et al. 2008) 
 EIPA  III Upregulates SRSF3 (Yuo et al. 2008) 






III Downregulation of hnRNP A2/B1 (Sakla and Lorson 2008) 
 PTK-SMA1 Synthetic tetracycline I/III n.d. (Hastings et al. 2009) 
 Sodium orthovanadate ATPase inhibitor  n.d. (Zhang et al. 2001) 
 Indoprophen Anti-inflamatory  n.d. (Lunn et al. 2004) 
Table 1.1 Continued 




Cardiac glycosides II Increase of exon 10 inclusion (Stoilov et al. 2008) 
 Lithium Chloride Antidepressant III 
GSK3 inhibition of SC35 phosphorylation 
(Hernandez et al. 2004) 
 AR18 Synthetic thiazole III/II (Bhat et al. 2003) 
IKBKAP 
Phosphatidylserine Food supplement III 
Increase of exon 20 inclusion 
(Keren et al. 2010) 
Epigallocatechin galate Antioxidant III (Anderson et al. 2003) 
Kinetin Used in cosmetic products III (Slaugenhaupt et al. 2004) 
NF1 Kinetin Used in cosmetic products III Inhibits exon skipping (Pros et al. 2010) 
Slo DHEA Glycocorticoid III STREX exon inclusion on BK channel (Lai and McCobb 2002) 
DRD2 
Ethanol Drink supplement 
III Induces dopamine receptor D2L isoform (Oomizu et al. 2003) 
N-type Ca2+ channel III Induces α12.2 isoform lacking exon 31 (Newton et al. 2005) 
GABAA III Decreases GABAA subunit gamma2 L/S ratio (Petrie et al. 2001) 






Anticancer drugs III Inhibits Topo I to increase exon 9 inclusion (Solier et al. 2004) 
 Chlorhexidine Disinfectant II 
Inhibits Clk phosphorylation of SRSF4, 
SRSF6, SRSF10 
(Younis et al. 2010) 
CASP-9 Gemcitabine Anticancer drug III 
Via de novo ceramide signaling and SRSF1 
upregulation 
(Chalfant et al. 2002; 
Massiello and Chalfant 
2006) 
Bcl-x NB-506 Anticancer drug I/III Inhibits Topo I phosphorylation of SRSF1 (Pilch et al. 2001) 
 Emetine Antibiotic III PP1 inhibition to promote Bcl-xS (Boon-Unge et al. 2007) 
 Cisplatin, Fluorouracil Anticancer drug III Promotes Bcl-xS splicing (Shkreta et al. 2008) 
 Staurosporine Antibiotic II PKC inhibition to promote Bcl-xS (Revil et al. 2007) 
 Oxaliplatine Anticancer drug III Promotes Bcl-xS via ATM-, CHK2-, p53-
mediated genotoxic response 
(Shkreta et al. 2011) 
 
PHB  
Trychostatin A Antifungal III Increases splicing of long growth suppressor 
isoform 
(Puppin et al. 2010) 
Sodium Butyrate Dietary supplement III  
Bim PLX4721 Anticancer drug III Promotes BimS splicing through SRSF6 Jiang et al., 2010) 
Clk1/Sty TG003 Synthetic benzothiazole III Inhibits SRSF1 phosphorylation by Clk1 (Muraki et al. 2004) 
Coilin, ILF2,  
CCDC56, IK 
Flunarizine Calcium channel blocker I/II 
n.d. 
(Younis et al. 2010) 
Clotrimazole Antifungal I/II  
Ron IDC48,78,92 Indole derivatives III Inhibit SRSF1-mediated exon skipping (Ghigna et al. 2010) 
 
 
Table 1.1 Continued 
 Compound Characteristics Assay Mode of action Citation 
In vitro splicing modulators 
Synthetic mRNA precursors 
HIVI-D1-A2 
IDC16 Indole derivative I Inhibition of SRSF1 splicing of HIV-1 mRNA (Bakkour et al. 2007) 
Ellipticine Anticancer drug I Inhibits SRSF1 exon recognition through Topo 
I independent pathway 
(Soret et al. 2005) 
C77,C83 Indole derivatives I  
β-globin Diospyrine derivatives Antibiotics I Stepwise inhibition of spliceosome assembly (Tazi et al. 2005) 
NCAM DMSO Analgestic/ drug carrier I Improves ionic interactions between SR 
proteins 
(Bolduc et al. 2001) 
 
Interleukin-2 Dehydromutactin,      
MS-444, Okicenone 
Derived from microbial broth I Prevent HuR multimerization (Meisner et al. 2007) 





gallate, Ellagic acid, 
(-)-Epicatechin gallate, 
Rhamnetin 
Antioxidants, edibles I Prevent HuC RNA binding (Kwak et al. 2009) 
Other genes 





1.4.2. Alternative splicing modulators affecting genes with neurological function  
Further to inhibition of general splicing, it has been shown that some compounds can 
interfere very specifically with a particular splicing event responsible for the production of 
alternative isoforms of products from a range of genes. This specificity has been used to 
identify compounds that modulate alternative splicing of various disease-related genes. Ways 
to upregulate the rate of inclusion of exon 7 of the SMN2 gene have been exploited as 
potential therapeutical approaches to treat Spinal Muscular Atrophy (SMA) (Lorson et al., 
2010). Sodium butyrate, valporic acid, SAHA, aclarubicin and sodium 4-phenylbutyrate have 
been described as potent promoters of exon 7 inclusion. Although these compounds have 
been identified as inhibitors of histone deacetylases (HDACs), the specific mechanism of 
action and the relationship to their structures is not well understood. Recently, histone 
modifications have been shown to directly change alternative splicing, reviewed by (Luco et 
al., 2011), but also indirect effects through altered expression or acetylation of splicing 
factors are possible mechanisms. MAPT splicing has also been shown to be susceptible to 
certain xenobiotics. Lithium chloride, which has been used for the effective treatment of 
bipolar disorder and depression, as well as AR-18, has been shown to promote the inclusion 
of exon 10 of the MAPT gene (Hernandez et al., 2004) by inhibition of GSK-3-mediated 
phosphorylation of splicing factor SRSF2 (Bhat et al., 2003). Tyrphostin-9, 5-iodotubercidin 
and digoxin, a prescribed cardiotonic steroid, have also been reported to promote exon 10 
inclusion of MAPT but the mechanism of this regulation is still not well understood (Stoilov 
et al., 2008). Alcohol consumption modulates splicing of the neuronal γ-Aminobutiryc acid 
(GABAA) and Dopamine D2 (DRD2) receptor genes, resulting in splice variants that affect 
alcohol tolerance and can provide the basis of the pathophysiological effect of alcoholism 
(Sasabe and Ishiura, 2010).  
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Many splicing factors, including SR proteins, are prominently regulated by phosphorylation 
and dephosphorylation (Stamm, 2008). Splicing regulation by cellular signaling, however, is 
poorly understood. Thus, small molecule approaches hold great potential for better 
understanding of this aspect of splicing regulation. Kinase inhibitors that target 
Topoisomerase I or II have been shown to modulate the splicing of several apoptosis-related 
genes. Topo I has been shown to phosphorylate many SR proteins (Rossi et al., 1996). 
Inhibition of the kinase activity of Topo I does not result in a uniform inhibition of splicing. 
NB-506, a glycosylated indolocarbazole, used as a potent anticancer drug, diminishes the 
kinase activity of Topo I and blocks phosphorylation of the splicing enhancer SRSF1, which 
in turn modulates the splicing of Bcl-X, CD44, SC53 and Sty (Pilch et al., 2001). Similarly, 
NB-506 has failed to affect inclusion of exon 9 of Caspase-2, which also has been shown to 
be dependent on Topo I or II kinase activity (Solier et al., 2004). Using Caspase 2 as a 
reporter gene other anticancer agents, which inhibit Topo I such as camptothecin, and Topo 
II such as amsacrine, etoposide, doxorubicin and mitoxanrone have been shown to promote 
splicing of the shorter, anti apoptotic, isoform of Caspase 2, Caspase-2S by promoting the 
exclusion of exon 9 (Solier et al., 2004). Another kinase implicated in SR protein 
phosphorylation is the Clk (Cdc2-like kinase) family (Ngo et al., 2005). TG003, a synthetic 
benzothiazole derivative, has been shown to effectively inhibit the kinase activity of 
Clk1/Sty and Clk4, which suggests that this type of inhibition may have an effect on 
alternative splicing. In fact, TG003 has been shown to affect splicing of Clk1/Sty itself, as 
well as, SRSF2 (Muraki et al., 2004, Ngo et al., 2005).  
Apart from kinase inhibitors, phosphatase inhibitors are also a prominent group of 
compounds that have been shown to alter splicing. Many phosphatase inhibitors act through 
protein phosphatase 1 (PP1). Furthermore, PP1 has been suggested to interact directly with 
splicing factors by binding to a RVXF motif located on the beta-4 sheet of the RNA 
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recognition motif (RRM) (Novoyatleva et al., 2008). As an example, the alkaloid emetine 
has been shown to influence Bcl-X splicing through a PP1-mediated mechanism, where 
emetine promotes the expression of the short proapoptotic Bcl-xS isoform (Boon-Unge et 
al., 2007). The sphingolipid ceramide has been shown to induce PP1-mediated 
dephosphorylation of SR proteins and induce altered splicing of Bcl-X and Caspase 9 to the 
anti-apoptotic forms in lung adenocarcinoma cells (Chalfant et al., 2001, Chalfant et al., 
2002). Further data have demonstrated that the effect of ceramide can be specific to Bcl-X 
and Caspase 9 alternative splicing. Exogenous ceramide applied to lung adenocarcinoma 
cells switches the splicing pattern of the pro apoptotic Bcl-xL and Caspase 9b to the anti-
apoptotic Bcl-xS and Caspase 9a. Besides exogenous addition of ceramide, endogenous 
production of ceramimde can be stimulated by application of gemcitabine, a 
chemotherapeutic drug (Massiello and Chalfant, 2006).  
 
1.4.3 In vitro splicing modulators 
In vitro splicing experiments are invaluable in determining the mechanisms by which 
xenobiotics interfere with the process. One of the first described inhibitors of spliceosome 
assembly, diospyrine derivatives, was engineered to inhibit T opo I kinase activity and affect 
alternative splice site choice. However, using in vitro studies, these compounds were found 
to stall spliceosome assembly on a substrate pre-mRNA of the beta-globin gene by either 
inhibiting complex A or B assembly (Tazi et al., 2005). Indole derivatives, a second 
compound class that inhibits spliceosome assembly, directly interacts with a number of the 
SR proteins and interferes with exon definition. Indole derivatives were identified in a screen 
of 4000 compounds in in vitro splicing assays on a beta-globin alternative splicing reporter 
(Soret et al., 2005). Independent follow up studies further revealed that these substances can 
not only specifically inhibit SRSF1-mediated splicing of HIV-1 pre-mRNA and compromise 
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production of essential viral proteins but also inhibit SRSF1-mediated exon skipping of the 
proto-oncogene Ron and promote expression of its pro-apoptotic isoform (Bakkour et al., 
2007, Ghigna et al., 2010). Human homologues of the Drosophila ELAV RNA binding 
protein have been implicated mainly in cytoplasmic events of mRNA processing, e.g. RNA 
stability, localization and translation. ELAV/Hu family members, however, have recently 
also been shown to regulate splicing in both humans and Drosophila (Zhu et al., 2008, Lisbin 
et al., 2001, Soller and White, 2003). Interestingly, HuC and HuR RNA binding to TNF-α 
RNA was found to be susceptible to interference by the same phytochemicals, e.g. 
quercetine, in electrophoresis mobility shift assays (Kwak et al., 2009, Chae et al., 2009). 
Using in vitro binding assays, dehydromutactin, MS-444 and okicenone, isolated from 
microbial broth (Actinomyces sp), were found to interfere with HuR RNA binding, as well as 
HuR dimerization, trafficking, cytokine expression and T-cell activation (Meisner et al., 
2007).  
 
 1.5. The ELAV/Hu family of RNA binding proteins 
ELAV/Hu proteins are evolutionarily highly conserved (Soller and White, 2004). The family 
comprises of four mammalian (HuR, HuB, HuC and HuD), three Drosophila (ELAV, FNE 
and RBP9), and one C.elegans (c-EXC-7) members (Figure 1.5A). Except for HuR and 
RBP9, which are found ubiquitously and also in gonads, respectively, all family members are 
neuronal and Drosophila ELAV is widely used as a pan-neuronal marker in flies (Yao, 
Samson et al. 1993) (Pascale et al., 2008).. ELAV/Hu proteins have three ‘RNA recognition 
motif’ (RRM) domains, the first two of which are in tandem and are separated by a hinge 
region from the third (Robinow, Campos et al. 1988) (Figure 1.5B). ELAV/Hu family 
members share significant amount of identity within their respective RRMs, whereas, the N- 





Figure 1.5. ELAV/Hu proteins structure and their evolutionary conservation 
 (A) A phylogenic tree illustrating evolutionary relationship between ELAV/Hu 
proteins. The nuclear/cytoplasmic localization is indicated. (B) Graphical representation of ELAV/Hu 
protein structure. The N-terminal domain and hinge region are indicated.  This figure was adapter 
from Soller and White 2004.
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1.5.1. Human Hu proteins  
Hu proteins bind to the 3´ UTRs of adenosine and uracide-(AU) rich RNA elements (AREs) 
which are unstable due to extensive presence of uracil. They are involved in splicing, 
polyadenylation, RNA editing, RNA nuclear export, RNA localization and RNA degradation 
(Hinman and Lou, 2008). A common feature is their ability to shuttle between cellular 
compartments and can be found in the nucleus, cytoplasm or both compartments (Figure 
1.5A).  
Hu family members are regulated by post-translational modifications such as phosphorylation 
and methylation. Failure of Hu proteins to be adequately modified can result in 
downregulation of target mRNAs important for cell survival and neuronal differentiation or 
induce the expression of cancer-related mRNAs. Phosphorylation of HuR by Cdk1 at S202 
within the hinge region keeps the protein in the nucleus where it acts as an antiapoptotic 
factor during G2 (Kim et al., 2008). Chk2 phosphorylates multiple HuR sites to stabilize 
HuR-mRNA complexes, e.g. the HuR-SIRT1 complex where, in response to oxidative stress, 
SIRT1 mRNA is released from the complex, in turn promoting SIRT1 mRNA decay, 
reducing protein levels, and lowering cell survival (Abdelmohsen et al., 2007). 
Hyperphosphorylation of HuR by PKCdelta at Serine 318 induces tumorous properties of 
colon carcinoma cells, through increased binding and stabilization of colon cancer-associated 
COX-2 and cyclinA mRNAs (Doller et al., 2011). Threonine phosphorylation of HuB, HuC 
and HuD by PKCalpha results in the redistribution of the proteins to the cytoplasm and 
stabilization of GAP-43, which is a well known target of HuD, and a neuronal differentiation 
factor (Pascale et al., 2005). In contrast, arginine methylation has been shown to negatively 
regulate Hu binding to RNA. CARM1 methylation at Arg236 of HuD decreases the RBP’s 
binding affinity in PC12 cell line, which maintained the culture in its proliferative state and 
failed to differentiate into neurons under NGF induction (Fujiwara et al., 2006).  
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Apart from post-translational modifications, levels of neuronal Hu proteins have also been 
shown to be important in nervous system function. Neuronal Hu proteins have been linked to 
mediate learning and memory as up-regulated levels of these proteins promote memory 
formation in a spatio-temporal manner in both rats and mice (Quattrone et al., 2001). 
Intriguingly, HuD is up-regulated in the hippocampus of rats subjected to the Morris water 
test and maintained high levels after a month of training illustrating a potential link between 
HuD levels and long-term memory acquisition (Pascale et al., 2004). In contrast, down-
regulated levels of HuD have been found in post-mortal brain samples of Alzheimer’s disease 
patients, which is the most common type of dementia (Amadio et al., 2009). HuD levels have 
been shown to be regulated by microRNA silencing, where up-regulation of mir-375 
effectively down-regulated HuD by binding to an evolutionary conserved site in its 3´ UTR, 
lowering HuD mRNA stability and translation, resulting in decreased neurite differentiation 
(Abdelmohsen et al., 2010). 
Unprecedentedly of their roles in RNA processing, Hu proteins are ectopically expressed on 
the membrane of small-cell lung tumors (Darnell, 1996, Darnell, 2011) and are commonly 
known as target antigens in paraneoplastic neurological disorders (Hu syndromes) associated 
with this cancer type. Hu syndrome presents as the immune response against the tumor’s Hu 
antigents expands to attacking healthy nervous tissue which normally expresses Hu proteins. 
As a result patients develop rapid progressive neurodegeneration and die from neurological 
causes shortly after diagnosis (Dalmau et al., 1992). Hu proteins have been identified as 
markers for paraneoplastic neurological disorder. The molecular mechanisms of why small-
cell lung cancer tumors overexpress Hu proteins and what implications that has towards the 




1.5.2. Drosophila ELAV family proteins  
1.5.2.1. ELAV 
Up to date, there has been only one example illustrating the relationship between ELAV 
nuclear localization and a particular protein sequence. Despite sequence differences in the 
hinge region of ELA/Hu proteins a constant octapeptide is present in all members. Deletions 
of the ocatapeptide in ELAV results in mislocalization of the protein to the cytoplasm 
(Yannoni and White, 1999).  
ELAV is present exclusively in all immature and mature neurons in Drosophila. Null mutant 
alleles of elav are embryonic lethal and mutant embryos have an abnormally formed neuropil. 
Hypomorphic mutants have an aberrant eye, defective electroretinograms and flight defects 
(Campos et al., 1985b).  
Three targets have been identified for ELAV: EWG (Erect Wing),  NRG (Neuroglian) and 
Arm (Armadillo) where the relationship between neuronal ELAV-mediated splicing and 
target mutant phenotypes has been best described for EWG. EWG is a transcription factor, 
vital for the development of the nervous system and the indirect flight muscles (DeSimone et 
al., 1996). ewg null mutants are embryonic lethal. Hypomorphic mutants have, however, 
erect wings and mostly absent dorsal longitidual muscles (DLMs) (DeSimone et al., 1996). 
EWG is a major target of ELAV, as expression of the neuronal ELAV-mediated EWG 
isoform rescues elav associated lethality (Haussmann et al., 2008). Based on EWG null 
mutant clonal analysis it has been shown that EWG loss of function causes a synaptic 
overgrowth phenotype at the neuromuscular junction which is associated with misregulation 
of multiple signaling pathways under EWG’s transcriptional control and this overgrowth 
phenotype can also be rescued by expression of the neuronal ELAV-mediated EWG isoform, 
illustrating that ELAV-mediated splicing of EWG accounts for EWG’s role in restriction of 
synaptic growth (Haussmann et al., 2008).  
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EWG is broadly expressed and on the molecular level, its expression is mediated by ELAV 
alternative and inefficient splicing (Koushika et al., 1999). To overcome sequence 
redundancy of regulatory elements ELAV binds an extended binding site of over 150 
nucleotides (Haussmann et al., 2008, Haussmann et al., 2011, Soller and White, 2003). The 
major product formed out of this regulation is a 116 kDa protein expressed predominantly in 
neurons. ELAV’s effect is attributed entirely to the inhibition of 3´-end processing. ELAV 
binds as a multimer to a stretch of AU-rich sequence 3´ of the regulated polyA site in intron 6 
of ewg’s pre-mRNA to inhibit intronic 3´-end processing and promote inclusion of 
downstream exon J (Soller and White 2003). Notably, ELAV’s RRM3 is implicated in 
multimerization as loss-of function mutations significantly reduce ELAV splicing activity in 
vivo. Therefore, RRM3 could serve as a bi-functional domain binding RNA as well as protein 
(Toba and White, 2008). Interestingly, replacement of RRM3 from RBP9 and HuD into 
ELAV restores the protein’s functionality, whereas replacement of RRM1 and RRM2 does 
not (Lisbin et al., 2000) 
Nrg is a cell adhesion molecule, which promotes axonal cone growth during sensory axon 
guidance (Martin et al., 2008, Garcia-Alonso et al., 2000). ELAV-mediated alternative 
splicing of the Nrg transcript involves inclusion of a 3´-terminal exon to produce a neuronal 
isoform, where ELAV binds four (U)-rich sequences along the alternatively spliced intron 
(Garcia-Alonso et al., 2000).  
Arm is a Drosophila catenin homologue; both a structural component of adherens junctions 
(Cox et al., 1996) and a transducer of the Wingless signaling pathway (Noordermeer et al., 
1994). ELAV promotes exclusion of exon 6 from ubiquitous Arm (u-Arm) pre-mRNA to 
produce a shorter neuron specific isoform, n-Arm, with a truncated carboxyl terminus 




Originally, the RNA binding protein 9 (Rbp9) gene was shown to be solely expressed in 
neuronal nuclei with peak expression levels at mid-pupal stage (Kim and Baker, 1993).  A 
neuronal function for RBP9 has not yet been identified, however, the protein has been 
implicated to play a role in maintaining the integrity of the blood brain barrier (BBB) as 
dextran beads penetrate through the BBB much more effectively in RBP9 mutants (Kim et 
al., 2010). A potential mechanism for RBP9’s involvement in the BBB can be through 
regulating the expression of adhesion proteins like Neurexin IV and Gliotactin which are 
down-regulated in Rbp9 mutants (Kim et al, 2010).  
RBP9 was also detected in the cytoplasm of cystocytes during oogenesis and a role in mRNA 
stability was attributed to the protein (Kim-Ha et al., 1999). Female RBP9 null mutants are 
sterile due to cyctocytes failure to differentiate. This is caused by up-regulation of Bag-of-
marbles (BAM), which encodes a developmental regulator of germ cells. RBP9 binds to 
BAM mRNA to downregulate BAM’s expression to promote cyctocyte differentiation (Kim-
Ha et al., 1999, Jeong and Kim-Ha, 2004). RBP9 was also shown to be involved in germline 
sex determination, where elevated levels of male germline markers such as Sxl male 
transcripts were identified in RBP9 mutant ovaries, that form ovarian tumors characteristic 
for sex transformation of female germ cells (Lee et al., 2000).  
RBP9 and ELAV have been suggested to function along similar pathways to maintain the 
functional integrity of the adult nervous system based on life span assays on elav 
hypomorphic and Rbp9 null mutant alleles where the elav and Rbp9 mutants had reduced 
survival curves compared to controls with elav mutants having shorter life-span compared to 
Rbp9. Double mutants of elav;Rbp9 did not show an additive effect on longevity compared to 
the elav single mutant alone (Toba et al., 2010). This could imply that elav is epistatic to 
Rbp9, however, a life-span test cannot be conclusive in regards to specific gene function and 
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mRNA target specificity of the two RBPs, as lethality is a broad phenotype that can result 
from misregulation of various genes that do not function along the same pathway. Therefore, 
a more in depth analysis, such as testing the ability of the two proteins to bind to the same 
mRNA targets, is required to make a functional analogy between ELAV and RBP9. 
 
1.5.2.3 FNE 
Found in neurons (FNE) is the most recently described member of the ELAV family and was 
originally characterized by Samson and Chalvet in 2003. FNE is expressed in neurons of the 
CNS and PNS. Unlike ELAV, FNE is cytoplasmic, appears shortly after ELAV during 
embryogenesis and its expression levels remained unchanged in ELAV null embryos 
(Samson and Chalvet, 2003). Recently, a neuronal function was discovered for FNE in the 
formation of the beta-lobes of the mushroom bodies and promotion of male courtship (Zanini 
et al., 2012).  
A potential interaction between FNE and ELAV was suggested based on neuronal 
overexpression of FNE where a decrease of stable transcripts from the endogenous fne and 
elav loci was detected (Samson and Chalvet, 2003).  It is possible that FNE autoregulates and 
that it also regulates ELAV as both proteins were found to bind in vitro to a sequence present 
in elav 3' UTR (Samson and Chalvet, 2003).  
 
1.6. Drosophila as a model system for neurotoxicity testing 
Drosophila melanogaster has been used as a model organism for over a hundred years 
(Rubin and Lewis, 2000, Bier, 2005) and is an invaluable tool for the characterization of: (a) 
novel genes and their function; (b) genetic networks spanning from fundamental processes to 
complex behavior; (c) disease models and underlying molecular mechanisms. The fly’s 
genome was fully sequenced (Adams et al., 2000). More than 60% of human disease-causing 
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genes have a Drosophila homologue (Reiter et al., 2001). In fact, not only individual 
domains and proteins, but entire complexes and multi-step pathways are conserved between 
fly and man, such as the Janus Kinase/Signal Transducer and Activator of Transcription 
(JAK/STAT), (Arbouzova and Zeidler, 2006), Notch (de la Pompa et al., 1997) and Toll 
signaling pathways (Hoffmann, 2003).  
Drosophila offers certain experimental advantages: flies are small, inexpensive and require 
simple food medium; their short life cycle is completed within 10 days at 25°C; work with 
Drosophila lacks the need of a Home Office License, required to experiment on vertebrates. 
 
1.6.1. Drosophila transgenesis  
 
The Gene Disruption Project in Drosophila utilizing transposable elements yielded 
disruption of nearly 70% of all protein coding genes by either abolishing gene function 
completely, creating hypomorphic alleles or providing a platform for further genetic 
manipulations (Bellen et al., 2011). There are three types of transposable elements in use in 
Drosophila: the long used P and piggyBac elements, which insert more frequently in certain 
genomic regions (termed hotspots), and the relatively recent Minos elements, which insert 
randomly and do not show positional preferences.  
 Introducing transgenic constructs into the fly’s genome is accomplished by embryo 
microinjections. The transgene bearing plasmid is co-injected together with a helper plasmid, 
source of an integrase. Drosophila research was greatly dependent on this technique, despite 
its two major drawbacks: there exists a size limitation for the integrated construct and the 
insertion sites could not be controlled, in some instances resulting in several insertions per 
transformation event. Furthermore, in cases when differential expression of a set of 
constructs was to be assessed, randomized integration brought a certain degree of ambiguity 
due to the possibility of unforeseen positional effects from nearby genomic sequences 
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(enhancers or silencers). Recently, a more elegant approach has been developed in order to 
bring greater accuracy and efficacy in manipulating the fly’s genome (Groth et al., 2004). 
This technique utilizes the bacteriophage ΦC31 integrase, which integrates large transgenic 
constructs at defined docking sites in the fly genome (Venken et al., 2006). This approach 
also introduced a user-friendly DNA modification platform, called recombineering into the 
fly field (Venken and Bellen, 2007).      
A widely used and well established technique for targeted gene expression in Drosophila is 
the UAS/GAL4 system (Brand and Perrimon, 1993). GAL4 is a transcriptional activator 
which encodes a 881 amino acids protein, originally identified in the yeast Saccharomyces 
cerevisiae as a regulator of gene expression induced by galactose (Laughon and Gesteland, 
1984). GAL4 directly binds to an Upstream Activating Sequence (UAS), defined by a 
pattern of four related 17 bp sites (Klueg et al., 2002).  
The UAS/GAL4 system is a binary system that allows the selective activation of any cloned 
gene in a wide variety of tissue and cell-specific pattern (Figure 1.6) (St Johnston, 2002). It 
separates the expression of a gene of interest (target gene) from the transcriptional activator 
in two distinct transgenic lines. In one line the target gene remains silent in the absence of 
the activator, whereas in the second line the activator protein is present but has no target 
gene to activate. It is only when the two lines are crossed, that the target gene is turned on in 
the progeny, and the phenotypic consequences can be studied. A library of GAL4 lines can 
be built up, each line expressing GAL4 in a different spatiotemporal pattern. The UAS- 
target gene is silent in the absence of a GAL4, which allows the UAS line to be viable even 
if the UAS-target gene is lethal when ectopically expressed (Phelps and Brand, 1998). 
 
1.6.2. Drosophila as a model for neurodegeneration 




Figure 1.6 A schematic represenatioan of the UAS/Gal4 system in Drosophila 
The Gal4 protein and UAS-transgene (gene X) are separated in two lines. Only by combinig them 
after a cross between the lines, the Gal4 would recognise the UAS and drive the expression of gene X 
in the progeny. Thus, gene X expression is confined to the expression pattern of the Gal4 which 
determines spacial nad temporal control of gene X expression. This figure and its legend are adopted 
from St Johnston, 2002. 
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tremors and ataxia to loss of cognition and memory due to aberrant function or loss of 
specific neurons. Many of these diseases are associated with the accumulation and formation 
of inclusions of misfolded proteins, failed to be cleared, in the cytoplasm of neurons. They 
are typically referred to as inclusion bodies in Polyglutamine (polyQ) diseases, amyloid 
plaques and neurofibrillary tangles in Alzheimer’s disease and Lewy bodies (LB) in 
Parkinson’s disease. Drosophila models for all of these as well as other motor-neuron 
disorders like Fragile-X, SMA and ALS have been generated and have been extensively 
reviewed in (Bilen and Bonini, 2005, Hirth, 2010). Sophisticated genetic platforms allow 
manipulation of the fly’s genome to: (1) express mutated human genes under spatial and 
temporal control and study their pathogenicity; (2) knock-down fly homologues of human 
disease-associated genes by RNAi or through generation of null mutant alleles to elucidate 
their roles in nervous system function; (3) perform genetic screens to identify enhancers or 
suppressors of disease-related phenotypes and further understand the complexity of the 
disease. Ultimately, lessons learned from the fly would contribute to finding better treatment 
for battling neurodegenerative disorders.    
The underlying cause of polyQ diseases is the expansion of a CAG trinucleotide repeat that 
encodes polyQ in the ORF of one of the following known proteins: Huntingtin, Atrophin, 
Androgen receptor, Ataxin 1-7, causing HD, DRPLA, SBMA, SCA1-7, and 17. Dominance 
of polyQ toxicity is determined by a threshold length of the CAG repeat and the severity of 
the diseases is directly proportional to the CAG expansion (Paulson et al., 2000). For 
example in the case of HD severity, a polyQ count of less than 26 CAG repeats is classified 
as not being pathogenic, 27-35 repeats determines intermediate disease status, 36-39 repeats 
determines reduced disease penetrance and over 40 repeats determines full penetrance of HD 
(Walker, 2007).  Drosophila models of polyQ diseases have been helpful in understanding 
the underlying mechanisms of protein accumulation and subsequent neurodegeneration. 
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Targeted expression of the expanded polyglutamine repeat of the SCA-3 protein has been 
shown to lead to nuclear inclusion (NI) formation and late-onset neurodegeneration in a 
SCA-3 fly model demonstrating that cellular mechanisms of human glutamine-repeat disease 
are conserved in invertebrates (Warrick et al., 1998). Also, co-expression of human Hsp70 in 
HD and SCA-3 Drosophila models reduced polyQ-associated toxicity and suppressed 
neurodegeneration (Warrick et al., 1999, Chan et al., 2000). Genome-wide screens for 
modifiers of polyQ toxicity have been instrumental in identifying chaperones and 
components of the ubiquitination and lysosome degradation pathways as suppressors of 
polyQ toxicity (Fernandez-Funez et al., 2000, Steffan et al., 2004). It has been shown that 
transcriptional dysregulation is affected in polyQ diseases where polyQ-containing 
Huntingtin inhibits acetyltransferase activity of histone modifying enzymes lowering 
acetylated histones H3 and H4 levels (Steffan et al., 2001). HDAC inhibitors, like SAHA, 
have been shown to increase H3 and H4 in in vitro and in vivo HD models, where SAHA fed 
flies as a result exhibited significantly reduced HD-associated neurodegeneration and 
lethality (Steffan et al., 2001).  
Alzheimers’s disease (AD) is the most common cause of dementia and is characterized by the 
accumulation of neurofibrillary tangles of abnormal Tau protein and senile plaques of 
Amyloid beta (Aβ) peptides in the cytoplasm which impair neuronal function and lead to 
subsequent neuronal death. Hyperphosphorylation of Tau causes dissociation of the protein 
from microtubules, where free Tau self-assembles in neurofibrillary tangles of helical and 
straight filaments (Alonso et al., 1996). Mutations in the genes amyloid precursor protein 
(APP) and the γ-secretase subunits Presinilin 1 and 2 (PS1 and PS2) have been associated 
with inherited AD. β- and γ-sectretases cleave APP at the β and γ sites, respectively, to 
produce various types of Aβ peptides, where in the case of AD Aβ40 and 42 are produced 
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with Aβ42 being the major aggregate found in senile plaques.  
Modeling Alzheimer’s disease in flies is challenging because Drosophila APP, APPL, lacks 
the Aβ domain and flies do not have β-sectretase activity. Also, overexpression of 
Drosophila APPL and human wild type and mutant APP did not result in neurodegeneration, 
but caused a blistering wing phenotype (Fossgreen et al., 1998). Directed expression of Aβ40 
and Aβ42 peptides in the nervous system, however, caused AD-like phenotypes such as 
decreased learning ability with Aβ42 also reducing longevity and promoting aggregate 
formation similar to amyloid plaques in Kenyon cells of the mushroom bodies (Iijima et al., 
2004). Furthermore, co-expression of the human β and γ-sectretase components (βeta-site 
APP-cleaving enzyme- BACE, PS1 and PS2) together with APP in flies produced Aβ40 and 
Aβ42 fragments and lead to progressive neurodegeneration of the retina, reduced longevity 
and defects of the wing vein (Greeve et al., 2004). Interestingly, neuronal expression of 
human Tau in flies did not lead to the formation of neurofibrillary tangles, but caused 
formation of vacuoles in the central brain and eye-specific expression produces small and 
rough eyes (Wittmann et al., 2001). The Tau eye phenotype has been utilized in 
overexpression modifier screens, where phosphatases and kinases were found to modulate the 
phenotype (Shulman and Feany, 2003). Transgenic AD fly models have successfully been 
used to test pharmacologically active substances for their therapeutic potential, where BACE 
and glutaminyl cyclase inhibitors, Congo Red and quinone-based small molecules were 
shown to decrease AD-related phenotypes in flies (Greeve et al., 2004, Scherzer-Attali et al., 
2010, Schilling et al., 2008, Crowther et al., 2005).  
Parkinson’s disease (PD) is a degenerative disorder of the CNS characterized by death of 
dopaminergic (DA) neurons in the substania nigra and accumulation of α-Synuclein into 
inclusions called Lewy bodies (LBs). Development of PD has been linked to genetic 
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mutations and environmental stress. PD has also been associated with dysfunction of 
chaperons and the ubiquitin proteasome pathway (Leroy et al., 1998). Missense mutations in 
α-Synuclein have been associated with autosomal dominant familial PD (Maries et al., 2003). 
When overexpressed in Drosophila human mutant α-Synuclein produced adult-onset loss of 
dopaminergic neurons and formation of LBs resulting in locomotion defects (Feany and 
Bender, 2000). Co-expression of the molecular chaperone Hsp70 with mutant α-Synuclein in 
flies prevented dopaminergic loss and interference with endogenous chaperone activity 
accelerated α-Synuclein mediated neurodegeneration (Auluck et al., 2002). Mutations in the 
human PARK2 gene, an E3-specific ubiquitin ligase, cause Autosomal recessive-Juvenile 
parkinsonism (Kitada et al., 1998). Loss of function mutations in the Drosophila homologue 
parkin, however, did not account for loss of DA neurons, but caused muscle degeneration 
linked to mitochondrial pathology, as well as reduced body mass and infertility (Pesah et al., 
2004, Greene et al., 2003). Further evidence of the importance of mitochondrial dysfunction 
in the progression of autosomal recessive Parkinsonism came from studies of the pink1 gene, 
a putative serine/threonine kinase localizing to mitochondria. (Gandhi et al., 2006). pink1 has 
been shown to interact with parkin and both have similar mutant phenotypes in Drosophila 
models. Also, expression of human pink1 and Drosophila parkin restored normal 
mitochondrial morphology and male fertility in pink1 mutant flies (Clark et al., 2006). 
Recently, vitamin K was shown to be necessary and sufficient in transferring electrons in 
Drosophila pink1 deficient mitochondria, thus, providing insights into novel therapeutic 
approaches for PD (Vos et al., 2012).  
Dysfunction and missassembly of mitochondria complex I in the electron transport chain 
(ETC) has been implicated in the development of sporadic PD (Schapira et al., 1990, Keeney 
et al., 2006). Inhibition of the complex’s catalytic activity is a property of PD model 
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neurotoxins, like MPTP, paraquat and rotenone. MPTP, originally developed as an opioid 
drug, is rarely used to model PD in Drosophila, however, it has been instrumental in 
modeling mammalian idiopathic PD (Dawson et al., 2002). The active metabolite MPP+ 
inhibits ATP production and promotes superoxide radical formation resulting in DA damage 
(Przedborski et al., 2000, Dawson et al., 2002). Paraquat, a widely used herbicide, is 
traditionally used to induce oxidative stress in Drosophila to implicate novel roles of genes 
and chemicals in oxygen metabolism by analyzing sensitization or resistance to the drug. 
parkin adult mutant flies showed increased sensitivity to prolonged low-dose exposure to 
paraquat resulting in reduced longevity (Pesah et al., 2004). Similarly, null mutants of the 
copper/zinc superoxide dismutase conferred hypersensitivity to paraquat, resulting in reduced 
longevity and infertility (Phillips et al., 1989). Adult wild type flies acutely exposed to high-
doses of paraquat in combination with one of the following drugs melatonin, glutathione, 
serotonin, minocycline, lipoic acid and ascorbic acid showed increased levels of viability and 
resistance to paraquat (Bonilla et al., 2006). Rotenone, a widely used pesticide, has 
effectively been used to model PD in Drosophila. Sub-lethal chronic exposure of adult flies 
to rotenone caused dose-dependent locomotion impairments and loss of dopaminergic 
neurons. Similarly, as in human PD patients, intake of L-dopa reduced the locomotion defects 
but not neuronal cell death. Application of the antioxidant melatonin, however, had a 
protective effect on both locomotion and neuronal survival (Coulom and Birman, 2004). 
Creatine has also been shown to have neuro-protective roles against rotenone-induced 
oxidative stress by reducing mortality and improving climbing ability through restoring 
glutathione, nitric oxide and dopamine levels (Hosamani et al., 2010). 
Modeling neurodegenerative diseases in Drosophila has provided insights into the 
development and progression of neurodegenerative disorders and has helped elucidate 
underlying molecular mechanisms of pathogenicity, which could benefit future treatment. 
 35 
Such are the discoveries that glutaminyl cyclase inhibitors and quinone-based molecules can 
reduce Aβ plaque formation in Alzheimer’s fly models and that vitamin K can rescue 
mitochondrial dysfunction caused by pink1 deficiency in Parkinson’s fly models and 
(Scherzer-Attali et al., 2010, Schilling et al., 2008, Vos et al., 2012). Modeling 
neurodegenerative diseases in flies has also opened a new dimension for research of 
neurotoxicity where the fly has the potential of being a prime test subject. Neurotoxicity 
occurs when the exposure to natural or artificial toxic substances, neurotoxins, alters the 
normal activity of the nervous system in such a way as to cause its damage (Segura Aguilar 
and Kostrzewa, 2004). On the molecular level, neurotoxicity has been associated with the 
excessive accumulation of protein aggregates (Dolan and Johnson, 2010); aberrations at the 
synaptic interface, leading to abnormal signal transduction and neuronal firing (Piercey et al., 
1990); and it has been shown that neurotoxicity can be reactive oxygen-specie mediated 
(Hirsch et al., 1997). Showing that Drosophila exhibits similar neurotoxic assaults as 
humans, however, has to be analyzed according to the fly’s ability to uptake and metabolize 
substances. Therefore, it is imperative that further research is undertaken to understand 
Drosophila’s natural protection against toxic compounds.   
1.6.3 Mechanisms for introduction of compounds 
 
An advantage of using Drosophila in in vivo toxicity studies is the high number of subjects 
that can be tested simultaneously in a single experiment, which is several-fold greater than in 
comparison with mammalian toxicity studies. There are three general ways of introducing a 
compound to the fly (Figure 1.7). Each approach has benefits and drawbacks (for detailed 
review see (Manev et al., 2003, Segalat, 2007, Pandey and Nichols, 2011).  
A compound can be administered by mixing the substance into the food culture. This method 
was traditionally used for testing herbicides like rotenone and paraquat (Coulom and 





Figure 1.7 A schematic representation of the modes of drug application in Drosophila 
In larvae drugs can be administered either by injection of the compound or mixed with the food 
culture and be fed to animals. In adults drugs can be administered in a vaporized form, mixed in the 
food, as drops to the severed neck of decapitated flies or through abdominal injections. This figure 
and its legend have been adopted from Pandey and Nichols, 2011. 
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levels it is difficult to draw dose-response curves, as in some cases the animals do not feed 
because the added substance repulses them. Hence, lethality as a scoring output may be 
caused by starvation rather than toxicity. Assessment from chronic exposures is more 
reliable, provided that the drug-feeding assays are performed at lower concentrations and 
have minimal effects on feeding potential.  
Another option for drug administration is exposure of the fly to vaporized chemicals, such as 
ethanol, cocaine and volatile organic compounds (Singh and Heberlein, 2000, Li et al., 2000, 
Inamdar et al., 2010). Determining the actual inhaled dose and the fact that the compound 
can vaporize, however, is limiting.  
 Invasive administration approaches  introduce a substance by abdominal injections, such as 
small peptides causing behavioral changes (Kubli, 1992); or by the form of a droplet to the 
severed neck of decapitated fly bodies that continue to exhibit movement to record, reflexive 
locomotion under induction of a dopamine receptor agonist (Andretic and Hirsh, 2000). 
These methods are time-consuming and challenging when performed at a large scale, 
however, the precise and timely control of administration of the chemical agent brings 
greater accuracy. Recently, a new technique for detection of novel physiologically active 
compounds was described by Mejia et al. where nanoinjections were paired with 
electrophysiological recordings from the Giant Fiber System of adult Drosophila to 
effectively deliver nanoliter quantities of a compound to the CNS (Mejia et al., 2012).  
 
1.6.4. Measurable endpoints to assess toxicity in Drosophila  
There are a number of endpoints to be scored for when assessing toxic effects on flies  (for 
detailed review see (Rand, 2009) and (Pandey and Nichols, 2011) . 
• Lethality  
Drosophila was originally used in tests for genotoxicity (Sobels and Vogel, 1976), when later 
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the fly was replaced by in vitro cell assays such as the Salmonella mutagenicity or Ames test 
(Ashby and Tennant, 1991). Lethality of adult flies subsequent to larval or adult chemical 
exposure has been proven highly effective in the analysis of heavy metals such as mercury 
and cadmium and in screening for genetically encoded resistance traits (Christie et al., 1985, 
Magnusson and Ramel, 1986). 
• Adult morphology 
Traditionally, scoring for teratogenic effects is performed by assessing the wing and eye. 
Aberrant wing notching can reveal interference of a xenobiotic with general developmental 
mechanisms, for example the Notch pathway (Lynch et al., 1991). Disturbed eye 
morphology can be used to score for chemical modifiers of neurodegenerative fly models, 
for example myotonic dystrophy 1 (DM1) (Garcia-Lopez et al., 2008).  
• Behaviour 
Different types of behaviour include locomotion, circadian rhythm, sleep patterning, 
courtship and mating, aggression, and grooming. Behavior-based assays were used to study 
lead toxicity in adult flies where courtship was examined post lead feeding to developing 
larvae (Hirsch et al., 2003). The courtship index, assayed as the number of matings occurring 
within 20 minutes of pair introduction, showed an increase at low lead concentrations and a 
decrease at higher dosage (Hirsch et al., 2003).  
 
1.6.5. Adapting Drosophila for drug testing 
There are a number of non-conserved characteristics that impede toxicological studies in the 
fly. Fly metabolism can differ greatly from that of mammalian models. This is important 
when toxicity of a substance is derived from its metabolites. Arsenic toxicity is caused by 
methylated forms of the toxin and it has been shown that arsenic is not methylated in 
Drosophila (Rizki et al., 2006). Methylation in flies does not play major epigenetic 
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regulatory roles as in mammals but it is restricted to early embryonic development and 
accomplished by a single DNA methyltransferase (Dnmt2) (Lyko et al., 2000, Kunert et al., 
2003). Despite this seemingly dramatic difference in metabolism, it has been shown that 
arsenic-mediated genotoxicity can be successfully assessed in Drosophila either by exposing 
flies to methylated arsenic forms or by expressing transgenic human arsenic 
methyletransferase (Rizki et al., 2006, Muniz Ortiz et al., 2011).   
One of the caveats of using Drosophila in compound screens to identify novel neurotoxins is 
that in comparison to mammals, metabolism of the CYP (cytochrome P450) superfamily of 
proteins is not that well characterized. P450s in Drosophila, as in mammals, have evolved to 
metabolize pheromones and detoxify environmental stressors (Feyereisen, 2006, Chung et 
al., 2009). 57 P450 genes have been identified in humans (Nelson et al., 1996). In 
comparison, 85 P450 genes are identified in Drosophila most of which remain 
uncharacterized (Tijet et al., 2001). It is possible that an overlapping detoxification 
mechanism exists between fly and human P450s, however, uniformity of such a mechanism 
cannot be concluded simply on the basis of sequence homology. A possible way to 
circumvent the uncertainties of metabolic activation while searching for novel neurotoxins is 
to pre-incubate compounds in rat liver S9 extracts to mimic mammalian metabolic condition 
(Jagger et al., 2009). Nonetheless, small molecule screens do not face challenges from 
metabolic activation and are suitable for performing in Drosophila. 
Using flies to determine relevant dose responses in mammals is not well established. Drug 
transport in Drosophila is poorly understood and this challenge has still not been 
circumvented. Systematic analysis of drug transporters is imperative for better 
characterization of drug exertion and absorption and would greatly benefit using Drosophila 
as a toxicological model.  
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1.6.6. Roles of drug transporters in determining toxicity in Drosophila 
The coordinated manner of drug uptake versus drug efflux is key for a compound’s 
absorption, distribution and subsequent elimination from the body. The passage of 
compounds across biological membranes depends on the compound’s size, charge and 
solubility. A compound’s influx or efflux may often be transport though simple diffusion, 
dependent on lipid solubility, and is facilitated via various transporters that are embedded 
within the cell’s membrane (Kim, 2003). Transporters often display redundancy in their 
substrate specificity and further complicate the pharmacodynamics involved in drug 
disposition (Kim 2003).  
Possibly, the most striking example of toxicological/pharmacological relevance of drug 
transporters in Drosophila is the fact that ouabain, a cardiac glycoside, fails to inhibit Na+-
K+ ATPases activity in Drosophila malpighian tubule (MT) secretion assays, even though it 
shows high binding affinity and inhibition to Na+-K+ ATPases in vitro (Lebovitz et al., 1989, 
Ogawa et al., 2009). This observation was termed the “ouabain paradox” and was attributed 
to the active transporter-mediated efflux of ouabain through the MT as the ATPase co-
localizes to an active OATP system that prevents the drug of reaching sufficient inhibitory 
concentrations (Ogawa et al., 2009).  
 
1.6.6.1. Organic Anion Transporting Peptides (OATPs) 
OATPs function in the uptake of substrates ranging from endogenous compounds to various 
xenobiotics, with molecular weights of more than 300kDa, reviewed in (Mikkaichi et al., 
2004, Obaidat et al., 2012). OATPs are expressed in a range of tissues and organs, all of 
which determine effective drug delivery (Kim 2003). Eight OATP genes have been identified 
in Drosophila through sequence similarity to vertebrate members of the family (Ogawa et al., 
2009).  
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1.6.6.2. ATP-binding cassette (ABC) proteins  
ABC transporters utilize energy liberated from ATP hydrolysis to flip a given substrate from 
the cytoplasm or inner lipid bi-layer to the extracellular medium and vice versa. They are 
mostly involved in drug efflux, and like OATPs, transport endo- and xenobiotics (Dean et 
al., 2001a). ABC transporters are implicated in promoting broad-spectrum drug resistance, 
for example of breast cancer to chemotherapy (Natarajan et al., 2012) and to drug treatments 
of various brain disorders, like epilepsy, schizophrenia and depression (Loscher and 
Potschka, 2005b). 
P-glycoproteins, the most studied of the ABC transporters, are conserved among eukaryotes 
(Dean et al., 2001b). In Drosophila three family members are found: Mdr49, Mdr50 and 
Mdr65. Mdr65 has been identified as a key component in the Drosophila blood-brain barrier 
and is homologous to the human p-glycoprotein Mdr1 (Mayer et al., 2009). The latter is 
present in the endothelial cells of brain capillaries and is a constituent of the blood brain 
barrier where it is responsible for the uni-directional transport of substances out of the brain 
(Schinkel, 2001). Mdr65 was also shown to export endogenous chemoattractants important 
for germ cell migration in the embryo (Ricardo and Lehmann, 2009). 
Multidrug resistance-associated proteins (MRPs) are also members of the ABC superfamily, 
however, they share little homology with the p-glycoproteins (only 15%), suggesting a high 
degree of evolutionary divergence (Grailles et al., 2003). MRPs are evolutionary conserved 
across eukaryotes (Grailles et al., 2003) and are responsible for the transport of large 
polypeptides, inorganic ions, and numerous anticancer drugs (Hipfner et al., 1999). 
Drosophila MRP, alike Mdr65, is a constituent of the BBB (Dallas et al., 2006). 
Interestingly, the MRP gene undergoes alternatively splicing yielding up to 14 functionally 
diverse isoforms, possibly, as a mechanism for increasing receptor variability in response to 
different toxins (Grailles et al., 2003).    
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1.6.7. The Blood Brain Barrier (BBB)  
The BBB is a physiologically dynamic barrier composed of a single layer of vascular 
epithelium that ensures brain homeostasis and protection against toxic molecules and 
pathogenic organisms (Figure 1.8). The impermeability of the BBB is mostly due to 
specialized lateral junction components, called tight junctions (Wolburg and Lippoldt, 2002), 
and asymmetrically arrayed ATP binding cassette (ABC) transporters present in the vascular 
epithelium (Mahringer et al., 2011, Loscher and Potschka, 2005a). Tight junctions prevent 
paracellular diffusion of charged molecules, and the transporters actively expel lipophilic 
molecules back into the humoral space. Together, these complimentary systems prevent the 
majority of xenobiotics from reaching the vertebrate nervous tissue (Pardridge, 2005) (Figure 
1.9A). 
Similarly to the human brain, Drosophila’s brain is efficiently insulated by a blood brain 
barrier, composed of glial cells providing a finely tuned homeostasis of ions and other small 
molecules (Stork et al., 2008) (Figure 1.9B). Drosophila has an open circulatory system and 
its CNS is separated from the heamolymph by means of a thin layer of glia (Stork et al., 
2008). Despite, the topological simplification, Drosophila BBB shows strong evolutionary 
conservation in the chemo-protective mechanisms against foreign substances (Mayer et al., 
2009).  
In particular, one specific cell layer of the fly’s BBB, the subperineural glia (SPG), comprises 
laterally localized homotypic junctional complexes, called septate junctions, which 
components are almost identical to the vertebrate proteins that form the tight junctions  
(Banerjee et al., 2006). In addition to the SPG, the Drosophila CNS is further protected by an 
outer layer of neural lamella, covering both perineurial and subperineurial glia, and an inner 
layer of glial cells, termed cortex. 






Figure 1.8. A graphical representation of substance transport through the BBB  
Substances can be transported through transcellular lipophilic or paracellular transport through the 
BBB depending on their size and solubility. Small molecules are actively expels though transporter-







Figure 1.9. A graphical representation of the blood brain barrier   
(A) The mammalian BBB is comprised of endothelial cells connected via tight junction. Polyglycans, 
MRPs and OATPs actively transport substances between the blood and endothelial. Astrocytes 
encapsulate the endothelial layer. (B) The BBB in Drosophila separates the neuronal cortex from the 
hemolymph. It is comprised of a layer of subperineural glia (SPG). Glial cells are connected via 
septate junctions. MDR65 transports substances out of the SPG into the hemolymph.  
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Schwabe et al., 2005), however, increased permeability has not yet been fully characterised 
in insects. Loss of function alleles that compromise the integrity of the fly BBB have been 
mapped to the moody gene which is important for the formation of septate junctions in the 
SPG and to the gcm gene which knockout causes a complete loss of the BBB (Daneman and 
Barres, 2005). Furthermore, important for the formation of septate junctions are Neurexin 
IV, Contactin, Coracle, Neuroglian, Na+/K+ ATPase, Glioactin and Claudin-like proteins: 
Sinous and Megatrachea (Stork et al., 2008, Daneman and Barres, 2005).  
Drosophila and mammalian systems have shown to exhibit glial differentiation directed by 
similar molecular mechanisms. Glial differentiation is dependent on regulation of pre-
mRNA splicing in both the systems (Stork et al., 2008) such as dysmyelination phenotype in 
mice and disrupted glial differentiation was found in response to mutation in splicing 
regulator Quaking gene (Hardy, 1998) and Drosophila ortholog HOW (Edenfeld et al., 






The complexity of alternative splicing predisposes the process to be susceptible to 
interference with xenobiotics, however, that has not been shown in vivo in the nervous 
system. Roles of ELAV members during nervous system development and neurotoxicity 
derived from misregulation of RNA processing remain elusive. Roles of Drosophila 
transporters in drug absorption and excretion are not well understood. 
 
 
The aims of my thesis are: 
(1) To characterize mutant phenotypes for elav, fne and Rbp9.  
(2) To identify genetic conditions for drug transport to perform a neurotoxic screen 
effectively in Drosophila. 
(3) To develop a tool to assess drug interference with neuronal ELAV-mediated splicing. 




Chapter 2: Materials and methods 
 
 
2.1. Molecular Biology 
2.1.1 Genomic DNA preparation 
Genomic DNA for cloning was extracted from 20 healthy wild type (CS) adults, which were 
shock-frozen in liquid Nitrogen and homogenized in 200 µL of extraction buffer (100 mM 
NaCl, 10 mM Tris-HCl (pH 7.5), 1 mM EDTA). The mix was subsequently adjusted with 
1% SDS and 1 mg/µL Proteinase K. The homogenisation mix was incubated at 55°C for 4 
hours. DNA was extracted by adding an additional 200µL of extraction buffer and 1 volume 
of Phenol/Chloroform/Isoamylalcolhol (50:49:1) mix. This was spun at 16000 rpm for 5 
minutes to form a biphasic mixture, where nucleic acids partition into the upper aqueous 
phase and proteins partition into the bottom organic phase. The upper phase was transferred 
into a new eppendorf and purified by adding an additional 200 µL of extraction buffer and 1 
volume of Chloroform/Isoamylalcolhol (49:1), to remove any remaining phenol. The 
mixture was spun at 16000 rpm for 5 minutes to separate the aqueous and organic phases. 
The aqueous phase was transferred into a new eppendorf and DNA was precipitated with 1 
µl of glycogen and 2.5 volumes cold ethanol for 5 minutes at room temperature and later 
centrifuged for 5 minutes at 16000 rpm. The supernatant was discarded and the DNA-
containing pellet was washed with 750 µL of 70% Ethanol, air dried and dissolved in 100 µL 
of Tris-EDTA buffer (TE) for better solubilisation and protection of DNA from degradation.  
 
For quick amplification (as for single fly PCR) tissue was prepared from a single male fly 
transferred to standard 250 µL microtubes and frozen at -20°C for half an hour. 200 µL of 
Isopropanol was added and incubated at room temperature for one hour. The liquid was 
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removed via SpeedVac for 30 minutes. PCR mix was added immediately.  
 
2.1.2. Polymerase Chain Reaction (PCR) 
DNA was amplified from a genomic, cDNA or plasmid source. When high fidelity was not 
required, DreamTaq DNA polymerase from Fermentas (5000 U/ml) was used. For cloning, 
however, high fidelity is essential and the proofreading Phusion polymerase from Finnzymes 
(100 U/50µL) was used. 
 
For quick amplification from genomic DNA, as in the case of validating fly strains, the 
single fly PCR protocol was used. The PCR mix was added directly to the dry fly tissue. 
Reactions were of a total volume of 50 µL: 5 µL of 10xTaq buffer including 20 mM MgCl2, 
1µL dNTP (10 mM), 1 µl of each primer (20 µM), 0.25 µl DreamTaq Polymerase (5 U/µL), 
H2O (41.75 µL).  
The PCR program used was as following: initial denaturation was for 30 seconds at 94°C; 
followed by 30 cycles of a 30 seconds denaturation step at 94°C, 45 seconds of an annealing 
step at Tm-3°C (where the lower Tm of the two primers was taken) and an extension step of 
1 minute/kb at 72°C; final extension was at 72°C for 5 minutes. 
 
When amplifying from a cDNA source (as in the case of semi-quantitative PCR), the above 
PCR mix was used together with 2 µL of cDNA.   
 
For cloning, PCR fragments were amplified from plasmid sources with proofreading Phusion 
Polymerase. The PCR mix per reaction was: 100-500 ng/µL of DNA template, 10 µL of 
5xPhusion Buffer HF, 1µL dNTP (10 mM), 1 µL of each primer (20 µM), and 0.5 µL of 
Phusion Polymerase (0.02 U/µL) and water to bring up the reaction mix to a final volume of 
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50 µL.  
The PCR program used was as following: initial denaturation was for 30 seconds at 98°C; 
followed by 30 cycles of a 30 seconds denaturation step at 98°C, 40 seconds of an annealing 
step at Tm-3°C (where the lower Tm of the two primers was taken) and an extension step of 
15 sec/kb at 72°C; final extension was at 72°C for 5 minutes. 
 
2.1.3. Electrophoresis and agarose gel preparation 
Agarose gel electrophoresis was used to visualize PCR products, determine sizes of DNA 
fragments and as part of the DNA purification procedures of digested fragments used for 
cloning.  
A stock solution of 50xTAE (Tris-acetate–EDTA) buffer was prepared by dissolving 24.2% 
Tris base, 10% 0.5 M EDTA pH 8.0 and 5.71% glacial acetic acid in ionized water. The pH 
was adjusted to 8.0 with HCl. Working buffer solution was 1xTAE buffer, containing a final 
concentration of 40 mM Tris, 20 mM acetic acid, and 1 mM EDTA. 
9x DNA loading buffer stock was prepared from 50% glycerol, 10% 0.5 M EDTA (pH 8-
8.5), 1% 50 mM Tris (pH 7.5), 0.5% xylene cyanol FF and 0.5% bromophenol blue. 1xDNA 
loading buffer was used for loading of samples.  
To visualize DNA fragments smaller than 500 bp 2.5% agarose gel was used, whereas, for 
fragments larger than 500 bp, 1% agarose gel was used. Ethidium bromide (0.00004%) was 
added before the gel set. Gels were run at 150-180 V for 30-40 minutes.  
 
2.1.4. Media preparation 
Luria Bertani (LB) medium was prepared by dissolving 1% peptone, 0.5% yeast extract and 
0.5% sodium chloride in ddH20. The pH was adjusted to 7.0 with 5 M sodium hydroxide. 
The medium was then autoclaved. 
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2YT medium was prepared by dissolving 1.6% peptone, 1% yeast extract and 0.5% sodium 
chloride in ddH20. The pH was adjusted to 7.0 with 5 M sodium hydroxide. The medium 
was then autoclaved.  
SOC medium was prepared by dissolving 0.5% yeast extract, 2% tryptone, 10 mM NaCl, 2.5 
mM KCl, 10 mM MgCl2, 10 mM MgSO4 and 20 mM glucose. The medium was then 
autoclaved. 
LB plates were made by adding 1.5% technical quality agarose to LB medium and 
autoclaving.  
Ampicillin was the antibiotic used to provide selection in all cloning procedures. It was 
stored at 50 mg/ml stock solution at -20°C. Ampicillin at a final concentration of 100 µg/ml 
was added to the medium (+/- agarose) after it cooled to < 50°C.  
  
2.1.5. Preparation of electro-competent cells 
Frozen glycerol stock of DH5α strain was stroked onto an LB antibiotic free plate and grown 
overnight. Single colony was picked and inoculated in 10 ml of LB and cultured overnight at 
37°C with vigorous shaking. 1 L of LB media was inoculated with 1/100 (10 ml) of the fresh 
overnight culture at 37°C with vigorous shaking to OD600 of 0.5-0.7 (approximately 4.5 
hours). The following was carried out at 4°C: cells were harvested by centrifugation at 3000 
rpm for 15 minutes; the supernatant was removed and the bacterial pellet was resuspended in 
1 L of ice-cold 10% glycerol; this was centrifuged at 5000 rpm for 15 minutes; the latter was 
subsequently repeated with 0.5 L and 250 ml of ice-cold 10% glycerol; the pellet was 
resuspended in a final volume of 3.5 ml of ice-cold 10% glycerol where final concentration 
of cells was approximated to be 1-3x1010 cells/ml. Aliquots of 100 µL were stored at -80°C.  
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2.1.6. Primer phosphorylation 
17 µL of 20 µM primers were phosphorylated in a total volume of 20 µl with 1 µL (10 U) of 
T4-PNK from NEB and 2 µL of 1xT4 DNA ligase buffer also from NEB (50 mM Tris-HCl, 
10 mM MgCl2, 10 mM DTT, 1 mM ATP, pH 7.5). Phosphorylation was carried out at 37°C 
for 30 minutes.  
 
2.1.7. Cloning with oligos 
Oligos were diluted to a working solution of 20 µM concentration. Oligos were 
phosphorylated with T4 PNK in ligase buffer (containing ATP) in a 10 µl reaction volume. 
Next, oligos were mixed 1:1 from the phosphorylation reaction and boiled for 5 minutes and 
left to anneal slowly by cooling down. For ligation molarities were adjusted accordingly. For 
example, 150 ng of a 3 kb vector is 75 fmol and was ligated with 0.5 µl of the annealed 
oligos (2.5 pmol). 
 
2.1.8. Purification of PCR products 
PCR products for cloning (50 µL) were brought to a final volume of 200 µl with ddH2O. 1 
volume (200 µL) of phenol/chloroform/isoamyl alcohol (50:49:1) was added and the mix 
was centrifuged at 16000 rmp for 5 minutes. The top aqueous phase was transferred into a 
new eppendorf and an equal volume of chloroform/isoamyl alcohol (49:1) was added. The 
mix was centrifuged at 16000 rpm for 5 minutes. DNA was precipitated using 0.3 M sodium 
acetate and 2.5 volumes of absolute ethanol at -80°C for 10 minutes. The mix was then 
centrifuged at 16000 rpm for 30 minutes. The supernatant was discarded and the DNA pellet 
was washed 3 times with 750 µl of 70% ethanol at 16000 rpm for 5 minutes. The pellet was 
air dried and resuspended in ddH2O. 
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2.1.9. Cloning with restriction enzymes 
Constructs were cloned by conventional ways. Plasmids and PCR products were cut with 
restriction enzymes from NEB, unless specified. When cloning of PCR products, DNA was 
amplified with primers incorporating the desired restriction enzyme. Enzymatic digests were 
set according to the NEB catalog recommended fold over-digestion so that at least 95% of 
fragments could be ligated and recut.  Digestion reactions were carried out in 50 µL volumes 
with 50 ng of final DNA amount, 1x of the appropriate buffer and 1x BSA (Bovine Serum 
Albumine) in accordance to NEB recommendations. Digests were carried out at 37°C. 
Whenever, double digests could not be performed in a single step, digestion was carried out 
in two sequential reactions with phenol-chloroform purification (2.1.8) in between.  
Once digestion was complete, the enzymes were inactivated with 100 µL of 
phenol/chloroform/isoamyl alcohol (50:49:1). The mix was spun at 16000 rpm for 5 minutes 
and the upper aqueous phase was loaded on a 1% agarose gel.  
Cut fragments and vectors were purified using a Fermentas Silica Bead DNA Gel Extraction 
Kit according to the manufacturer’s instruction. DNA was eluted in 30 µL of ddH2O. 
 
To determine approximate DNA yield, purified DNA was run on a 1% agarose gel together 
with a Lambda HindIII-EcoRI ladder (Promega). DNA concentrations were determined by 
comparing the relative intensity of the fragment band to that of the Lambda ladder bands, 
which were readily quantified by the manufacturer.   
 
Equimolar amount of inserts and vector were ligated with 1µL of T4 DNA Ligase (NEB) in a 
10 µL reaction volume with added 1xT4 DNA Ligase buffer. Ligation reactions were 
incubated at 16 °C overnight.  
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2.1.10. Electro-transformation of E. coli 
Ligations were transformed into electro-competent E.coli (DH5α strain) by electroporation. 4 
µl of the ligation mix was dialyzed through 0.025 µm, Millipore membrane to remove 
excess salts for 30 minutes. The membrane was washed 3 times with 8 µl of water. Electro-
competent cells were thawed on ice. The electroporation mix consisted of 30 µL of cells, 28 
µl of ligation and was brought up to a final volume of 90 µl by adding water. Electroporation 
was performed in 1 mm electroporation cuvette in a pulser apparatus (Biorad) by applying 
an electrical pulse of 2 kV at capacity of 25 µF and resistance of 200 Ω. Successful electro-
transformation was confirmed by a time constant higher than 4.5. Bacteria were left to 
recover for 40 minutes in 500 µl of SOC media and plated on LB ampicillin positive plates, 
and inoculated overnight at 37 °C. 
 
2.1.11. Identification of correct clone 
DNA from electro-transformed colonies was isolated by a boiling mini-prep method. Single 
colonies were inoculated in a 3 ml 2YT shaking overnight culture at 37°C and processed the 
following day. Bacteria were span for 5 minutes at 300 rpm and pellets were resuspended in 
400 µl of STET (8% sucrose, 0.5% Triton X-100, 50 mM EDTA pH8.0, 50 mM Tris-Cl, pH 
8.0). Bacteria were lysed with 4 mg/ml of lysozyme for 5 minutes followed by boiling the 
tubes for 1-3 minutes. Cell debris was removed after 10 minutes centrifugation at 15000 rpm 
and the supernatant containing the DNA was precipitated with 3 M NaAc and RNase A 
treated at 50 µl/ml for 5 minutes. 1 volume of isopropanol was used to precipitate DNA and 
the pellet was washed once with 70% Ethanol. Lastly, pellets were dissolved in 50 µl of TE 
buffer. 
An analytical digest of 1 hour in a volume of 20 µl and 5 U of enzyme was carried out to 
determine the correct clone. The number of mini-preps screened per cloning procedure 
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varied. For simpler experiments 12 colonies were sufficient, in other more complicated 
scenarios up to 72 colonies were screened. From the correct clone a starter of 3 ml was set for 
5 hours out of 1ml was inoculated in 33 ml of LB overnight.  
DNA from the overnight culture was extracted with a QIAGEN Plasmid Midi Kit and eluted 
in a final volume of 100 µl in TE Buffer. 
 
2.1.12. DNA sequencing 
Midi-preps of constructs, obtained through PCR amplification of the insert, were sent for 
sequencing at the Biosciences sequencing facility. The amounts of plasmid DNA required for 
sequencing was given according to the sequencing facilities guidelines together with 0.3 µl of 
the appropriate sequencing primer in a total of 11 µl reaction volume.  
 
2.1.13. Cloning strategies 
All primer sequences used for the cloning strategies are given in Table 2.1.  
 
2.1.13.1. Generation of pUASTattB-elav/Hu constructs 
Targeted overexpression of Drosophila and human ELAV proteins and their modified forms 
was achieved by generation of UAS constructs from a pUAST vector that required certain 
modifications. The PhiC31 transformation platform was used to integrate all constructs into 
the same cytological landing site, however, the pUAST vector at hand (named pUAST-MOD3 
and provided by Matthias Soller) lacked an attB site, which is necessary for PhiC31-mediated 
integration of transgenes into a predetermined docking site in the fly genome. An attB site 
was amplified with attB PstSpeAge F1 forward and attB Xba R1 reverse primers. The attB 
amplicon was digested BamHI/SphI and cloned into BglII/SphI sites of the pUAST MOD3 
Table 2.1. Primers used for cloning. Restriction site sequence is indicated in bold. 
Original name Sequence (5′ to 3′) Description 
pUAST cloning  
pUAST SEQ FOR in 
attB 
GAAGCCCTCGCCCTCGAAACC To sequence UAS sequence downstream 
of attB site. Forward primer 
pUAST SEQ FOR in 
ADH 
GAAGTCACCATGTCGACCG To sequence insert sequence downstream 
of Adh. Forward primer 




To sequence insert upstream of SV40 
trailer. Reverse primer 
pUAST EZ F1 CCCTTAGCATGTCCGTGGGGTTTGAA Upstream of attB site. 
elav TAG R1 CCGCGGCCACCGCTTGCTGTGTC To amplify upstream of elav sequence. 
Reverse primer 
attB PstSpeAge F1 ATCCTGCAGAAACTAGTATACCGGTGACGATGTAGGTCA
CGGTCTCGAAG 
To amplify attB site, Forward primer 
attB Xba R1 GATTCTAGATGCCCGCCGTGACCGTCGAGAAC To amplify attB site, Reverse primer 
Adh Met linker C AATTCGAGATCTAAAGAGCCTGCTAAAGCAAAAAAGAAG
TCACCATGTCGACCGGC 
To construct Adh Kozak sequence. Has 
partial EcoRI and XhoI sites. Forward 
strand. 
Adh Met linker D TCGAGCCGGTCGACATGGTGACTTCTTTTTTGCTTTAGC
AGGCTCTTTAGATCTCG 
To construct Adh Kozak sequence. Has 
partial EcoRI and XhoI sites. Reverse 
strand. 
NLS Linker C AATTCGAGATCTAAAGAGCCTGCTAAAGCAAAAAAGAAG
TCACCATGTCGACCGGCGTGAGCCGCAAGCGCCCCCG
CCCCGGC 
To make Adh Kozak NLS sequence. Has 
partial EcoRI and XhoI stites. Forward 
strand. 
NLS Linker D TCGAGCCGGGGCGGGGGCGCTTGCGGCTCACGCCGGT
CGACATGGTGACTTCTTTTTTGCTTTAGCAGGCTCTTTAG
ATCTCG 
To make Adh Kozak NLS sequence. Has 
partial EcoRI and XhoI stites. Reverse 
strand 
 
Fne Nhe I  HindIII 
FOR 
CATGGCTAGCAAGCTTGACCAACGCCATGGATATTG 5′ of Fne just after ATG. Forward primer 
Table 2.1. Continued 
 
Fne Xba REV CAGGTCTAGACTAAGTGGTTTTGGTCTTGTTAG 3′ of Fne just after TAG. Reverse primer 
Fne Sac II Rev 
 
CGGAGGGCAGAGCTCCGGCCAAAC Reverse primer in Fne used to make ΔOH. 
Has partial SacII site.  
Fne SacII FOR CGGGTCGCATTCTATTGGCCAATTCGATTTTACCGGGAA
ATGC 
Rorward primer in Fne used to make ΔOH. 
Has partial SacII site. 
RBP9 NheI HindIII 
FOR 
CTGCGCTAGCAAGCTTGGTCGAGGGTCAGACAGC 5′ of Rbp9 just after ATG. Forward primer 
RBP9 Xba REV CTCGTCTAGATTACGTTTGCTTGTTCTTGTTGGTC 3′ of Rbp9 just after TAG. Reverse primer 




5′ of HuR just after ATG. Forward primer 
HuR Xba REV CTAGTCTAGATTATTTGTGGGACTTGTTGGTTTTGAAGG 3′ of HuR just after TAG. Reverse primer 
HuB HindIII Blunt FOR 
 
TGGAAACACAACTGTCTAATGGGCCAAC 5′ of HuB just after ATG. Forward primer 




3′ of HuB just after TAG. Reverse primer 





5′ of HuC just after ATG. Forward primer 




3′ of HuC just after TAG. Reverse primer 





5′ of HuD just after ATG. Forward primer 
HuD Xba REV 
 
CTAGTCTAGATCAGGACTTGTGGGCTTTGTTGG 3′ of HuD just after TAG. Reverse primer 
UASelav A Xba CCCAAATGGAAGTGGACAAGGACGCAGCGGGAGCACCA
GCAACCACAACCCATTAT 
To construct 3′ of Elav sequence. Has 
partial XbaI site. Forward strand. 
 
Table 2.1. Continued 
 
UASelav B Xba CTAGATAATGGGTTGTGGTTGCTGGTGCTCCCGCTGCGT
CCTTGTCCACTTCCATTTGGG 
To construct 3′ of Elav sequence. Has 
partial XbaI site. Reverse strand 
elavS472D R CCGCTCTACTTGGCTTTGTTGGTCTTGAAGTCGACCTGC
AGCACCCGATTG 
Introduce a phosphomimetic site at S472 by 
substitution with a D. Reverse primer 
Fne REV ex1 
CONFIRM 
GCGATCGCATCTCCTCCTGCG Reverse primer. Confirms Fne with pUAST 
SEQ FOR in ADH 
FNE FOR Hinge 
CONFIRM 
GGTACTCACCGCTGGCTGGCG Forward primer. Confirms ΔOH with pUAST 
SEQ REV in SV40. 
RBP9 REV ex1 
CONFIRM 
CTGACTGTTGGTCACATTGTTGGC Reverse primer. Confirms Fne with pUAST 
SEQ FOR in ADH 
HuR REV CONFIRM CCAATGCTGCTGAACAGGCTTCG Reverse primer. Confirms HuR with pUAST 
SEQ FOR in ADH 
HuB REV CONFIRM GGACTCTATCTCGCCAATGCTC Reverse primer. Confirms HuB with pUAST 
SEQ FOR in ADH 
HuC REV CONFIRM 
 
GTAGGTAGTTGACGATGAGGTTGGTC Reverse primer. Confirms HuC with pUAST 
SEQ FOR in ADH 
HuD REV CONFIRM CCAATGCTCCCGAAGAGACTCC Reverse primer. Confirms HuD with pUAST 
SEQ FOR in ADH 
ELAV REV CONFIRM CTGTTGCACCTGTTGCTGCTGC Reverse primer. Confirms Elav with pUAST  
NLS REV CONFIRM GCGGGGGCGCTTGCGGCTCAC Reverse primer. Confirms Elav with pUAST 
SEQ FOR in attB 
C4MM cloning  
F6i 
 
CGCGGAGAAATGAGTTTACGAG Amplifies ewg exon J before the MfeI site. 
Forward primer 
ewgVSV R3 NheI ATCGGTGTAGCTAGCTTGTTCCATAATAATCGTGTC
TTCGGACT 
Amplifies end of ewg exon J. Reverse 
primer 
ewg UTR F Stu 
 
CCTAAGGAGCCCATAGAAGGCATGATTTCG Amplifies beginning of ewg 3′ UTR. Forward 
primer. Has partial StuI site. 
 




GGAAACAGCTATGACCATG Amplifies 3′ downstream of ewg 3′ UTR. 
Reverse primer 






5′ of GFP1 just after ATG. Forward primer 




3′ of GFP1 just after TAG. Reverse primer. 
Has partial StuI site. 




5′ of GFP1 just before ATG. Forward 
primer 
GFP2 R PspOMI GCTGGGCCCAAGATCTGAGTACTTGTACAGCTCG 3′ of GFP2 just before TAG. Reverse 
primer.  
GAL4 DB NOT F CAACTAGCGGCCGCCAAGCTACTGTCTTCTATCGAACAA
GC 
5′ of Gal4 BD. Forward primer 
GAL4 DB ACC R CAAAGGTCAAAGACAGTTGACTGTATCGGGTACCGTATC 3′ of Gal4 BD. Reverse primer. 




5′ of Gal4 AD. Forward primer 
GAL4A R STU CCTATTACTCTTTTTTTGGGTTTGGTGGGGTATC 3′ of Gal4 AD. Reverse primer. 
GAL4 DB NOT F CAACTAGCGGCCGCCAAGCTACTGTCTTCTATCGAACAA
GC 
5′ of Gal4 BD. Forward primer 
GAL4 DB ACC R CAAAGGTCAAAGACAGTTGACTGTATCGGGTACCGTATC 3′ of Gal4 BD. Reverse primer. 








vector to generate pUAST MOD3-attB. Ligation between BamHI and BglII caused deletion of 
the restriction sites (Figure 2.1).  
The original pUAST vector also lacked a polyA trailer, which promotes export of mRNA to 
the cytoplasm and its translation as well as protects the mRNA from degradation. An SV40 
PolyA trailer was cloned with EcoRI/StuI into pUAST MOD-attB to generate pUAST MOD-
aatB-SV40PolyA (Figure 2.2). Hereafter, pUAST MOD-aatB-SV40PolyA will be referred to 
as pUAST-attB only.  
To make pUAST-attB-elav and pUASTattB-elavNLS, a fragment, containing the elav ORF 
(with two HA tags at the 5! end) and 60 nt of the elav3!UTR, was cloned into pUAST-attB 
(Figure 2.3). Additionally, a Kozak sequence, important for translation initiation that has the 
consensus (gcc)gccRccAUGG, and a Nuclear Localization Signal (NLS) were incorporated as 
oligos and were cloned 5! of the elav ORF. The Kozak sequence was made of Adh Met linker 
C and Adh Met Linker D, and the NLS sequence was made of NLS linker C and NLS linker D. 
The phosphorylated and annealed oligos incorporated 5! an EcoRI and 3! an XhoI site. The 
elav fragment was digested XhoI/XbaI. The oligos and the elav fragment were cloned 
EcoRI/XhoI/XbaI in a three way ligation into EcoRI/XbaI sites of pUAST-attB to generate 
pUASTattB-elav and pUASTattB-elavNLS. 
Modified versions of the elav ORF, elavΔOH and elav-13, were cloned XhoI/XbaI into 
pUASTattB-elav and pUASTattB-elavnls to generate pUASTattB-elavΔOH, pUASTattB-elavnls 
ΔOH, pUASTattB-elav-13 and pUASTattB-elavnls-13 (Figure 2.4). 
To substitute Serine at position 472 with Aspartate, the amino acid change was incorporated 
into the reverse primer elavS472D where AGC (Ser) was changed to GAC (Asp). This 
substitution also created a SalI site, which was later used for screening the correct clones. 
elavS472D was amplified with pUAST SEQ FOR in ADH forward primer and the 




Figure 2.1. Making of pUAST MOD3-attB 
(A) Cloning strategy for introducing an attB site into an empty pUAST MOD3 vector to make 
pUAST MOD3-attB. (B) Sequence map of pUAST MOD-3-attB. Correct clones were screened 
with SacII and PvuII which resolved in 6628, 483 and 1372 bp fragments. To validate, the 






Figure 2.2. Making of pUAST MOD3-attB SV 40PolyA 
(A) Cloning strategy for introducing an SV40 PolyA trailer into previously obtained pUAST 
MOD3-aatB to generate pUAST MOD3-attB-SV40 PolyA (pUAST-attB) (B) Sequence map of 
pUAST MOD-3-attB- SV40 PolyA. Correct clones were screened with PvuII which resolved in 






Figure 2.3. Making of pUAST-attB-elav+/- NLS 
(A) Cloning strategy for introducing ADH Kozak (in blue) and NLS (in red) sequences together 
with elav ORF into pUAST-attBto generate pUAST-attB-elav+/- NLS.  (B) Sequence map of 
generate pUAST-attB-elav+/- NLS. Correct clones were screened with firstly with HindIII 
(introduced in elav) which resolved 6863, 3037 and 836 bp fragments.; secondly, with EcoRI and 
BamHI which resolved in 8427, 1424 and 1066 bp fragments. The MCS was disrupted and the 




Figure 2.4. Making of  pUAST-attB-elav MOD+/- NLS 
(A) Cloning strategy for substituting wild type elav ORF with elav MOD, which stands for 
elav∆OH and elav-13 sequences, into pUAST-attB-elav +/- NLS to generate pUAST-attB-ELAV +/-NLS 
∆OH and pUAST-attB-ELAV+/-NLS -13.  (B) Sequence map of pUAS-attB-elav MOD+/- NLS. Correct 
clones were screened with EcoRI and BamHI which resolved in 8427, 1424 and 1066 bp 
fragments. To verify successful insertion of elav∆OH, those clones were further digested with NruI 
(characteristic of the ∆OH) and EcoRI to resolve 5912, 3764 and 1239 bp fragment. To verify 
successful insertion of elav -13, positive clones from the first digest were sent for sequencing.  
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elavS472D fragment lacked the elav3!UTR portion present in all the other elav constructs. 
elav3!UTR was reconstituted with a pair of phosphorylated oligos (UASelav A Xba and 
UASelav B Xba) which had an XbaI site at the 3!end.  elavS472D was cloned in a three way 
ligation with elav3!UTR XhoI/Blunt/XbaI (blunt ligation between elavS472D  and elav3!UTR ) 
into XhoI/XbaI sites of pUASTattB-elav and pUASTattB-elavNLS  to generate pUASTattB-
elavS472D pUASTattB-elavNLS S472D (Figure 2.5). 
pUAST-attB-fne/rbp9/HuR/HuB/HuC/HuD were cloned in a similar way by three way 
ligation between the UAS sequence, the insert, and the vector (Figure 2.6). The UAS sequence 
was amplified from pUAST-attB-elav with pUAST EZ F1 forward primer and elav TAG R1 
reverse primer, there the latter annealed to the elav sequence 500 bp downstream of the two 
HA tags. The insert (fne/rbp9/HuR/HuB/HuC/HuD) was amplified with a FOR NheI, HinDIII 
forward primer and a Rev Xba reverse primer. The downstream HindIII site was chosen for 
sticky end ligation between the UAS and insert sequence (unlike XhoI which was used in the 
previous cloning strategies) to avoid incorporation of the HA repeated sequence into a 
primer, which would result in PCR amplification ambiguity. The UAS amplicon was digested 
SphI/HindIII and the insert amplicon was digested HindIII/Xba, and were cloned 
SphI/HindIII/XbaI into SphI/XbaI sites of pUAST pUAST-attB-elav to generate pUAST-attB-
fne/rbp9/HuR/HuB/HuC and HuD constructs. 
 
2.1.13.2. Generation of C4MM-tcgER constructs 
To obtain the final C4MM-tcgER::GFP construct  a number of sub-cloning steps were 
undertaken in pBluescript SK+ vector (named SC3N) and the final construct was then sub-
cloned into the pCaSpeR transformation vector (named C4MM).  
The starting construct was SC3N-Δ7-vir (Haussmann et al, 2011), which contained a D. 





Figure 2.5. Making of pUAS-attB -elav+/- NLS  S472D 
(A) Cloning strategy for substituting wild type elav ORF with elavS472D, into pUAST-attB-elav+/- 
NLS to generate pUAST-attB-elav+/-NLS S472D.  (B) Sequence map of pUAST-attB-elav+/- NLS S472D. 
Correct clones were screened with SalI (where the S472D generates an additional SalI site), 
which resolved in 5659, 2904, 1495 and 859bp fragments. To verify the elavS472D sequence, 




Figure 2.6. Making of pUAST-attB- fne/rbp9/HuR/HuB/HuC/HuD 
(A) Cloning strategy for substituting wild type elav ORF with fne, rbp9, HuR, HuC, HuD, into 
pUAST-attB-elav to generate pUAST-attB constructs for all inserts. Since there was a HindIII site 
in the HuB ORF, pUAST-attB-HuB was cloned blunt between the UAS and the HuB sequences. 
After digestion of the UAS PCR product with HindIII, the site was made blunt by T4 fill in. HuB 
was amplified with a 5´phosphorylated forward primer beginning with a T, which reconstituted 
the HinDIII site upon ligation. (B) Sequence map of pUAST-attB-insert. Correct clones were 
screened with HindIII and Xba, which resolved in 5567, 3037, ~1000 and 771 bp fragments. In 
the case of vector background from the ELAV backbone, the bands resolution will differ in the 
~1000 fragment, which in the case of ELAV is 1500 bp. All constructs were sequenced for the 
UAS and ORF insertion. 
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Firstly, I exchanged virilis exon J from SC3N-Δ7-vir with the melanogaster exon J (Figure 
2.7 A). The latter was amplified with F6i forward primer and ewg VSV R3 NheI reverse 
primer, and cloned MfeI/NheI into SC3N-Δ7-vir to generate SC3N-Δ7-EWGexJ. 
The shorter Δ7 intron was replaced with the wild type ewg inton 7 sequence (m2t1) by 
KpnI/MfeI cloning into SC3N-Δ7-EWGexJ to generate SC3N-m2t1-EWGexJ (Figure 2.7 B). 
Next, two copies of GFP were cloned sequentially in frame downstream of exon J (Figure 2.8 
C and D). The first GFP was amplified with Flag GFPI F NheI PspOMI forward primer and 
GFPI R StuI reverse primer. The GFP amplicon was cloned NheI/StuI into SC3N-m2t1-
EWGexJ to generate SC3N-m2t1-EWGexJ 1xGFP. The second copy of GFP was cloned 
upstream of the first using the NheI and PspOMI sites incorporated in Flag GFPI F NheI 
PspOMI. This GFP was amplified with GFPII NheI EcoRV forward primer and GFP II R 
PspOMI reverse primer and cloned NheI/PspOMI into SC3N-m2t1-EWGexJ1xGFP to 
generate SC3N-m2t1-EWGexJ2xGFP. Positive clones were later screened with EcoRV, 
which was incorporated into the GFPII NheI EcoRV primer. To generate SC3N-m2t1-EWG 
Δ7exJ2xGFP identical cloning strategy as for generation of SC3N-m2t1-EWGexJ2xGFP was 
undertaken starting from SC3N-Δ7-EWGexJ. To generate SC3N-m2t1-EWGexJGAL4 split 
Gal4 construct, Gal4 BD was amplified with Gal4 DB Not F forward primer and Gal4 DB 
Acc R reverse primer and was cloned into with NotI/Acc65 in SC3N-m2t1-EWGexJ2xGFP to 
generate SC3N-m2t1-EWGexJBD. The Gal4 AD was amplified with Flag Gal4A F Nhe BsiW 
forward primer and Gal4A R Stu reverse primer and was cloned NheI/StuI into SC3N-m2t1-
EWGexJBD to generate SC3N-m2t1-EWGexJBDAD. 
Lastly, SC3N-m2t1-EWGexJ 2xGFP was sub-cloned into C4MM using Acc65I/SpeI to 
generate the final C4MM-m2t1-EWGexJ 2xGFP construct, which, hereafter, will be 









Figure 2.7. Cloning strategy of tcgER::GFP 
To generate tcgER::GFP a series of cloning steps were performed in an SC3N backbone to obtain 
SC3N m2t1 ewg exJ 2xGFP, for short  hereafter tcgER::GFP, which was later sub-cloned into a 
C4MM transformation vector. (A) Exchange of D. virilis ewg exon J with exon J from D. 
melanogaster. (B) Exchange of a deletion ∆7 in ewg intron 6 with wild type intron sequence-
m2t1. (C) Cloning in frame first copy of GFP after exon J- GFP I. (D) Cloning in frame second 






Figure 2.8. Obtaining C4MM tcgER::GFP fly transformation vector 
(A) Cloning strategy for sub-cloning SC3N tcgER::GFP into a fly transformation vector making 
final C4MM tcgEG::GFP to be used in later drug screens. (B) Sequence map of C4MM 
tcgER::GFP. Positive clones were identified via an EcoRV digest which resolved 7307, 4045, 
2897, 2135, and 932 bp fragments.  
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2.1.14. RNA isolation 
Total RNA was isolated from larval or adult fly source. The tissue was homogenized in 400 
µl of Trizol (Sigma). Extraction of RNA was with 200 µL of Chloroform:Isoamyl alcohol 
(49:1). The mix was kept on ice for 5 minutes until the aqueous and lipid phase separated. 
The mixture was centrifuged at 16000 rpm for 10 minutes. Then, 250 µL of the aqueous 
phase (containing RNA) was transferred into a new eppendorf. Nucleic acids were 
precipitated with 1 µl of glycogen and 250 µL of Isopropanol. The mix was centrifuged at 
16000 rpm for 10 minutes. The supernatant was discarded and the pellet was washed with 
750 µL of 70% Ethanol at 16000 rpm for 10 minutes. The supernatant was removed and the 
RNA pellet was left to air dry. The pellet was dissolved in 10 µL DEPC treated de-ionized 
water and stored at -20°C. DEPC treated water was made by adding 0.1% (v/v) DEPC to de-
ionized water kept for 2 hours at room temperature with intermittent shaking. DEPC was 
inactivated though autoclaving. 
 
2.1.15. Reverse-Transcription PCR (RT PCR) 
The RNA extraction protocol also isolates a fraction of genomic DNA. To eliminate genomic 
contamination all RT reactions were DNase treated with DNaseI (Invitrogen). To protect 
RNA from the ribonuclease activity of RNases, samples were also treated with an RNase 
inhibitor- RNasein (Promega). 
Prior to RT, 7.4 µL of isolated RNA was incubated in a total volume of 11 µL with 1 µL of 
DNase I, 1.1 µL of 10x DNaseI buffer, 1 µL DTT (10 mM) and 0.5 µL of RNasin for 15 
minutes at room temperature. 1 µL of 25 mM EDTA was used to chelate the Mg2+ from the 
DNaseI buffer. The reaction was carried out for 2 minutes at room temperature.  
Samples were heated at 70°C for 15 minutes. The RT reaction was primed with 1 µL of  
OligodT (0.5 µg/µl) for at 50°C for 10 minutes. In the same time as adding the primer, the 
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RT mix (without Superscript) was added. It comprised 1 µL of 10x RT buffer (200 mM Tris-
HCl, 500 mM KCl, pH 8.3), 1 µL of 10 mM DTT, 1 µL of 100 mM MgCl2, 0.5 µL of 
RNAsin and 1 µL of 10 mM dNTPs. RT was carried out at 46ºC for 1 hour with 1 µL of 
Superscript II Reverse Transcriptase (100 U/µL Invitrogen) added in the beginning of this 
step. Final extension was at 70°C for 15 minutes. 
 
2.1.16. Semi-quantitative PCR 
mRNA levels were assessed by semi-quantitative PCR using DreamTaq polymerase. Primers 
used to assess expression levels are given in Table 2.2. 
32P γ-ATP (143 µCi/µl, 6000 Ci/mmol (Perkin Elmer) was used for radioactive labeling of 
forward primers. 10Units of T4 polyunucleotide kinase (T4-PNK) were used to label 10 µM 
primers with 143 µCi 32P γ-ATP in 1x PNK buffer (70 mM Tris-HCl, 10 mM MgCl2, 5 
mM DTT, pH 7.6). The reaction mixture was incubated at 37°C for 30 minutes. Incubating 
the primer mix at 80°C for 10 minutes inactivated the T4-PNK. 
PCR products were resolved on an 8% native polyacrylamide gel. The gel was prepared from 
20% (v/v) of 40% Acrylamide solution (19:1), 20% (v/v) 5x TBE (445 mM Tris-borate, 10 
mM EDTA, pH 8.3), 60% (v/v) H2O, 0.8% (v/v) 10% ammonium persulfate (APS) and 
0.04% (v/v) TEMED. 1 μl of PCR product was mixed with 4 μl of Blue Juice (1:3 in H2O) 
and loaded on the gel. Gels were run at 70 V for 45 minutes in 1x TBE buffer. The gel was 
transferred onto wet filter paper and heat vacuum dried at 85°C for 2 hours. Depending on 
the radioactivity’s rate of decay, the gel was exposed for different times on a Kodak imaging 
screen (Biorad). Exposure was 12 hours for radioactivity as old as its half-life. For every 
extra week, the exposure time was increased by 4 hours. The imaging screen was scanned on 
a molecular imager (Biorad) and the image was obtained through Quantity One software 
(Biorad). The radioactive signal on the imaging screen was erased against a screen eraser 
Table 2.2. Primers used to evaluate expression levels 
Original name Sequence (5′ to 3′) Description 
Ken F1 CATCGTCTGCGAGAACAAAGTAAAGC Forward primer in exon 1 of ken 
Ken R1 GCAGCAGCAGGTCGTGCAGATAGTTC Reverse primer in exon 2 of ken 
Ewg 4F1 ATGGTACAACTGCCCAGGTTCA Forward primer in exon 4 of ewg 
Ewg 5R1 TGAGATCACATTGCTCACCGAA Reverse primer in exon 5 of ewg 
Ewg 6F1 ATATCCCGTTTCGGTGAGCAAT Forward primer in exon 5 of ewg 
Ewg 6R1 CGGAATTAATGGCCTCCATAGC Reverse primer in exon 6 of ewg 




tcgER::GFP specific reverse primer 
Nrg Forward CGGAAAGTACGATGTCCACG Forward primer in constitutive exon 5 of nrg 
Nrg Reverse (3S) TAAATCAAAGTCCTTTGCGTCC Reverse primer in alternative exon 3S of 
nrg 
Nrg Reverse (3L) TGATGCGCCGCAGCGGAATTGT Reverse primer in alternative exon 3L of nrg 
Arm Forward GCAGGATTACAAGAAGCGGCT Forward primer in constitutive exon 4 of 
arm 
Arm Reverse CTCCAGACCCTGCATCGAATC Reverse primer in constitutive exon 6 of 
arm 
OATP 58Db Forward  GCATCCCAGTCTCAGATCGC Forward primer in exon 4 of Oatp58Db 
OATP 58Db Reverse CTCTGTTTGGCCTGCACCG Reverse primer in exon 5 of Oatp58Db 
OATP 58Dc Forward GTGTTGCCTGAAGTTCGTGG Forward primer in exon 5 of Oatp58Dc 




To assess exponential increase of PCR product from a single primer pair 5 µl were taken out 
of the PCR reaction every two cycles. Once, the cycle number where the growth curve 
remained exponential was determined a semi-quantitative PCR at this cycle number was 
performed.  
The average intensity of each band was calculated by using the volume rectangle tool in the 
Quantity One software. It measures the total signal intensity within a defined border drawn 
around the band by adding the intensities of all pixels within the volume boundary 
multiplied by the pixel area (intensity units x mm2).  The background intensity was 
subtracted from the band intensity using the local background subtraction method. This 
method adds the intensities of all pixels in a 1-pixel boundary around the border drawn and 
divides it by the total number of boundary pixels. This gives a measure of the average 
background intensity around each volume drawn, which is then subtracted from the intensity 
of each pixel within the rectangle volume. 
 
2.1.17. Western Blotting 
5-day-old adults were homogenized in 10 µl per fly of 2x sample buffer (125 mM Tris-HCl 
pH 6.8, 4% SDS, 0.01% bromophenol blue, 100 mM DTT, 15% glycerol). Samples were 
freeze-thawed in liquid nitrogen three times and denatured at 95°C for 4 minutes.  
Proteins were resolved on 10% SDS-PAGE gels. The stacking gel was made of 3% 
acrylamide, 125 mM Tris-HCl pH 6.8, 0.1% SDS, 0.1% APS and 0.001% (v/v) TEMED. 
The resolving gel was made of 8% acrylamide, 0.1% ammonium persulphate (APS) and 
0.001% TEMED (v/v) in 1xresolving buffer containing 375 mM Tris and 0.125% SDS (pH 
8.8). Running buffer was made of 25 mM Tris, 191 mM glycine, 0.1% SDS, pH 8.3. The 
samples were run at constant voltage of 20 mA in the stacking gel and 25 mA in the 
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resolving gel. A semi-dry blotting apparatus (Biorad) was used to transfer proteins to the 
nitrocellulose membrane. The transfer was carried out at 0.8 mA/cm2 for 20-30 min and the 
membrane was then air-dried. After re-wetting the nitrocellulose membrane in 1xTBST, it 
was blocked with 5% dry milk dissolved in 1xTBST (0.05% Tween 20 in 1x TBS buffer – 
25 mM Tris, 137 mM NaCl, 2.68 mM KCl, pH 7.4) at room temperature for 30 minutes 
shaking. After blocking, the membrane was incubated in 1x TBST/0.5% dry milk solution, 
containing the primary antibody for two hours on a shaker. After the primary antibody 
incubation, the membrane was briefly washed twice followed by three 10-minute washes in 
1x TBST. Primary antibodies used were as following: mouse monoclonal anti-ELAV (1:20) 
and rat monoclonal anti-HA (1:20). 
The membrane was then incubated in 1x TBST/0.5% dry milk solution, containing a 
peroxidase-conjugated anti-rat or ani-mouse secondary antibody (Amersham) in a 1:10 000 
dilution for 1.5 hours shaking. 
The blot was exposed to an X-ray film and developed by chemiluminescence (ECL Super 
Signal West femto, Thermo Scientific). 
 
2.1.18. Immunohistochemistry 
Brains and imaginal discs from mutant and wild type wandering larvae or adult CNS were 
dissected in 1x PBS; fixed in 4% formaldehyde for 20 minutes; followed by washing with 1x 
PBT for an hour. Blocking and antibody incubation were performed as previously described 
(Mardon et al., 1994). DAPI was used to visualize the nucleus in a concentration of 3 µM for 
15 minutes prior to last washing cycle. Finally, the samples were mounted in Vectashield 
mounting medium and detected using confocal microscopy (Leica DM-RXA, Wetzlar, 
Germany). 
The antibodies used were as following: primary antibodies were rat monoclonal α- HA, 
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mouse monoclonal α- ELAV and rabbit polyclonal α- GFP at concentrations of 1:50, 1:20, 
and 1:100, respectively; secondary antibody were Alexa 488 Goat α- rat, Alexa 647 Goat α- 
mouse and Alexa 546 Goat α- mouse, all at concentrations of 1:250.  
 
2.2. Genetics 
2.2.1. Fly husbandry 
Flies were bred in glass vials containing 10ml of standard agar food medium (8.5% sugar, 
6% cornmeal, 2.5% nipagin, 1% agar in water) and supplemented with dried live yeast for 
better egg laying. Unless indicated, experiments were carried out in 12-hour photoperiods at 
a constant temperature of 25°C and 70% relative humidity. A minimum of two copies per 
stock was kept at room temperature, where alternating copies were transferred into fresh food 
culture every 2 weeks.  
 
2.2.2.   Drosophila strains  
Strains used in this study are given in Table 2.3.  
 
2.1.3. Genetic Crosses 
Standard genetics techniques were used to combine mutant alleles.  
Recombination on the X chromosome, following the crossing scheme in Figure 2.9, was used 
to generate elav e5 fne 25 and elav ts1 fne 25 double mutant stocks. 
Recombination on the 2nd chromosome, following the crossing scheme in Figure 2.10, was 
used to generate the mrp Mdr49 double mutant stock. 
Recombination on the 3nd chromosome, following the crossing scheme in Figure 2.11, was 
used to generate the M10; ewgelav::GFP, M18;ewgelav::GFP and Mdr65 oatp74D double 
mutant stocks. 
Table 2.3. Fly stocks 
Strain Genotype Description Source 
CS wild type wild type Soller lab collection 
yw y1 w1888 Stock without markers  Soller lab collection 
Binsinscy Df(1)Sxl-bt, y1/Binsinscy  X chromosome balancer Bloomington 
FM7i ewgl1/FM7i X chromosome balancer Soller Lab collection 
T36 TM3Sb/TM6B 3rd chromosome balancer Soller Lab collection 
CyO y[-]w[-] ; Sco/CyO Balancer for the 2nd Soller Lab collection 
FC ewgl1/FM7i ; Sco/CyO Double balancer for X and 2nd  Soller Lab collection 
FS ewgl1/FM7i ; Sco/SM6 Double balancer for X and 2nd Soller Lab collection 
FTSb ewgl1/FM7i ; PrDr/TM3Sb Double balancer for X and 3rd  Soller Lab collection 
FTSer ewgl1/FM7i ; PrDr/TM3Ser Double balancer for X and 3rd Soller Lab collection 
CTSb Sco/CyO ; PrDr/TM3Sb Double balancer for 2nd and 3rd  Soller Lab collection 
STSer Sco/CyO ; PrDr/TM3Ser Double balancer for 2nd and 3rd Soller Lab collection 
76A y1 w1888; PBac (y+-attP-9A)VK00013 Insertion line at cytological position 76A Soller lab collection 
elavC155-Gal4 w1888 P{w+mW.hs=GawB}elavC155 Enhancer trap in the elav promoter Soller lab collection 
eG(2) w1888 elave5/FM7;P{w+mC=elav-Gal4} elav-Gal4 insersion on the 2nd  Soller lab collection 
eG(3) w1888 elave5/FM7;P{w+mC=elav-Gal4} elav-Gal4 insersion on the 3rd  Soller lab collection 
Ddc-Gal4 w1888; P{w+mC=Ddc-GAL4.L}4.36 Dopaminergic/ serotonergic Gal4 driver on the 3rd  Soller lab collection 
GMR-Gal4 w*; P{w+mC=GAL4-ninaE.GMR}12 Enhancer trap in glass driving GAL4 in the eye disc in all cells behind the morphogenetic furrow. On 2nd  Soller lab collection 
201Y-Gal4 w1888; P{w+mW.hs=GawB}Tab2201Y Mushroom body Gal4 driver on the 2nd  Soller lab collection 
UngA; dpp-Gal4 
P{w+mW.hs GFPUgGA=UnGA}; 
P{w+mW.hs GAL4dpp.blk1 = GAL4-
dpp.blk1} 
nrg GFP splicing reporter and wing disc Gal4 driver Soller lab collection 
UAS-elav y1 w1888; P{w+mC=UAS-elav} PhiC31-mediated transgenesis of pUASTattB-elav in position 76A This work 
 
Table 2.3. Continued 
 
UAS-elavnls y1 w1888; P{w+mC =UAS-elavnls} PhiC31-mediated transgenesis of pUASTattB-elavnls in position 76A This work 
UAS-elavnls ΔOH y1 w1888; P{w+mC =UAS-elavnls ΔOH} PhiC31-mediated transgenesis of pUASTattB-elavnls ΔOH in position 76A This work 
UAS-elavΔOH y1 w1888; P{w+mC =UAS- elavΔOH} PhiC31-mediated transgenesis of pUASTattB-elavΔOH in position 76A This work 
UAS-elav-13 y1 w1888; P{w+mC =UAS-elav-13} PhiC31-mediated transgenesis of pUASTattB- elav-13 in position 76A This work 
UAS-elavnls -13 y1 w1888; P{w+mC =UAS-elavnls -13} PhiC31-mediated transgenesis of pUASTattB-elavnls -13 in position 76A This work 
UAS-fne y1 w1888; P{w+mC =UAS-fne} PhiC31-mediated transgenesis of pUASTattB-fne in position 76A This work 
UAS- rbp9 y1 w1888; P{w+mC]=UAS-rbp9} PhiC31-mediated transgenesis of pUASTattB-rbp9 in position 76A This work 
UAS-HuR y1 w1888; P{w+mC =UAS-HuR} PhiC31-mediated transgenesis of pUASTattB-HuR in position 76A This work 
UAS-HuB y1 w1888; P{w+mC =UAS-HuB} PhiC31-mediated transgenesis of pUASTattB-HuB in position 76A This work 
UAS-HuC y1 w1888; P{w+mC =UAS-HuC} PhiC31-mediated transgenesis of pUASTattB-HuC in position 76A This work 
UAS-HuD y1 w1888; P{w+mC =UAS-HuD} PhiC31-mediated transgenesis  of pUASTattB-HuD in position 76A This work 
elave5 w* sn elav[e5/ FM6/Dp(1;Y) elav amorphic allele  Soller lab collection 
elave5;eG(2) w1888 elave5/FM7;P{w+mC=elav-Gal4} elav amorphic allele on the X with elav-Gal4 on 2nd  This work 
elave5;eG(3) w1888 elave5/FM7;P{w+mC=elav-Gal4} elav amorphic allele on the X with elav-Gal4 on 3rd  This work 
elavedr y
1 w1888 elave5/FM6; 
P{w+mC=elav edr} elav hypomorph from rescue insertion on 2
nd  Soller lab collection 
elavts1 y1 elavts1/ FM7i Temperature sensitive elav allele Soller lab collection 
 
 
Table 2.3. Continued 
hecf06077 w
1888 PBac{WH} hecf06077 
 Piggy-Bac transposon insertion in 3’ UTR of hec  Bloomington 
fnef06439 w
1888 PBac{WH}fnef06439 
 Piggy-Bac transposon insersion in fne  Bloomington 
fne25 fne25 
fne deletion by FLP/FRT-mediated recombination 
between the 3!FRT site of hecf06077 and the 5!FRT 
site of fne f06439 Piggy-Bac transposons 
Soller lab collection 
Df(fne) Df(1)ED7165/FM7i Deleted segment 11B15--11E1 Bloomington 
rbp9P[2690] w*; P{w+mC=lacW}rbp9P[2690]/CyO GFP 
rbp9 null allele derived from P-element 
mutagenesis (Kim-Ha et al, 1999) Soller lab collection 
Df(rbp9) Df(2L)ED206/ CyOGFP Deleted segment 23B8--23C5 Bloomington 
elav e5 fne 25 w* sn elave5 fne25/FM6/Dp(1;Y)y+ sc Double mutants for elav and fne This work 
elav ts1  
fne 25 y
1 w* elavts1 fne25/ FM7i Double mutants for elav and fne This work 
elav e5 rbp9P[2690] w* sn elav
e5 / Fm7i/Dp(1;Y)y+ sc;  
rbp9 P[2690]/ CyO GFP 
Double mutants for elav and rbp9 This work 
elav ts1; Df(rbp9) y
1 elavts1/ FM7i/ Dp(1;Y)y+ sc; 
Df(2L)ED206/CyOGFP 
Double mutants for elav and Df(rbp9) This work 
elav e5 fne25; 
rbp9P[2690] 
w* sn elave5 fne25 /FM7i;  
rbp9P[2690]/ CyoGFP 
Triple mutant for elav, fne, rbp9 This work 
elav ts1  fne25; 
Df(rbp9) 
y1 elavts1 fne25/ FM7i; 
Df(2L)ED206/CyOGFP 
Triple mutant for elav, fne, Df(rbp9) This work 
fne25;rbp9P[2690] fne25; rbp9 P[2690] / CyOGFP Double mutants for fne and rbp9 This work 
Df(fne); Df(rbp9) Df(1)ED7165/ FM7i; Df(2L)ED206/ CyOGFP 
Double mutant for Df(fne) and Df(rbp9) This work 
ewgelav::GFP y1 w1888; P{w+mC =ewgelav::GFP} PhiC31-mediated transgenesis of  C4MM-tcgER::GFP in position 76A This work 
ewgelav Δ7::GFP y1 w1888; P{w+mC =ewgelav Δ7::GFP} PhiC31-mediated transgenesis of  C4MM-tcgER Δ7::GFP in position 76A This work 
 
Table 2.3. Continued 
 
ewgelav- Gal4 y1 w1888; P{w+mC =ewgelav -Gal4} PhiC31-mediated transgenesis of  C4MM-tcgER-GAl4 in position 76A This work 
ewg Δ y1 w1888  ewg[Δ]/FM7i ewg null allele ewg null allele 
M10 w1888;P{w+mC=UAS-moody[109601]RNAi UAS-Moody RNAi (M10) against moody gene on the 2nd VDRC 
M18 w1888;P{w+mC=UAS-moody[1800]RNAi UAS-Moody RNAi (M18) against moody gene on the 2nd  VDRC 
M10; ewgelav::GFP 
y1 w1888; P{w+mC = 
UAS-moody[109601]RNAi;  
P{w+mC=ewgelav::GFP} 
UAS-Moody RNAi (M10) and tcgER::GFP 
transgene on the 3rd  This work 
M18;ewgelav::GFP y
1 w1888; P{w+mC =UAS-moody[1800]RNAi; 
P{w+mC = ewgelav::GFP} 
UAS-Moody RNAi (M18) and tcgER::GFP 
transgene on the 3rd  This work 
spg-Gal4  w*; P{w[+mC]=Spg-Gal4} moody Gal4 driver (gift from R. Bainton) Soller lab collection 







P-element insertion of GAL4 under the spg 
promoter on the 2nd recombined with UAS-Dcr2 
RNAi and tcgER::GFP transgene on the 3rd  
This work 
oatp26F y1 w*;Mi{MIC}oatp26FMI00338 Insertion on 2L (26F3) Bloomington 
oatp30B y1 w67c23; P{SUPorP}oatp30BKG01566 Insertion on 2L (30B10) Bloomington 
oatp33Ea y1 w67c23; P{SUPorP}oatp33EaKG04960 Insertion on 2L (33E5) Bloomington 
oatp58Db w1118; Mi{ET1}oatp58Db[MB04546] Insertion on 2R (58D2) Bloomington 
oatp58Dc w1118; Mi{ET1}oatp58Dc[MB03731] Insertion on 2R (58D2) Bloomington 
oatp74D w1118; Mi{ET1}oatp74DMB05332 Insertion on 3L (74D1) Bloomington 
mdr49 w1118; Mi{ET1}mdr49MB04959 Insertion on 2R (49E3) Bloomington 
mdr50 PBac{PB}mdr65c00522 Insertion on 2R (50E6 ) Harvard 
mdr65 y1 w67c23;  P{SUPor-P}mdr65KG08723 ry506 Insertion on 3L (65A10) Bloomington 
mrp w1118; PBac{PB}mrpe00116 Insertion on 2L (33F3-F4) Harvard 
mrp4 w1118; Mi{ET1}mrp4[MB09770] Insertion on 3R (86E11) Bloomington 
 
Table 2.3. Continued 
mdr49;mdr65 w * ; Mi{ET1}mdr49MB04959; P{SUPor-P}mdr65KG08723 ry506 Double mutant on 2nd and 3rd  This work 
mdr49;oatp74D w 1118; Mi{ET1}mdr49MB04959; Mi{ET1}oatp74DMB05332 Double mutant on 2nd and 3rd This work 
mdr65 oatp74D w*; P{SUPor-P}mdr65KG08723 ry506 Mi{ET1}oatp74DMB05332 Double mutant on 3rd This work 
mrp;mdr65 w *; PBac{PB}MRPe00116; P{SUPor-P}mdr65KG08723 ry506 Double mutant on 2nd and 3rd This work 
mrp;oatp74D w1118; PBac{PB}mrpe00116; Mi{ET1}oatp74DMB05332 Double mutant on 2nd and 3rd This work 
















Figure 2.9. Recombination on the X chromosome 
To recombine mutant alleles on the X chromosome transheterozygous female virgins (F1) 
were crossed to males carrying the Binsinscy X balancer chromosome which contains the 
following markers: bar (B1), scute (sc8  and scS1), singed (snX2), white (w1) and yellow 
(yc4). Single females from F2 , bearing the recombined X chromosome were out-crossed 









Figure 2.10. Recombination on the 2nd chromosome 
To recombine mutant alleles on the 2nd chromosome transheterozygous female virgins or 
males (F1) were crossed to the respective gender of a 2
nd chromosome balancer. Single 
males from F2, bearing the recombined 2
nd chromosome were out-crossed to a different 2nd 
chromosome balancer. F3 females and males of the right genotype were crossed inter se 
































Figure 2.11. Recombination on the 3rd chromosome 
To recombine mutant alleles on the 3rd chromosome transheterozygous female virgins or 
males (F1) were crossed to the respective gender of T36 flies. Single males from F2, 
bearing the recombined 3rd chromosome were out-crossed to T36 again. F3 females and 
males of the right genotype were crossed inter se and a stock was established. bbbbbbbbb
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Combining mutants alleles on the X and 2nd chromosomes following the crossing scheme in 
Figure 2.12 generated elave5;eG(2), elav e5 rbp9P[2690] , elav ts1; Df(rbp9), elav e5 fne25; 
rbp9P[2690] and elav ts1  fne25; Df(rbp9) double and triple mutant stocks. 
Combining mutants alleles on the X and 3rd chromosomes following the crossing scheme in 
Figure 2.13 generated elave5;eG(3) double mutant stock. 
Combining mutants alleles on the 2nd and 3rd chromosome following the crossing scheme in 
Figure 2.14 generated fne25; rbp9P[2690], Df(fne); Df(rbp9), Mdr49;Mdr65, Mdr49;oatp74D, 
mrp;Mdr65 and mrp;oatp74D double mutant stocks.  
spg-Gal4 UAS-Dcr2 RNAi; ewgelav::GFP was obtained in two steps. Firstly, spg-Gal4 and 
UAS-Dcr2 RNAi were recombined on the 2nd (Figure 2.10). Then, they were combined with 
ewgelav::GFP by following the crossing scheme is figure 2.14. 
Transgenic stocks following PhiC31 integration were established according to the crossing 
scheme in Figure 2.15. 
Transgenes were expressed in flies using the UAS/GAL4 system (Brand and Perrimon, 
1993). A list of Gal4 drivers and UAS lines used is given in Table 2.3.  
 
2.1.4. Transgenesis 
DNA was obtained with a QIAGEN Plasmid MidiPrep Kit according to the manufacturer’s 
instructions. The injection mix comprised 2.5 µg of total DNA, 1xinjection buffer (5 mM 
KCl, 0.1 mM Na3PO4, pH 7.8), 1 mM MgCl2 and 0.2 µM green food dye in a total volume of 
10 µl. Mixes were stored at -20°C. Prior to microinjection, the mix was centrifuged at 16000 
rpm for a minimum of 10 minutes and kept on ice throughout the procedure. For 
microinjection, borosilicate glass micropipettes with filament (outer diameter 1 mm, inner 
diameter 0.22 mm, Intracel) were pulled with a PC-10 Micropipette Puller (Narishige), and 













Figure 2.12. Double mutants for 1st and 2nd chromosome 













Figure 2.13. Double mutants for 1st and 3rd chromosome 












Figure 2.14. Double mutants for 2nd and 3rd chromosome 









Figure 2.15. Establishing transgenic stocks 
This protocol was used to screen for and establish transgenic stocks. All transgenic 
insertions were on the 3rd chromosome at position 76A. The PhiC31 transposase was 
marked with GFP, therefore, the X chromosome bearing the PhiC31 had to be out-
crossed at all times.  
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Transgenic lines were obtained by PhiC31 transformation (Groth et al, 2004). All plasmids 
carried an attB docking site allowing site-specific integration of the construct into the genome 
of flies with a pre-determined landing site (attP) at cytogenetic location 76A on the 3rd 
chromosome (strain 76A). The recombination reaction was mediated by a constitutively 
expressed PhiC31 integrase on the X chromosome.  
Prior to transgenesis, around a 1000 76A flies were placed in a large cage with grape-juice 
agar plates, supplemented with live yeast paste for at least 3 days, where the plate was 
changes once daily. On the day of injections, plates were changed 3 times every 45 minutes 
to synchronize egg laying.  
The injection cycle was on average 70 minutes at 18°C. Embryos were collected every 30 
minutes, dechorionated for 45 seconds in 33% sodium hypochlorite (VWR) solution, washed 
3 times with water, and left to air-dry briefly. On average 40 embryos were aligned and 
attached to a 22x22 mm glass coverslip (VWR) with heptane glue (Scotch tape dissolved in 
heptane). Embryos were left to dehydrate in a dessication chamber with silica gel beads for 
13 minutes after which were covered with halocarbon oil 700 (Sigma) and mounted for 
injections on a Nikon inverted microscope. The DNA mix was injected from the posterior 
end, prior to poll cell formation, with an IM-30 microinjector (Narishinge), mounted to an 
MN-153 micro-manipulator (Narishinge), connected to a JunAir 3-4 air compressor. After 
injections embryos were placed in a humid chamber at 18°C. 48 hours later, first instar larvae 
were collected and placed on standard fly media, and left to develop at room temperature. 
On average 200 stage 14 embryos were injected per construct. Eclosed flies (G0) from the 
injected embryos were outcrossed with yw (white-eyed, yellow body color) flies. Apart from 
the attB site, the pUAST vector also carried a positive transformation marker-mini white 
(encoding for orange eye color). Transformants (F1) were identified and their stable stocks 
were established following Figure 2.15. Statistics on embryo survival after injections and 
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transformation rates are given in Table 2.4. 
UAS-Fne, UAS-Rbp9, UAS-FneOH, UAS-HuB, UAS-HuC, UAS-HuD, UAS-HuR, UAS-Elav-
S472D and UAS-NLS Elav-S472D constructs were injected in pairs from a common injection 
mix. After transgenic flies were obtained, they were resolved by single fly PCR with primers 
given in Table 2.2.  
 
2.3. Phenotypic analysis 
2.3.1 Survival Index  
The viability of transheterozygous (mutant/deficiency) adult flies of ELAV, FNE and RBP9 
mutant alleles was assessed in the progeny of a cross between balanced mutants and the 
corresponding balanced deficiency. Balancers used were FM7i for mutants on the X 
chromosome, CyO for mutants on the 2nd chromosome and FM7i;CyO for combination of 
both chromosomes. Detailed crossing schemes and Mendelian segregation can be found in 
fig. 2.1. The survival index (SI) is a measure of the degree of the mutant alleles affecting 
viability. In the majority of cases only female flies were taken into account as ELAV and 
FNE are on the X chromosome, and the expected segregation between the transheterozygotes 
females and the balanced control females was 1:1, therefore in this case: 
 
 
In the case of Rbp9, which is on the 2nd chromosome, female and male flies were taken into 
account. Mendelian segregation between the transheterozygotes and the balanced controls 
was 1:2, therefore in this case: 
 
 
Table  2.4. Transgenic flies obtained and transformation statistics.  
Construct Embryos 
injected 








pUAST&aatB&elav- 300# 70# 24# 20# 1# 8%# 5%# Obtained#
pUAST&aatB&elav&13- 300# 110# 39# 19# 3# 13%# 16%# Obtained#
pUAST&aatB&rbp9-
pUAST&aatB&HuR-
200# 50# 19# 18# 4# 10%# 22%# Both#obtained#
pUAST&aatB&fne-
pUAST&aatB&HuB-




300# 60# 40# 33# 6# 13%# 18%# Both#obtained#
pUAST&aatB&elavNLS-S472-
pUAST&aatB&HuD-




200# 35# 12# 10# 4# 6%# 40%# pUAST&aatB&elavnls-&13-
obtained#
pUAST&aatB&elavnls-&13- 150# 20# 5# 5# 1# 3%# 20%# Re9injected#
pUAST&aatB&fne- 300# 100# 49# 33# 13# 16%# 40%# Re9injected#
pUAST&aatB&fneΔOH- 300# 75# 24# 17# 5# 8%# 30%# Obtained#
pUAST&aatB&HuD- 300# 75# 28# 22# 3# 10%# 14%# Obtained#
CaSpeR&constructs& # # # # # # # #
C4MM&tcgER::GFP- 200# 74# 39# 39# 3# 20%# 8%# Obtained#
C4MM&-tcgER-Δ7::GFP- 300# 77# 22# 21# 1# 7%# 5%# Obtained#
C4MM&-tcgER-Δ7::GFP- 300# 175# 43# 42# 6# 14%# 14%# Obtained#
C4MM&-tcgER-Gal4::GFP- 150# 33# 14# 14# 1# 9%# 7%# Obtained#
- # # # # # # # #
-




- # # # # # 10.75%# 14.75%#
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2.3.2. Longevity assay 
On average 100 flies, not more than 20 flies per vial, were aged for up to 60 days at 25°C 
degrees where the number of live animals was recorded every three days. Viable flies were 
transferred to fresh food media every 3 days to avoid bacterial or fungal contaminations. 
 
2.3.3. Negative geotaxis assay 
This assay was performed as described previously by Coulom et al, 2004. Adult flies were 
rapidly anesthetized under CO2 and placed in a vertical column with a conical end (25 ml 
pipette), after which were left to recover for 30 minutes at 25°C. To perform the assay, the 
column was gently tapped, in a comparable fashion in between experiments, to assure all flies 
were at the bottom after which the animals were left undisturbed for a period of 1 minute. 
The number of flies that have gone above the 25 ml mark (ntop) and the ones remaining below 
the 2 ml (nbottom) were recorded. In between each run, the test subjects were left to recover for 
at least 1 minute. A performance index (PI) was calculated using the following formula:  
 
PI = 0.5 x (ntotal + ntop – nbottom)/ ntotal 
 
2.3.4. Paraffin sectioning 
Up to 15 anaesthetized adult flies of a certain age were aligned per collar and fixed overnight 
at 4°C in FAAG (formaldehyde 37%:EtOH : HAc=10:8:5 + 1%Gluteraldehyde) fixative. On 
the next day the samples were dehydrated with 4 consecutive 4 minutes transfers in 100% 
dried EtOH. They were then kept for 1 hour in methylbenzoate at 60°C and in 1:1 
methylbenzoate:paraffin for an hour. The collars were the tissue was washed 3 times each for 
1 hour with melted pure paraffin. Collars were then embedded in paraffin and left to solidify 
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at on ice. Sectioning was at 10 µM slices. Samples were imaged on a Zeiss inverted 
microscope equipped with a fluorescent lamp.  
 
2.4. Toxicological testing 
2.4.1. Compounds used in the study 
The compounds selected for screening can be found in Table 2.5 and were applied directly to 
the food culture at room temperature in four descending concentration, in triplicates per 
concentration. Beginning with the stock concentration found in the table a further three ten-
fold dilutions were prepared. Compound were dissolved at room temperature as described in 
table 2.5 and stored at 4°C for up to two weeks. In all experimental set ups toxicity to the 
solvent was tested at the relevant concentration. For example 200 mM stock concentration 
was diluted to 20 mM, 2 mM and 0.2 mM solutions; application of 500 µL of the respective 
concentration in 10 ml food culture resulted in a final applied concentration of 10 mM, 1 
mM, 0.1 mM and 0.01 mM respectively. Since 50% Ethanol was the only solvent used apart 
from water, toxicity was also assessed from application of 50%, 5%, 0.5% and 0.05% 
Ethanol which resulted in a final concentration of 2.5%, 0.25%, 0.025% and 0.0025% of 
Ethanol. Unless otherwise specified, compounds were obtained from Sigma Aldricht. All 
compounds were powders. To effectively bring them into solution a standard calculation to 




















Compound Source MW Drug Class Solubility Stock 
Ouabain Octahydrate Sigma O3215 728.77 Cardiac glycoside H2O  
50mM stock solution: 
250mg/6.9ml 




50mM stock solution: 
1g/26.68ml 
Flunarizine dihydrochloride Sigma F8257  477.42 
Calcium  channel 




Chlorhexidine diacetate salt 
hydrate 
Sigma C6143 

















50mM stock solution: 
0.689g/40ml 
Naringin Sigma N1376  
580.53 
 Flavonoids 50% EtoH 
50mM stock solution: 
1.161g/40ml 




1- Napthyl phosphate 




Solution: 0.25g in 
4.73ml 















Solution: 0.218g in 
5.06ml 
Sodium Orthovanadate Sigma 450243 183.91 Phosphatase and ATPase Inhibitor H2O 
200mM stock 
Solution: 0.26g in 
7.068ml 
Sodium Flouride Sigma S6521 41.99 Phosphatase Inhibitor H2O 
400mM stock 
Solution: 0.238g in 
14ml 







Solution: 0.25g in 
3.695ml 
Sodium Butyrate Sigma 303410 110.09 Inhibits HDAC activity H2O 
200mM stock 
Solution: 0.55g in 2.5 
ml 
Phosphocreatine disodium salt 
hydrate Sigma P7936 255.08 Energy source H2O 
200mM  stock 
Solution: 0.128g in 
2.5ml 
Phosphocholine chloride 
calcium salt tetrahydrate Sigma P0378 329.73 
Activator of in vitro 
pre-mRNA cleavage H2O 
200mM  stock 
Solution: 0.165g in 
2.5ml 
Colchicine C9754 399.44 Inhibits microtubule polymerization H2O 
0.016mM  stock  
Solution: 
Ethanol Soller Lab 46.07 Solvent H2O 50% 
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2.4.2.  Larval exposure  
 
2.4.2.1 Acute exposure and toxicity assessment 
Compounds in four descending concentrations were applied in a larval feeding assay as 
following:  
• On day one: three healthy, mature males and females were transferred into a fresh 
food culture for 24 hours at 25oC in order to allow the females to lay eggs at their full 
potential  
• On day two: the flies were removed 
•  On day four: 500 µL of compound solution was applied to the food. By this stage 
larvae within the vial have progressed to second instar and active feeding state 
• On days twelve, fourteen, sixteen and eighteen: emerged adult flies were counted and 
the total was recorded.  
Toxicity was assessed as a percentage of adult survival, i.e. the total number of viable adults 
from treated vials divided by the number of viable adults from control vials multiplied by 
100. Controls of the respective genotype were treated with corresponding concentrations of 
solvent in which the compounds were originally dissolved. All toxicity tests were performed 
three times in independent applications and significance of the result was calculated based 
on a standard deviation lesser than 0.5.  
 
2.4.2.2. Chronic exposure to xenobiotics 
To increase uptake of compounds into the fly brain for the assessment of xenobiotic 
interference with ELAV mediated splicing, chronic exposure was performed on 
ewgelav::GFP transgenic flies in a compromised BBB genetic background derived from 
RNAi knockdown of moody in SPG of the BBB. Similarly to acute exposure, compounds 
were diluted ten-fold four times. Chronic exposure was performed in a 24 well-plate format, 
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where 300 mg of instant dry food were added in each well and rehydrated with 3 volumes of 
compound solution and left for an hour to set before embryo seeding. 24-hour-old embryos 
laid at 250C were collected and 20 embryos were seeded per well. Seeded embryos were left 
to develop at 250C.  
 
2.4.3. Assessment of GFP expression 
GFP levels were assessed from wandering larvae (96h AEL), which were dissected in 1x 
PBS for their central brain under a fluorescent microscope (Leica). For both acute and 
chronic exposure visual assessment was carried out. For chronic exposure differences were 
established by eye, after which brains were briefly fixed (5 minutes) in 4% formaldehyde, 
followed by extensive washing in PBS (3x20 minutes) and finally mounted in Vectashield ® 
mounting medium on microscopy slides.  
Levels of fluorescence were immediately recorded on a Nikon eclipse Ti fluorescent 
microscope and quantified with Nikon’s NIS-Elements imaging software. At least three 
samples were imaged per genotype and the mean was calculated. GFP levels were calculated 
as a percentage of GFP from treated animals from GFP of controls.  
 
2.4. Statistical analyses 
Statistical analyses were carried out by using QI Macros SPC v.2011.3 in Excel. In all cases 
confidence interval were 95%. Normality of sample distribution was assessed by Anderson-
Darling test. Significance of variances as calculated according to Levene’s test. Across the 
whole range of genotypes to be tested, I applied the One-way ANOVA test to compare 
means. Pair-wise comparisons of two genotypes were carried out for multiple genotypes and 
in cases where there were only two genotypes, using the Student t-test. These data were 
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represented as bar charts or scatter charts showing the mean ± standard deviation. P values 






Chapter 3:  




To understand the biological consequences that could result from xenobiotics potentially 
interfering with ELAV-mediated alternative splicing I characterized phenotypes of ELAV 
mutants in greater detail than has been previously published (Campos et al., 1985a). The 
ELAV family in Drosophila has two additional members- FNE and RBP9, for which mutants 
did either not exist or had been only marginally characterized and I therefore also analyzed 
phenotypes of mutants for these two genes. Since ELAV, FNE and RBP9 are highly 
homologous (Samson, 2008), it is currently not clear if they act redundantly and if so to what 
extent. I therefore analyzed phenotypes of mutants of individual genes and all possible 
combinations.  
Apart from inhibiting ELAV-regulated processes, xenobiotics could potentially affect 
functions of ELAV family proteins through altering their subcellular localization that would 
impact on multimerization and RNA binding, therefore, I also analyzed phenotypes of flies 
where Drosophila ELAV family members and also human Hu proteins were overexpressed.  
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3.2. Analysis of loss of function mutants of ELAV family members indicates distinct and 
overlapping functions 
To characterize phenotypes of mutants of ELAV family proteins I analyzed viability, 
longevity, climbing ability and brain morphology of single mutants and combinations thereof.  
Null mutants in elav are embryonic lethal, therefore, I used a temperature sensitive allele- 
elavts1, which was shown to produce full-length ELAV protein when reared at 18°C and a 
truncated protein when reared at 25°C (Kim-Ha et al., 1999). For fne and Rbp9 I used fne25, 
which is an fne null allele where the fne ORF was deleted (generated by M. Soller through 
Flipase-mediated recombination of FRT sites in transposons inserted upstream and 
downstream of the fne ORF- fne5! and fne3!) and Rbp9P[2690], which is a null Rbp9 allele 
derived from a transposon insert in the Rbp9 ORF and has previously been described by 
(Kim-Ha et al., 1999). To minimize genetic background effects I analyzed transheterozygouts 
of elavts1 allele with the null allele elave5, and for fne and Rbp9, I used transheterozygouts 
with larger chromosomal deficiencies, Df(fne) and Df(Rbp9), respectively.  
Viability of elavts1/elave5 transheterozygous females was only 23% when reared at the 
permissive temperature of 18°C and no survivors were detected when reared at 25°C (Table 
3.1). In contrast, fne25/Df(fne) and Rbp9P[2690]/Df(Rbp9) transheterozygous females showed 
72% and 101% viability, respectively. Double mutants of elav with fne and elav with Rbp9 or 
the triple mutant of all three genes were not viable at 18°C in the same genetic combinations 
as used for the single mutants, with the exception of elav fne where I used fne25 homozygous 
instead of the transheterozygous combination with the deficiency. Since I could not obtain a 
recombinant chromosome for elave5 and Df(fne), and fne25/Df(fne) had reduced viability, I 
analyzed if Df(fne) or the two starting transposons (fne5! and fne3!) used to make the fne ORF 
deletion had reduced viability, which was not the case.  
  
 
Name Genotype  Viability (%) Total 
counted 
Raised at 18°C 
elav  elavts1/elave5 23% (258)  1360 
elav fne  elavts1fne25/elave5fne25 0 (0)  1689 
elav;rbp9 elavts1/elave5;rbp9P[2690]/Df(rbp9) 0 (0)  1598 
elav fne;rbp9 elavts1fne25/elave5fne25;rbp9P[2690]/Df(rbp9) 0 (0)  1872 
Raised at 25°C 
elav  elavts1/elave5 0  1290 
fne fne25/Df(Fne) 72% (319) 764 
rbp9 rbp9P[2690]/Df(rbp9) 101% (322) 958 
fne;rbp9 fne25/Df(Fne);rbp9P[2690]/Df(rbp9) 107% (243) 763 
fne3! hecf06077 /Df(fne) 111% (290) 523 
fne5! fnef06439 /Df(fne) 105% (230) 437 




Table 3.1. Viability of elav, fne and rbp9 single, double and triple mutants  
Viability for transheterozygous females in combination with the elave5 null and temperature-
sensitive elavts1 allele was measured at 18°C, except for elavts1/elave5, which was also raised at 
25°C. Viability for fne and Rbp9 mutants was assessed at 25°C. Viability was calculated as a 
percentage of females of the genotype of interest compared to females of the control 
genotypes (as described in section 2.3.1). The number of flies corresponding to the calculated 
percentage is indicated in brackets. The total number of flies counted is indicated in the last 
column.  
 
To obtain transheterozygous adult females for elav, fne and rbp9 single, double and triple 
mutants and their respective control genotypes the following crosses were set: 
(1) elavts1/FM7iGFP virgin females were crossed to elave5/YDp(1;Y) males to produce 
elavts1/elave5 and control elavts1/FM7iGFP females; 
(2) elavts1fne25/FM7iGFP virgin females were crossed to elave5 fne25/FM6Dp(1;Y) males to produce 
elavts1 fne2/elave5 fne2 and control elavts1 fne2/FM7iGFP females;  
(3) elavts1/FM7i;Df(rbp9)/CyO virgin females were crossed to elave5/FM6Dp(1;Y); 
rbp9P[2690]/CyOGFP males to produce elavts1/elave5;rbp9P[2690]/Df(rbp9) and control 
elavts1/FM7i;rbp9P[2690]/CyOGFP or elavts1/FM7i; Df(rbp9)/CyOGFP females;  
(4) elavts1 fne25/FM7i;Df(rbp9)/CyOGFP virgin females were crossed to elave5 fne25/FM6Dp(1;Y); 
rbp9P[2690]/CyOGFP males to produce  elavts1fne25/elave5fne25;rbp9P[2690]/Df(rbp9) and control 
elavtsfne251/FM7i;rbp9P[2690]/CyOGFP or elavts1 fne25/FM7i; Df(rbp9)/CyOGFP females;  
(5) Df(fne)/FM7iGFP virgin females were crossed to fne25/Y males to produce fne2/Df(fne) and 
control fne2/FM7iGFP females;  
(6) Df(rbp9)/CyOGFP virgin females were crossed to rbp9P[2690]/CyOGFP males to produce 
rbp9P[2690]/Df(rbp9) and control rbp9P[2690]/CyOGFP or Df(rbp9)/CyOGFP females;  
(7) Df(fne)/FM7iGFP/Df(rbp9)/CyOGFP virgin females were crossed to 
fne25/Y;rbp9P[2690]/CyOGFP males to produce fne2/Df(fne);rbp9P[2690]/Df(rbp9) and control 
fne2/Df(fne);rbp9P[2690]/CyOGFP or fne2/Df(fne);Df(rbp9)/CyOGFP females;  
(8) Df(fne)/FM7iGFP virgin females were crossed to hecf06077/Y males to produce hecf06077 
/Df(fne) and control hecf06077/FM7iGFP females; 
(9) Df(fne)/FM7iGFP virgin females were crossed to fnef06439/Y males to produce 
fnef06439/Df(fne) and control fnef06439/FM7iGFP females; 
(10) Df(fne)/FM7iGFP virgin females were crossed to +/Y wild type males to produce +/Df(fne) 
and control +/FM7iGFP females 
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Next, I analyzed longevity for the viable allelic combinations of elav, fne, Rbp9 and fne;Rbp9 
(Figure 3.1). For this analysis elavts1/elave5 were reared at 18 °C and shifted at 25°C degrees 
after eclosure, while transheterozygous fne, Rbp9 and fne;Rbp9 were reared at 25°C degrees. 
All mutants tested had reduced viability levels compared to wild type controls when aged at 
25°C. elavts1/elave5 flies had a very short life span characterized with a median life span of 7 
days and a maximum life span of 15 days. fne, Rbp9 and fne;Rbp9 transheterozygous females 
also had reduced  viability with median life span of 32, 29 and 39 days and a maximum life-
span of 50, 45, and 50 days, respectively.  
To then assess if in elav, fne, Rbp9 and fne;Rbp9 transheterozygous mutants basic neuronal 
functions were  impaired, I tested these mutants for their ability to climb (Figure 3.2). 
Consistent with their reduced survival rate, elav mutants had less than half of the control’s 
ability to climb on the first day after eclosure, which was lost completely after 10 days. 
Twenty-day old fne mutants did not reveal a significant impairment in their ability to climb 
compared to 20-day old control flies. Twenty-day old Rbp9 and fne;Rbp9 mutants showed a 
50% reduction in their ability to climb compared to 1-day old controls. 
The age-dependent loss in climbing ability potentially could indicate neurodegeneration in 
the absence of ELAV family proteins. I therefore analyzed the morphology and the 
occurrence of age-dependent neurodegeneration in elav, fne, Rbp9 and fne;Rbp9 
transheterozygous mutants.  
elavts1 homozygous mutants were shown to have developmental defects in the organization of 
the adult brain, for example, the medulla fails to rotate and it is not clear if the lamina is 
present (Campos et al., 1985a). When analyzing brains of older transheterozygous 
elavts1/elave5 females I found signs of age-dependent neurodegeneration indicated by 
vacuolozation in specific parts of the central brain. All the brains analyzed (10/10) had 






Figure 3.1.  Reduced lifespan of elav, fne, Rbp9 and fne;Rbp9 mutants.  
Lifespan of transheterozygous females of the indicated genotypes as described in the legend 
of Table 3.1 were compared to that of wild type (CS) females and is shown as mean from 






Figure 3.2.  Age-dependent climbing ability of elav, fne, Rbp9 and fne;Rbp9 mutants.  
Climbing ability of transheterozygous females of the indicated genotypes, obtained as 
described in Table 3.1 legend is presented as Performance Index in relation to the days on 
which the negative geotaxis assay was carried out (x axis).  Control was wild type. Three 
independent sets of 20 flies per genotype were tested three times. Error bars represent 
standard deviations. Red stars indicate significant difference in climbing ability compared to 
control (p<0.0045 after Bonferonni correction in the t-test) and blue stars indicate significant 
age-dependent differences for individual genotypes (p<0.016 after Bonferonni correction in 
the t-test).  
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in other parts of the brain. While I did not find signs of age-dependent neurodegeneration in 
40-day old fne and Rbp9 transheterozygous mutants, fne;Rbp9 double mutants at this age 
showed age-dependent vacuolization specifically in the lamina region (10 out of 12 brains), 
but not at 10 days (Figure 3.3).  
Although in elavts1 mutants photoreceptor neurons degenerate during pupal development and 
this degeneration is not light dependent (M. Soller, personal communication), photoreceptor 
neurons were present in fne, Rbp9, and fne;Rbp9 transheterozygous mutants (Figure 3.4). 
 
3.3. Gain of function mutants of ELAV family members cause distinct and overlapping 
phenotypes 
Apart from downregulation, xenobiotics could also increase ELAV activity. Function of 
ELAV/Hu proteins is regulated by numerous post-translational modifications through a 
number of cellular signaling pathways (Doller et al., 2008), therefore, xenobiotics that inhibit 
phosphatases or kinases could also upregulate the protein’s activity. To address that, I looked 
at ELAV overexpression phenotypes that would reveal a phenotypic endpoint for interference 
of xenobiotics with ELAV functions. Here, I analyzed longevity, climbing ability and adult 
brain morphology of flies overexpressing ELAV family members in the nervous system 
(Table 3.2.).  
Since there were previously described UAS-ELAV transgenic lines inserted on the 2nd or 3rd 
chromosome, UAS-ELAVeQ12H3, inserted on 2nd or 3rd (Toba and White, 2008) and UAS-
ELAV2e2 on 2nd (Koushika et al., 1996). I compared if their neuronal overexpression would 
differ from that of the UAS-ELAV at cytological position 76A. Overexpression of the two 
UAS-ELAVeQ12H3 and UAS-ELAV2e2 with the enhancer trap elavC155-Gal4, inserted in the 
elav gene and expressed in the elav neuronal pattern, resulted in 1st instar, embryonic and 





Figure 3.3.  Age-dependent vacuolization in elav, fne, Rbp9 and fne;Rbp9 mutants.  
Representative panels of paraffin sections illustrating brain morphology on specified days for 
indicated genotypes of transheterozygous females as described in Table 3.1 legend. Heads 







Figure 3.4.  elav but not fne and rbp9 is required for photoreceptor development.  
Photoreceptors visualized from paraffin sections are shown from transheterozygous females 
of the indicated genotypes as described in the legend of Table 3.1. The raw image for panel B 
(absence of photoreceptors in elav) was provided by M. Soller. 
  
Table 3.2. Phenotypic examination of UAS elav/Hu transgenic lines expressed with various Gal4 drivers. The majority of Gal4 lines are neuronal 
with the exception of Dpp-Gal4, which is expressed in a central stretch of epithelial cells in larval imaginal discs.  
ND=protein not detected with the α-HA antibody.  
 






Ap-Gal4 Sev-Gal4 Dpp-Gal4 
UAS-elav2e2 1st instar lethal - - -  -  - 
UAS-elav3e1 embryonic lethal - - - - - 
UAS-elavN26 pupal lethal - - - - - 
UAS-elav viable, rough eye viable 2nd instar lethal - - viable 
UAS-RBP9 male lethality - - - - viable 
UAS-FNE male lethality - - - - viable 
UAS-NLSelav viable, rough eye viable 2nd instar lethal - - viable 
UAS-NLSelavΔOH viable, rough eye viable 2nd instar lethal - - viable 
UAS-elavΔOH viable, rough eye viable 2nd instar lethal - - viable 
UAS-elav-13 viable, rough eye viable 2nd instar lethal viable viable viable 
UAS-NLSelav-13 viable, rough eye viable 2nd instar lethal - - viable 
UAS-elavS472D viable, rough eye - - - - viable 
UAS-NLSelavS472D viable, ND - - - - viable 
UAS-HuR embryonic lethal viable 2nd instar lethal 3rd instar lethal viable viable 
UAS-HuB embryonic lethal - - 3rd instar lethal 2nd instar lethal viable 
UAS-HuC embryonic lethal - - viable, ND viable viable 
UAS-HuD embryonic lethal - - viable, ND viable, ND viable, ND 
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respectively. Overexpression of UAS-ELAV, integrated at 76A with elavC155-Gal4 resulted 
in viable adults with a mild rough eye phenotype. Next, I tested if overexpression of ELAV 
would differ depending on the elav-Gal4 driver used. Overexpression of UAS-ELAV with 
elav-Gal4(eG2), inserted on the 2nd chromosome, and elav-Gal4(eG3), inserted on the 3rd, 
resulted in either viable adults with no obvious external phenotypes and  3rd instar larval 
lethality for elav-Gal4(eG2) and elav-Gal4(eG3), respectively. Since, UAS-ELAV 
overexpression with elav-Gal4(eG2) was viable, I next tested, if UAS-ELAV driven by elav-
Gal4(eG2) would rescue elave5 null mutant associated embryonic lethality, which it did not. 
Since expression levels of UAS ELAV transgenes varied depending on the P-element 
insertion site, all the transgenes generated in this study were integrated at the same genomic 
location, which was 76A on the 3rd chromosome. Since, the three elav-Gal4 drivers produced 
different phenotypes with the same UAS transgene, which can be due to positional effects 
based on their insertion site having an effect on their expression, I only used elavC155-Gal4 to 
assess longevity, climbing ability and brain morphology resulting from ELAV proteins 
overexpression.  
Similarly, to overexpression of ELAV, FNE and RBP9 from UAS constructs with elavC155-
Gal4, resulted in viable adults with slight rough eye as the only visible external phenotype 
(Table 3.2.). Unexpectedly, overexpressing FNE and RBP9 resulted in male pupal lethality. 
To avoid ambiguity from male and female generated results, which could arise from sex-
specific gene expression and not neuronal causes, all further analysis was restricted to 
females overexpressing the transgenes.  
Next, I analyzed longevity of females overexpressing ELAV, FNE and RBP9 with elavC155-
Gal4 at 25°C (Figure 3.5). All three genotypes had a reduced life span compared to the 
control elavC155/+ females. elavC155-Gal4;;UAS-elav flies had a median life span of 45 days 




Figure 3.5. Overexpressing ELAV, FNE and RBP9 reduces lifespan. 
Lifespan of females overexpressing ELAV, FNE and RBP with the pan-neuronal elavC155-
Gal4 driver compared to elavC155-Gal4/+ control females is shown as mean from three 
independent experiments with a minimum of 100 females per genotype. 
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Gal4;;UAS-Rbp9 flies had a shorter life span characterized with a median life span of 18 and 
12 days and a maximum life span of 35 and 30 days, respectively.  
To then assess if overexpression of ELAV, FNE and RBP9 with elavC155-Gal4 impaired basic 
neuronal functions, I tested these mutants for their ability to climb. Overexpression of ELAV 
resulted in 70% reduced performance in climbing assays compared to control females on day 
1 and remained unchanged when tested on days 10 and 20. In contrast, overexpression of 
FNE and RBP9 clearly resulted in age-dependent reduction in climbing ability. Females 
overexpressing FNE, had reduced climbing performance from day 1 to day 10 and climbing 
capability dramatically decreased to 15% on day 20.  Similarly, females overexpressing 
RBP9, had reduced climbing performance on day 1 after eclosure, which decreased to 35% 
and 2% on day 10 and 20, respectively (Figure 3.6). 
To assess if the impaired climbing ability of flies overexpressing ELAV, FNE and RBP9 
females was due to gross neurological defects I analyzed the morphology and the occurrence 
of age-dependent neurodegeneration by examining brain morphology on paraffin sections.  
Vacuolization was found in females overexpressing ELAV, RBP9 and FNE with elavC155-
Gal4 after 20 days, which was not a result of developmental defects as one-day old flies had 
normal brain morphology (20, 22 and 15 heads were analyzed for 1-day old ELAV, FNE and 
RBP9 overexpression flies, respectively) (Figure 3.7). Brain regions affected were different 
between ELAV overexpressing flies and FNE and RBP9, as vacuolization in ELAV flies was 
found in the central brain (occurrence was in 15 out of 15 heads analyzed) and vacuolization 
in FNE and RBP9 was found specifically in the lamina region (occurrence was in 12 out of 
15 heads analyzed for FNE flies and 10 out of 15 heads analyzed for RBP9 flies).   
Since, ELAV/Hu family members have been shown to differentially localize to either the 
nucleus or cytoplasm depending on cell type, I analyzed if overexpression with elavC155-Gal4 





Figure 3.6. Age-dependent reduction in climbing ability in females overexpressing FNE 
and RBP, but not ELAV. 
Climbing ability of females overexpressing ELAV, FNE and RBP9 with elavC155-Gal4 is 
presented as Performance Index in relation to the days on which the negative geotaxis assay 
was carried out (x axis). Control genotype was elavC155-Gal4/+. Three independent sets of 20 
flies per genotype were tested three times. Error bars represent standard deviations. Red stars 
indicate significant difference in climbing ability compared to control and blue stars indicate 
significant age-dependent differences for individual genotypes, where p<0.00555 after 







Figure 3.7.  Age-dependent vacuolization in females overexpressing ELAV, FNE and 
RBP9. 
Representative panels of paraffin sections illustrating brain morphology on day 1 and day 20 
of females overexpressing ELAV (A-A!), FNE (B-B!) and RBP9 (C-C!). Control was 1 and 
20 day old elavC155/+ females. Heads were sectioned at 10µm. 
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data (Figure 3.8). Proteins expressed from the UAS constructs were detected by the HA-tag 
at the N terminal of the protein (see figure 2.6). ELAV originating from overexpression 
localized to the nucleus, whereas, overexpressed FNE was detected in both the nucleus and 
cytoplasm as previously published for endogenous ELAV and FNE (Samson and Chalvet, 
2003). Unexpectedly, overexpressed RBP9 revealed preferential localization in the cytoplasm 
with minor levels of the protein found in the nucleus, which differed from previously 
described nuclear localization for RBP9 (Kim and Baker, 1993).  
To elucidate if cytoplasmic localization of transgenic FNE and RBP9 was due to 
overexpression I assessed the localization of endogenous FNE and RBP9 proteins (Figure 
3.9). Since an anti-FNE and RBP9 antibodies were not available, I looked at the localization 
of HA- and myc-tagged FNE and RBP9 proteins from genomic rescue constructs in the 
respective null mutant background (transgenic flies were made by M. Soller). Similarly, to 
the overexpression pattern, FNE localized to both nucleus and cytoplasm in midline neurons 
of the VNC in 3rd instar larvae and also neurons of the adult thoracic ganglion, while RBP9 
localized preferentially to the cytoplasm of adult thoracic ganglion neurons.  
Both FNE and RBP9 showed cytoplasmic localization and their overexpression was more 
toxic compared to ELAV overexpression based on longevity and climbing assays. An ELAV 
mutant, ELAVΔOH, has an 8 amino acid deletion in the hinge region, and has been shown to 
preferentially localize to the cytoplasm (Yannoni and White, 1999). I tested, if 
overexpressing ELAVΔOH, would render ELAV more toxic. I also analyzed if forcing ELAV 
to the nucleus would reduce ELAV toxicity. As a control I overexpressed an ELAV 
transgene, ELAVNLS ΔOH, which bears both the NLS and ΔOH deletion and would localize 
preferentially to the nucleus, as the NLS signal would overwrite the cytoplasmic ΔOH 
distribution.  








Figure 3.8 Cellular localization of overexpressed ELAV, FNE and RBP9 
HA-tagged ELAV (A-A!!), FNE (B-B!!) and RBP9 (C-C!!) were overexpressed with elavC155-
Gal4 driver are visualized with anti-HA antibody. Cellular localization is compared to nuclear 









Figure 3.9 Cellular localization of FNE and RBP9 from genomic rescue constructs. 
HA-tagged FNE and myc-tagged RBP9 were visualized with anti-HA and anti-myc 
antibodies and their localization was compared to nuclear ELAV staining from single 
confocal sections in larvae for FNE (A-A!!) and in adults for FNE (B-B!!) and RBP9 (C-C!!).   
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with elavC155-Gal4 and looked at their localization in midline neurons of the VNC in 3rd instar 
larvae (all proteins were HA-tagged as described in Materials and Methods). As expected 
ELAVNLS localized preferentially to the nucleus, ELAVΔOH was detected in both the nucleus 
and cytoplasm and ELAVNLS ΔOH was detected preferentially in the nucleus (Figure 3.10). 
Next, I assessed if overexpressing ELAVNLS, ELAVΔOH and ELAVNLS ΔOH with elavC155-
Gal4 would have an effects on longevity (Figure 3.11).  ELAVNLS and ELAVNLS ΔOH 
overexpressing flies exhibited a longevity curve very similar to that of ELAV 
overexpressing females with median life span of 40 days and a maximum life span greater 
than 60 days. Interestingly, ELAVΔOH overexpressing females clearly showed reduced 
longevity with median life span of 12 days and a maximum life span of 55 days. 
To test if reduced longevity was correlated with defects in climbing, I compared climbing 
ability of females overexpressing ELAVNLS, ELAVΔOH and ELAVNLS ΔOH with elavC155-Gal4 
to that of elavC155-Gal4;;UAS-elav females (Figure 3.12). Similar to ELAV overexpressing 
females, ELAVNLS and ELAVNLS ΔOH females showed significant reduction in their ability to 
climb on day 1 compared to elavC155-Gal4/+ controls which unlike ELAV overexpressing 
females decreased with time to 10% and 5% on days 10 and 20 for ELAVNLS and to 20% on 
day 20 for ELAVNLS ΔOH. Surprisingly, ELAVΔOH overexpressing females had no significant 
climbing deficits compared to elavC155-Gal4/+ control females on day 1 but their ability to 
climb dramatically decreased on day 10 to 20 % and 7% on day 20.  
To test if the age-dependent reduction in climbing ability of ELAVNLS and ELAVΔOH could 
be associated with gross age-dependent neurodegeneration, I looked at the morphology of 
the central brain on paraffin sections (Figure 3.13). Similarly, as to my previous observations 
with ELAV overexpression, vacuolization was not detected in one-day old flies (more than 
20 heads analyzed for ELAVNLS and ELAVΔOH). In some head sections, however, 




Figure 3.10 Cellular localization of overexpressed ELAV, ELAVNLS, ELAVΔOH and 
ELAVNLS ΔOH 
HA-tagged ELAV (A-A!!), ELAVNLS (B-B!!), ELAVΔOH (C-C!!) and ELAVNLS ΔOH (D-D!!) 
were overexpressed elavC155-Gal4 driver. Localization of HA-tagged proteins was compared 





Figure 3.11. Overexpressing ELAV, ELAVNLS, ELAVΔOH and ELAVNLS ΔOH reduces 
lifespan  
Lifespan of females overexpressing ELAV, ELAVNLS, ELAVΔOH and ELAVNLS ΔOH with 
elavC155-Gal4 driver compared to elavC155-Gal4/+ control females is shown as mean from 





Figure 3.12.  Age-dependent reduction in climbing ability in females overexpressing 
ELAVNLS, ELAVΔOH, but not ELAV and ELAVNLS ΔOH. 
Climbing ability of females overexpressing ELAV, ELAVNLS, ELAVΔOH and ELAVNLS ΔOH 
with elavC155-Gal4 and is is presented as Performance Index in relation to the days on which 
the negative geotaxis assay was carried out (x axis). Control genotype was elavC155-Gal4/+. 
Three independent sets of 20 flies per genotype were tested three times. Error bars represent 
standard deviations. Red stars indicate significant difference in climbing ability compared to 
control and blue stars indicate significant age-dependent differences for individual genotypes, 





Figure 3.13.  Age-dependent vacuolization in females overexpressing ELAV, ELAVNLS, 
ELAVΔOH and ELAVNLS ΔOH 
Representative panels of paraffin sections illustrating brain morphology on days 1 and 20 of 
females overexpressing ELAV (A-A!), ELAVNLS (B-B!), ELAVΔOH (C-C!) and ELAVNLS ΔOH 
(D-D!). Blue arrows point reminiscence of tracheal tract, red arrows point vacuolizations. 
Control was 1 and 20 day old elavC155/+ females. Heads were sectioned at 10µm. 
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these were dismissed as vacuolization as this was an artifact of tissue sample preparation.    
Vacuolization was apparent in the central part of the brain in 10-day old females (occurrence 
was in all 10 heads analyzed for ELAVNLS and in all 15 heads analyzed for ELAVΔOH). 
 
Since ELAV-mediated splicing of ewg is about 50%, where only a fraction of transcripts are 
spliced (Soller and White 2003), I asked the question, if by overexpressing ELAV neuronal 
ewg splicing would increase. I also examined if this would be the case for ELAV-dependent 
splicing of nrg and arm. Surprisingly, there was no significant increase in levels of neuronal 
isoforms of ewg, nrg and arm, but also no increase was observed when ELAV was forced to 
the nucleus by the NLS (Figure 3.14A-C).  
To validate that all constructs expressed equal ELAV levels I analyzed their expression on 
western blots (Figure 3.14D). As expected all constructs expressed comparable levels from 
the respective transgenes. Since ELAV proteins from UAS constructs were HA tagged, they 
were distinguishable from the endogenous proteins by their slightly bigger size. 
Unexpectedly, endogenous ELAV levels were not downregulated by autoregulation as 
previously claimed (Samson, 1998). 
Since autoregulation was not the case of modulating ELAV levels, another possibility of how 
cells would compensate for excess ELAV levels is by altering ELAV subcellular 
localization. For example forcing transgenic ELAV to the nucleus via the NLS could result 
in re-localization of endogenous ELAV to compensate for the increased nuclear levels. To 
test this possibility I made two additional constructs: ELAVNLS-13, with a deletion of 13 
amino acids between RNP1 and 2 in RRM1, which amino acids are specific to ELAV and 
are recognized by the monoclonal ELAV antibody and whose deletion does not impair 
ELAV function (Yannoni and White, 1999); and a control ELAV-13 to assess if the -13 






Figure 3.14.  Increased nuclear ELAV levels do not affect splicing of ELAV targets. 
 ELAV, ELAVNLS, ELAVΔOH and ELAVNLS ΔOH were expressed with elavC155-Gal4 and RNA 
was extracted from 3rd instar female larval brains. (A-C) Splicing levels of ewg, nrg and arm 
assessed on semi-quantitative agarose gels were quantified from RCR band intensities from 
three independent RNA extractions and their mean is shown. Primers used for the PCR are 
indicated on the schematic gene structure. (D) Protein levels of ELAV, ELAVNLS, ELAVΔOH 
and ELAVNLS ΔOH overexpressing adult females visualized with anti-ELAV antibody. 1 is 
transgenic and 2 is endogenous ELAV. 
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elavC155-Gal4 did not result in re-localization of endogenous ELAV to the cytoplasm in 
midline neurons of the VNC in 3rd instar larvae (Figure 3.15), suggesting that ELAV activity 
is likely regulated by other means.  
To test if neuron-specific regulation was the reason for the restricted splicing ability of 
nuclear ELAV, I expressed ELAV, ELAVNLS, ELAVΔOH and ELAVNLSΔOH ectopically in 
epithelial cells of the wing disc with dpp-Gal4. To assess splicing ability, I quantified GFP 
levels, in the dpp pattern upon expression of the ELAV constructs, as a readout of ELAV-
mediated neuronal splicing from a previously described nrg GFP reporter construct (UngA) 
(Toba and White, 2008). As previously shown for ELAV, ELAVNLS, ELAVΔOH and 
ELAVNLSΔOH were also able to promote splicing of the nrg reporter. However, expression of 
none of the four constructs had a significant effect on GFP levels (Figure 3.16), showing that 
preferential nuclear localization does not play a role in modulating ELAV’s activity.  
Phosphorylation of HuR at a number of positions is important for HuR function (Doller et 
al., 2011), in particular substitution of serine 318 to aspartate mimics phosphorylation at this 
amino acid, promoting increased RNA binding and increased cytoplasmic localization of 
HuR. To test if overexpressing an ELAV protein, constitutively phosphorylated at the 
corresponding serine (in ELAV it is S472 which was changed to D) would have an impact 
on the protein’s splicing ability, I created ELAVS472D and ELAVNLSS472D. I tested if 
phosphomimetic ELAVS472D and ELAVNLSS472D can promote ectopic splicing of nrg when 
expressed with dpp-Gal4. Here, expression of both ELAVS472D and ELAVNLSS472D increased 
GFP levels produced by the nrg GFP splicing reporter (Figure 3.17A-D). Next, I tested if 
overexpression of ELAVS472D and ELAVNLSS472D with elavC155-Gal4 could result in 
increased cytoplasmic localization as reported for HuR S to D mutation at position 318. 
Interestingly, in midline neurons of the VNC in 3rd instar, ELAVS472D was detected in high 






Figure 3.15.  Localization of endogenous ELAV does not depend on increased nuclear 
ELAV levels.  
ELAVNLS-13 (A-A!!) and ELAV-13 (B-B!!) were overexpressed with elavC155-Gal4 and the 




Figure 3.16.  Ectopic overexpression of ELAV, ELAVNLS, ELAVΔOH and ELAVNLS ΔOH 
does not increase splicing of nrg GFP reporter.  
(A) Schematic representation of the nrg reporter construct (UnGA) as described in Toba and 
White, 2008. (B-E!!) HA-tagged ELAV, ELAVNLS, ELAVΔOH and ELAVNLS ΔOH were 
expressed with dpp-Gal4. Overlay projections of GFP produced from the nrg reporter 
construct and HA staining in the dpp patern from whole wing discs are shown. (F) 
Quantification of the average overlay intensity of GFP normalized to that of HA staining 
from 4 wing discs per genotype.  Error bars represent standard deviations. Stars indicate 




















































igure 3.17.  Ectopic overexpression of ELAVS472D nuclear ELAVNLSS472D increase splicing 
of nrg GFP reporter. 
(A-C!!) HA-tagged ELAV, ELAVS472D and ELAVNLSS427D were expressed with dpp-Gal4. 
Overlay projections of GFP produced from the nrg reporter construct and HA staining in the 
dpp patern from whole wing discs are shown. (D) Quantification of the average overlay 
intensity of GFP normalized to that of HA staining from 4 wing discs per genotype.  Error 
bars represent standard deviations. Stars indicate significant differences where p< 0.00416 
after Bonferonni correction in the t-test. (E-E!!) Cytoplasmic localization of ELAVS472D 




















































expressed in the same way (Figure 3.17E). Surprisingly, ELAVNLSS472D overexpressed with 
elavC155-Gal4 was not detected with the anti-HA antibody. Consistent with the rough eye 
phenotype of elavC155-Gal4/UAS-elav flies, ELAVS472D overexpressing females also had 
aberrant eye morphology, whereas, ELAVNLSS472D did not, possibly because of the short 
half-life of this protein in neurons (Table 3.2). 
 
FNE and RBP9 have not been shown to regulate alternative splicing. Therefore, I tested if 
FNE and RBP9 could promote splicing of the nrg reporter when expressed ectopically with 
dpp-Gal4. Interestingly, both FNE and RBP9 induced ELAV-mediated splicing of nrg, 
where GFP levels produced from FNE expression were significantly higher compared to 
those produced from ELAV (Figure 3.18).   
Historically, human Hu proteins were characterized for their roles in promoting transcript 
stability but not splicing regulation. Therefore, I attempted to express HuR, HuB, HuC and 
HuD in Drosophila and test their ability to splice ELAV targets. I expressed the four proteins 
with dpp-Gal4 and assessed the levels of GFP produced from the nrg splicing reporter. Here, 
HuR, HuB and HuC promoted ELAV-mediated splicing with different efficiency (Figure 
3.19). GFP levels produced from the nrg reporter were lower compared to those from ELAV 
when HuR and HuB were expressed. Expression of HuC resulted in GFP levels, significantly 
higher than when ELAV was expressed. Surprisingly, no expression of HuD was detected in 
the dpp pattern and that resulted in no GFP production.  
Next, I tested if Hu proteins expressed in the nervous system would have similar phenotypes 
as Drosophila ELAV proteins. Unexpectedly, when expressed pan-neuronaly with elavC155-
Gal4, overexpression of HuR, HuB, HuC and HuD was embryonic lethal, therefore, GAL4 
drivers with restrictive expression pattern were tested to analyze if animals survive so that I 





Figure 3.18.  Ectopic overexpression of FNE and RBP9 promote splicing of  the ELAV-
dependent nrg GFP reporter.  
(A-C!!) HA-tagged ELAV, FNE and RBP9 were expressed with dpp-Gal4. Overlay 
projections of GFP produced from the nrg reporter construct and HA staining in the dpp 
patern from whole wing discs are shown. (D) Quantification of the average overlay intensity 
of GFP normalized to that of HA staining from 4 wing discs per genotype.  Error bars 
represent standard deviations. Stars indicate significant differences where p<0.00416 after 










































Figure 3.19.  Ectopic overexpression of human Hu proteins in Drosophila promotes 
splicing of the ELAV-dependent nrg GFP reporter.  
(A-E!!) HA-tagged ELAV, HuR, HuB, HuC and HuD were expressed with dpp-Gal4. 
Overlay projections of GFP produced from the nrg reporter construct and HA staining in the 
dpp patern from whole wing discs are shown. (F) Quantification of the average overlay 
intensity of GFP normalized to that of HA staining from 4 wing discs per genotype.  Error 
bars represent standard deviations. Stars indicate significant differences where p<0.00416 















































subsets of neurons, the four Hu proteins showed different expression (Table 3.2.). 
Overexpression of Hu proteins with apterous-Gal4 resulted in 3rd instar lethality when HuR 
and HuB were overexpressed, whereas, HuC and HuD did not affect viability. HuR and HuB 
were detected in the nucleus of apterous expressing neurons (Figure 3.20A and B), whereas, 
HuC and HuD transgenic proteins were not detected by the anti-HA antibody. When 
overexpressed with sevenless-Gal4, HuR, HuC and HuD did not affect viability, whereas, 
overexpression of HuB resulted in 2nd instar lethality. HuR’s localization was clearly nuclear 
in 3rd instar larval photoreceptors and HuC localized preferentially to the nucleus but was 
also detected in the cytoplasm (Figure 3.20C and D). Here, HuD was also not detected with 
the anti-HA antibody. 
 
3.4. Summary 
The analysis of loss of function phenotypes for ELAV family proteins revealed distinct 
phenotypes for ELAV. In particular ELAV alone is required for photoreceptor development 
and low levels of elav resulted in dramatic reduction in climbing ability, abnormal 
development of the optic lobes and formation of vacuoles in the adult brain, which was not 
observed to a similar extend in fne and Rbp9 null mutants, and vacuolization was observed 
only marginally in the fne;rbp9 double mutant. As elav hypomorphic mutants were bred at 
18°C (permissive temperature) and shifted to 25°C (restrictive temperature) for aging, the 
shift to higher temperature might have accelerated the decline in viability, performance in 
climbing assays and brain morphology (Miquel et al., 1976). However, the occurrence of 
neurodegenerationin in the case of elav is likely due to downregulted elav levels during 
development which made the adult brain more susceptible, as such dramatic defects were not 
observed in temperature shift experiments with wild type flies (Miquel et al., 1976). 







Figure 3.20.  HuR, HuB and HuC expression in Drosophila  is neuron type specific 
(A-B!!) HA-tagged HuR and HuB were overexpressed with apterous-Gal4.  Localization of 
HA-tagged proteins was compared to that of CD8:GFP expressed simultaneously from a 
UAS transgene from single confocal sections (C-D!!) HA-tagged HuR and HuC were 
expressed with sevenless-Gal4 and their localization was compared to DAPI nuclear staining 
from single confocal sections.  
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assessment of xenobiotics interfering with ELAV function by downregulating the protein’s 
activity, as such drugs are to be administered in early larval life.  
The analysis of gain of function phenotypes for ELAV family members and ELAV modified 
proteins revealed distinct and overlapping phenotypes between ELAV, FNE and RBP9 based 
on reduced viability, climbing ability and vacoulization of the adult brain. In regards to 
viability, cytoplasmic RNPs (FNE, RBP9 and ELAVΔOH) showed significant differences 
compared to nuclear RBPs (ELAV, ELAVNLS and ELAVNLS ΔOH). This could indicate either 
of two points: 1) overexpressed proteins accumulate in the cytoplasm and lead to 
cytotoxicity, a common outcome of overexpression experiments; or 2) cytotoxicity is a result 
of excessive mRNAs processing. Excessive cytoplasmic mRNA binding would suggest a 
cytoplasmic role for ELAV, e.g. a role in mRNA stability and translation initiation. Overall, 
overexpression of nuclear and cytoplasmic forms of ELAV resulted in vacoulization in the 
adult brain, which could be used as a phenotypic endpoint for the assessment of xenobiotics 
interfering with ELAV by either increasing its levels or activity. 
Ectopic overexpression of ELAV/Hu family members in the wing disc revealed that 
Drosophila and human RBPs are able to bind and promote splicing of nrg- an ELAV target. 
The ELAV/Hu family shares over 60% homology in the RRMs (Samson, 2008), which 
would explain the commonality to bind the same mRNA ectopically. In neuronal tissues, 
however, specificity to mRNA targets is far more stringent, as ELAV, FNE and RBP9 have 
distinct mutant phenotypes that would suggest different targets; and overexpression of 
human Hu proteins differed between subsets of neurons, which would suggest their 
differential activity to that of Drosophila neuronal RBPs in the overexpression paradigm 
tested. Possible explanations to how specificity of such highly conserved RBPs in neurons is 
achieved could be: 1) RBP levels are spatially and temporally tightly controlled through 
transcriptional regulation: dpp-Gal4 overexpression of RBPs and the availability of mRNA 
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target ectopically overwrote endogenous transcriptional control and revealed binding ability 
which would otherwise not be possible, due to deficit of RBPs and target mRNA 
endogenously; 2) activity of RBPs is controlled by post-translational regulation: 
phosphorylated RBPs would render them more active, as in the case of constitutively 
phosphorypated ELAVS472D which induced higher nrg associated GFP levels than ELAV; 3) 
excessive and overactive neuronal RBPs are quickly degraded: pan-neuronal expression of 
HuD resulted in embryonic lethality indicating that the transgenic protein was made, 
however, its absence when expressed in only subsets of neurons would indicate its rapid 
degradation, similarly, when expressed in neurons nuclear phosphomimetic ELAVNLSS472D 
was also possibly degraded and therefore not detected, despite, being functionally more 
active than ELAV in promoting splicing of nrg ectopically in the wing disc.  
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Chapter 4: Evaluation of OATP and ABC transporters for genetic 




Many insects, including Drosophila, resist highly toxic plant metabolites upon dietary 
exposure. These adaptations have naturally evolved and likely provide resistance through 
rapid detoxification for example by excretion. Likely, mutations in genes involved in such 
resistance are not lethal, as they provide advantages upon exposure to xenobiotics and 
therefore mutants of these genes would not have a phenotype unless challenged with specific 
toxins. Thus, mutated transporter genes could provide a sensitized fly model for toxicity 
testing. Oatps have been proposed to play a role in excretion through the Malpighain tubules, 
which has been shown for Oatp58Db in clearance of ouabain in an ex vivo Malpighian tubule 
excretion assay (Torrie et al., 2004).  The Drosophila genome has eight Oatp genes, named 
after their cytological location (Oatp26F, Oatp30B, OATP33Ea, Oatp33Eb, Oatp58Db, 
Oatp58Dc, Oatp74D). 
Drug resistance in humans has been shown to be mediated by a number of ABC transporters, 
termed Mdr and MRP. The Drosophila genome has 5 Mdr and MRP genes: Mdr49, Mdr50, 
Mdr65, MRP and Mrp4. To evaluate if mutations in Oatp and Mdr/MRP genes would affects 
drug sensitivity I analyzed the expression patterns of these transporters and then tested for 
altered drug responses in Oatp and Mdr/MRP mutant backgrounds.  
 
Routs of oral administration involve uptake through the digestive system and rapid transport 
out of the circulatory system into the Malpighian tubules. An additional level of regulation in 
drug transport occurs at the BBB. Accordingly, transport mediated through Oatps and 
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Mdr/MRP proteins can be located to three tissues:  (1) transport in the digestive system; (2) 
transport in the Malpighian tubules and (3) transporter-mediated passage of drugs through 
the BBB. To associate potential functions with anatomical location I looked at mRNA 
expression levels of Oatp and Mdr/MRP proteins according to organ and developmental 
stage from publicly available microarray data of the FlyAtlas Anatomical Expression Data 
set (Figure 4.1). Oatps and Mdrs were predominantly expressed in the digestive system and 
Malpighian tubules, potentially providing initial selective control over uptake of nutrients 
and later facilitating rapid excretion. Very high expression in the digestive system was found 
only for MRP in adults and high expression was found for Oatp33Ea in larvae and adults, for 
Mdr50 in adults and for MRP in larvae. Very high expression in Malpighian tubules was 
found for MRP in adults and for Oatp58a-c in both larvae and adults and high expression 
levels were detected for Oatp30B and Oatp33Eb in adults and MRP in larvae. In the CNS 
high expression levels were detected for in adults and for Oatp74D and Mdr65 in larvae, 
which could potentially regulate selective uptake or clearance from the brain. A small 
fraction of Oatp and Mdr/MRP transporters were also expressed in moderate to high levels in 
the fat body, which is a multifunctional organ, best known for its role in energy storage, 
indicating that these transporters are involved in nutrient transport.  
 
Since characterized null mutants for the 13 transporter genes were not available and RNAi 
knockdown generally results in partial downregulation, I used mutants generated from 
transposon insertions in critical parts for expression of the transporter genes. The rational for 
choosing transposon mutants was: (1) if the transposon was inserted in the ORF it will lead 
to the production of a truncated protein and result in a null allele (2) if such mutants were not 
available, I chose lines where the transposon was inserted in the 5´ UTR or promoter as the 





Figure 4.1. Expression of OATP, MDR and MRP larval and adult tissue expression   
Drosophila transporters are differentially expressed in the CNS, digestive tract and 
Malpighian tubules during larval development and adulthood. Tissue-specific mRNA 
expression levels were collected from the FlyAtlas Anatomical Expresison Data available at 
Flybase.org and derived from hybridization of mRNA to Affymetrix Drosophila Genome 2 
microarrays. CNS expression analysis combined reads from central brain and abdominal 
thoracic ganglion (for adults). Digestive system represents combined reads from hindgut and 
midgut. 
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will result in reduced or absent expression, as described in Haussmann et al, 2008.  
To test for sensitization of Oatp and Mdr/MRP mutants I used the following five compounds: 
clotrimazole, chlorhexidine, flunarizine, digitoxin and ouabain (Figure 4.2). Clotrimazole, 
chlorhexidine, and flunarizine are commonly used drugs. Clotrimazole is a widely prescribed 
antifungal medication, chlorhexidine is an anticeptic used as the active ingredient in 
mouthwash and flunarizine is a calcium channel blocker used to medicate migraines and its 
application has also been associated with the development of Parkinson’s disease (Teive et 
al., 2004). Independently of their pharmacological properties, these three drugs were also 
identified as gene-specific alternative splicing regulators (Younis et al., 2010) 
Digitoxin and ouabain share similarities in their chemical structures and are toxic plant 
glycosides that inhibit Na+, K+ ATPases and resistance to ouabain in ex vivo preparations of 
Malpighian tubules was shown to be mediated through Oatp58Db (Torrie et al., 2004). 
Independent of its mechanisms of toxicity, digitoxin has been shown to promote alternative 
splicing of the Alzheimer’s disease associated MAPT isoform. A function in splicing has not 
been reported for ouabain.  
 
4.2. Dose response of Oatp and Mdr/MRP mutants to clotrimazole, chlorhexidine, 
flunarizine, digitoxin, and ouabain . 
To test for altered toxic responses of the 13 Oatp and Mdr/MRP mutants compared to wild 
type controls exposed to the relevant solvent, two-day old larvae were exposed at different 
concentrations and the number of adult flies eclosed on days 12,14,16 and 18 was assessed 
as the toxicity readout (this approach was undertaken for all toxicity testing in this chapter 
and is described under acute exposure in materials and methods). 
A dose-response curve to clotrimazole was obtained when wild type larvae were exposed to 




Figure 4.2. Chemical structures of the compounds used to determine sensitivity of Oatp 
and Mdr/MRP transporters adapted from sigmaaldricht.com website.  
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was observed at 250 µM (57%) and 2.5 mM (43%) concentrations (Figure 4.3). The 
Oatp33Ea mutant was more sensitive to clotrimazole at 250 µM and 2.5 mM (36% and 35% 
survival) and Oatp58Db and OatpDc were more sensitive at 2.5 mM (25% and 15% survival 
respectively). Mdr65 mutant also exhibited clear sensitization to the drug with decreased 
survival of 48%, 18% and complete lethality at 25 µM, 250 mM and 2.5 mM, respectively. 
Surprisingly, the Mdr50 mutant showed clear desensitization to the drug and had more than 
20% survival at 250 µM and 2.5 mM in comparison to wild type at these concentrations.  
A dose-response curve to chlorhexidine was obtained when wild type flies were exposed to 
10 µM, 100 µM, 1 mM and 10 mM of the drug, where sub-lethal concentration of 1mM 
resulted in 47% survival and a mere 5% at 10mM  (Figure 4.4). None of the Oatp and 
Mdr/MRP mutants exhibited significantly different dose responses in comparison to wild 
type at these concentrations.  
A dose response curve for flunarizine was obtained when wild type flies were exposed to 5 
µM, 50 µM, 500 µM and 5 mM of flunarizine, where the sub-lethal concentrations were 50 
µM and 500 µM (58% and 11% survival), and a lethal concentration was reached at 5 mM 
(Figure 4.5). None of the Oatp and Mdr/MRP mutants exhibited increased sensitivity to 
flunarizine, however, the Oatp58Dc showed resistance to the drug at 50 µM (75% survival) 
and Oatp30B mutants showed resistance at 500 µM (38% survival). 
A dose response curve to digitoxin was obtained when wild type flies were exposed to 2.5 
µM, 25 µM, 250 µM and 2.5 mM of digitoxin, where the sub-lethal concentration was 250 
µM (41% survival) and complete lethality was reached at 2.5 mM (Figure 4.6). Mutants of 
Oatp30B and Mdr50 were less sensitive to digitoxin at the sub-lethal concentration with 88% 
and 73% survival, respectively. In contrast, mutants of Oatp33Ea, Mdr65 and MRP were 
more sensitive compared to wild type when exposed to 250 µM digitoxin and had 12%, 5% 
and 3% survival rate, respectively.  
 
Figure 4.3. Dose-response curves for Oatp and Mdr/MRP mutants exposed to 
clotrimazole. 
Toxicity of clotrimazole to Oatp (A) and Mdr/MRP (B) mutants was determined from adult 
survival after exposure of two-day old larvae to 2.5 µM, 25 µM, 250 µM and 2.5 mM final 
concentrations plotted as means from at least three experiments. Survival levels were 
normalized to solvent exposed controls, in this case H2O. A solid line indicates the wild 
type’s dose-response. Significant differences between in (A) are indicated by one star for 
p<0.0071 and two starts for p<0.00071 and in (B) by two stars for p<0.001 and three starts 




Figure 4.4. Dose-response curves for Oatp and Mdr/MRP mutants exposed to 
chlorhexidine. 
Toxicity of chlorhexidine to Oatp (A) and Mdr/MRP (B) mutants was determined from adult 
survival after exposure of two-day old larvae to 10 µM, 100 µM, 1 mM and 10 mM final 
concentrations plotted as means from at least three experiments. Survival levels were 
normalized to solvent exposed controls, in this case H2O. A solid line indicates the wild 
type’s dose-response to chlorhexidine.  
 
Figure 4.5. Dose-response curve for Oatp and Mdr/MRP mutants exposed to flunarizine. 
Toxicity of flunarizine to Oatp (A) and Mdr/MRP (B) mutants was determined from adult 
survival after exposure of two-day old larvae to 5 µM, 50 µM, 500 µM and 5 mM final 
concentrations plotted as means from at least three experiments. Survival levels were 
normalized to solvent exposed controls, in this case 0.05%, 0.5%, 5% and 50% ethanol was 
used to dissolve 5 µM, 50 µM, 500 µM and 5 mM digitoxin, respectively. A solid line 
indicates the wild type’s dose-response curve. Significant differences in (A) are indicated by 




Figure 4.6. Dose-response curve for Oatp and Mdr/MRP mutants exposed to digitoxin. 
Toxicity of digitoxin to Oatp (A) and Mdr/MRP (B) mutants was determined from adult 
survival after exposure of two-day old larvae to 2.5 µM, 25 µM, 250 µM and 2.5 mM final 
concentrations plotted as means from at least three experiments. Survival levels were 
normalized to solvent exposed controls, in this case H2O. A solid line indicates the wild 
type’s dose-response. Significant differences in (A) are indicated by one star for p<0.0071 
and two stars for p<0.00071 and in (B) by one star for p<0.001 and two starts for p<0.0001 
after Bonferonni t-test.  
 86 
A dose-response curve to ouabain was obtained when wild type flies were exposed to 2.5 
µM, 25 µM, 250 µM and 2.5 mM of ouabain, where gradual decrease in survival was 
observed at 250 µM (55%) and 2.5 mM (43%) (Figure 4.7). Surprisingly, none of the tested 
Oatp and Mdr/MRP mutants showed increased sensitivity to ouabian. In contrast, Oatp26F, 
Oatp30B, Oatp33Ea and Oatp33Eb and Mdr50 were less sensitive to this drug at sub-lethal 
concentrations of 250 µM (77%, 84%, 100%, 87%, 76% and 80%, respectively). Oatp30B, 
Oatp33Ea and Mdr50 maintained resistance at 2. 5mM (80%, 65%, 63%, respectively). The 
highest concentration of ouabain did not exert the anticipated lethal effect as evident from 
the dose-response curve tipping off. This is likely due to reduced solubility of this compound 
at higher concentration.  
 
4.3. Dose response of Oatp and Mdr/MRP double mutants and BBB compromised 
mutants to clotrimazole, chlorhexidine, flunarizine, digitoxin and ouabain. 
The toxic response results indicated that there is no distinguished mutant among the 13 Oatp 
and Mdr/MRP tested that showed consistently reduced sensitivity to all 5 drugs. This 
indicated that some of the Oatp and Mdr/MRP transporters could act bi-directionally and 
their transport capabilities are redundant, when expressed in the same tissues. To address the 
question of redundancy and potentially identify a suitable genetic background that would 
result in reduced sensitivity to all compounds, I created double mutant combinations 
between transporters expressed in the gut and Malpighian tubules and those expressed in the 
nervous system. For the double mutant combinations I took into consideration those 
transporter mutants that did not show an effect and those that had only reduced sensitivity 
when tested. In this way I created double mutants for genes expressed in the nervous system- 
Oatp74D;Mdr65,  a double mutant for genes expressed in the digestive system and 
Malpighian tubules- Mdr49;MRP and double mutants for genes expressed in the gut and 
 
 
Figure 4.7. Dose-response curve for Oatp and Mdr/MRP mutants exposed to ouabain. 
Toxicity of ouabain to Oatp (A) and Mdr/MRP (B) mutants was determined from adult 
survival after exposure of two-day old larvae to 2.5 µM, 25 µM, 250 µM and 2.5 mM final 
concentrations plotted as means from at least three experiments. Survival levels were 
normalized to solvent exposed controls, in this case H2O. A solid line indicates the wild 
type’s dose-response. Significant differences in (A) and (B) are indicated by one star for 
p<0.0071 and for p<0.001 after Bonferonni t-test, respectively.  
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nervous system- Mdr49;Oatp74D and Mdr49;Mdr65. To attempt a combined mutant 
background between all three systems I combined the MRP mutant (which is highly 
expressed in both digestive system and Malpighian tubules) and the neuronal Oatp74D and 
Mdr65, to obtain MRP; Oatp74D and MRP;Mdr65. Double mutant combinations of 
transporters expressed in the nervous system, Malpighian tubules and digestive system 
(Oatp74D;Mdr65, Mdr49;MRP; Mdr49;MRP  and Mdr49;Mdr65) were viable, but not for 
those expressed in all three systems (MRP; Oatp74D  and MRP;Mdr65 were embryonic 
lethal). 
I exposed the viable double mutants to the same five drugs as before and to assess if reduced 
adult survival could be due to toxicity in the nervous system, I also tested a BBB 
compromised mutant background in parallel, where the gene responsible for the formation of 
septate junctions in the BBB- moody was down-regulated by RNAi in subperinurial (spg) 
glia (Daneman and Barres, 2005). The RNAi approach was used because moody null 
mutants do not survive until adulthood and partial downregulation by RNAi produced viable 
adults. Since there were two moody RNAi lines available I tested both UAS-moody(M10) 
and  UAS-moody(M18), expressed with an spg-Gal4 driver, for their increased sensitivity to 
the five compounds.  
I compared toxic responses of the double transporter mutants and the moody mutants to the 
previously assessed toxicity for wild type and respective single mutants.   
When exposed to clotrimazole Mdr49;Oatp74D, Mdr49;Mdr65 double mutants showed 
dramatically increased sensitivity in comparison to wild type and the respective single 
mutant controls at 25 µM and  250 µM (47%,63%) and at 2.5 mM complete lethality was 
achieved (Figure 4.8). The double mutant Mdr65;Oatp74D also showed reduced viability at 
250 µM (0.6%) compared to wild type and single mutant controls. Surprisingly, the double 
mutant Mdr49;MRP showed resistance to clotrimazole when compared to wild type and 
 
Figure 4.8. Dose-response curves for Oatp74D and Mdr/MRP double mutants and BBB 
compromised mutants exposed to clotrimazole. 
Toxicity of clotrimazole to Oatp74D and Mdr/MRP double mutants (A) and BBB 
compromised mutants (B) was determined as previously described in Figure 4.3 legend. 
Significant differences in (A) are indicated by one star for p<0.00625 and two starts for 
p<0.000625 after Bonferonni t-test.  
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single mutant controls at 250 µM (78% survival). moody mutants did dot show differences in 
their survival compared to wild type, which indicated that clotrimazole toxicity was not 
exhibited through interference with nervous system function (Figure 4.8).  
When exposed to chlorhexidine Mdr65;Oatp74D, Mdr49;Oatp74D, Mdr49;Mdr65 double 
mutants had significantly reduced survival (14%, 4% and 7%, respectively) at the sub-lethal 
concentration of 1 M compared to wild type and single mutant controls. As observed with 
clotrimazole, the double mutant Mdr49;MRP, was also resistant to chlorchexidine at 1 M 
and 10 M concentrations (99% and 72% survival, respectively). Downregulation of moody in 
the spg with UAS-moody(M18) RNAi line alone reduced survival at 100 µM, and 1M 
concentrations (36% and 11%), indicating that toxicity from chlorhexidine could be a result 
of nervous system dysfunction (Figure 4.9).  
When exposed to flunarizine none of the double mutants showed increased sensitivity 
compared to wild type and single mutant controls. The Mdr49;MRP double mutant, 
however, remained resistant to the drug at 1mM concentration with 72% survival. The BBB 
compromised mutants did not show differences in their survival compared to wild type, 
which indicated that flunarizine toxicity is not exhibited through interference with nervous 
system function (Figure 4.10). 
When exposed to digitoxin, none of the double mutants showed reduced survival when 
compared to single mutant controls. Here, the Mdr49;MRP double mutant was also resistant 
to digitoxin at 250 µM concentration with 87% survival rate. Similarly to chlorhexidine, 
only moody knockdown by UAS-moody(M18) RNAi caused increased sensitivity to the drug 
at 25 and 250 µM concentrations (34% and 17%, respectively), indicating that toxicity of 
digitoxin could be causing nervous system defects (Figure 4.11).  
 When exposed to ouabain, the double mutants Mdr65;Oatp74D and Mdr49;Oatp74D 




Figure 4.9. Dose-response curves for Oatp74D and Mdr/MRP double mutants and BBB 
compromised mutants exposed to chlorhexidine. 
Toxicity of chlorhexidine to Oatp74D and Mdr/MRP double mutants (A) and BBB 
compromised mutants (B) was determined as previously described in Figure 4.4 legend. 
Significant differences between in (A) are indicated by one star for p<0.00625 and two starts 
for p<0.000625 and in (B) by two starts for p<0.025 in Bonferonni t-test. 
 
 
Figure 4.10. Dose-response curves for Oatp74D and Mdr/MRP double mutants and BBB 
compromised mutants exposed to flunarizine. 
Toxicity of flunarizine to Oatp74D and Mdr/MRP double mutants (A) and BBB 
compromised mutants (B) was determined as previously described in Figure 4.5 legend. 
Significant differences in (A) are indicated by one star for p<0.00625 and two starts for 








Figure 4.11. Dose-response curves for Oatp74D and Mdr/MRP double mutants and BBB 
compromised mutants exposed to digitoxin. 
Toxicity of digitoxin to Oatp74D and Mdr/MRP double mutants (A) and BBB compromised 
mutants (B) was determined as previously described in Figure 4.6 legend. Significant 
differences between in (A) are indicated by one star for p<0.00625 and two stars for 
p<0.000625 in Bonferonni t-test and in (B) are indicated by two stars for p<0.025 and three 
stars for p<0.0025 after Bonferonni t-test. 
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µM, 25 µM, 250 µM and 2.5 mM of ouabain their survival was 34%,20%,9%,7% and  
50%, 15%, 7% and 0%, respectively. Also Mdr49;Mdr65 mutant had significantly reduced 
survival rates at 2.5mM (5%) compared to wild type and single mutant controls. Consistent 
will the previous exposures and the neuronal double mutants, moody knockdown with UAS-
moody(M18) caused increased sensitivity to ouabain, where at 2.5 µM, 25 µM, 250 µM and 
2.5 mM  the survival rate was 70%, 37%, 32% and 21%, indicating that ouabain is harmful 
to the nervous system (Figure 4.12).   
 
Since, mutants of Oatp58Db and Oatp58Dc did not show the anticipated sensitivity to 
ouabain as previously described, I examined the mRNA levels produced from the Oatp58Db 
and Oatp58Dc genes in their respective transposon insertion stocks (Figure 4.13). Here, 
insertion of the transposon in the ORF of Oatp58Db and Oatp58Dc completely abolished 
mRNA expression, confirming that these two mutants were in fact null.   
 
4.4. Summary 
The experiments from Chapter 4 aimed to reveal a sensitized genetic background that could 
be used for neurotoxic drug screening in Drosophila, where mutated transporters would 
increase uptake of xenobiotics to the brain. The results of this chapter, however, indicate that 
the fly’s uptake and excretion systems are more sophisticated than anticipated.  
A uniform sensitization for single and double transporter mutants could not be revealed. In 
fact, sensitization was achieved only for specific transporters, at specific concentrations for 
specific drugs. Further complexity to understanding the detoxification process was brought 
by the fact that some transporter mutants were resistant to certain compounds at sublethal 
concentrations (Mdr50 to clotrimazole, Oatp30B to flunarizine, Oatp30B and Mdr50 to 
digitoxin, Oatp33Ea, Oatp30B and Mdr50 to ouabain; and Mdr49;MRP showed resistance to 
 
 
Figure 4.12. Dose-response curves for Oatp74D and Mdr/MRP double mutants and BBB 
compromised mutants exposed to ouabain. 
Toxicity of ouabain to Oatp74D and Mdr/MRP double mutants (A) and BBB compromised 
mutants (B) was determined as previously described in Figure 4.7 legend. Significant 
differences between in (A) are indicated by one star for p<0.00625 and two stars for 





Figure 4.13. Expression of Oatp58Db and Oatp58Dc in the transposon stock. 
Schematic of the gene structure drawn to scale is shown on the left for Oatp58Db (A) and 
Oatp58Dc (B). Transposon insertion is indicated with a red triangle and primers used to 
determine expression levels are indicated with arrows. Semi-quantitative RT-PCR using P32 
labeled forward primers to show the linear level of amplification and to determine expression 
levels is shown to the right. Expression of ken was the control. PCR cycles are indicated on 
top of each panel. 
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clotrimazole, chlorhexidine, flunarizine and digitoxin).  
Two RNAi lines were tested for knockdown of the moody gene in spg glia. Here, UAS-
moody(M10) had little to no effect in promoting increased sensitivity, whereas knockdown 
with UAS-moody(M18) resulted in  increased toxicity to four out of the five compounds. 
This effect argues that expression of UAS-moody(M18) resulted in functional knockdown of 
moody and that this sensitized genetic background could be used to discover novel 
neurotoxins that interfere with ELAV-mediated splicing.. To validate the compromised 
structure of the BBB, however, two follow up experiments are required: 1) examination for 
the degree of dye penetration into the brain in wild type vs. moody knockdown in spg glia, 2) 
expression levels of moody are to be examined either by RT-PCR or western blotting. 
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Chapter 5: Development of a platform for in vivo screening of 
compounds interfering with ELAV-mediated alternative splicing 
 
5.1. Introduction 
Alternative splicing is particularly abundant in the brain and many neuronal genes, for 
example most ion channels, exhibit complex splicing patterns, suggesting that interference 
with alternative splicing regulation could affect neuronal functions. Since it has not been 
extensively tested if neurotoxicity could result from interference of xenobiotics with 
alternative splicing regulation I studied splicing regulation by ELAV, a neuronal RNA 
binding protein present in all neurons. Therefore, I pursued to develop a fluorescent reporter 
system, whose readout would be a direct measurement of ELAV activity and would allow 
rapid visual detection of changes in splicing in response to interference with ELAV function.  
 
5.2. An ewg splicing reporter to assess ELAV-mediated splicing  
The best-studied ELAV target is erect wing (ewg). It has been shown that ELAV-mediated 
neuronal alternative splicing of intron 6 of ewg pre-mRNA occurs at a rate of 50% (Soller 
and White 2003), which has the advantage to assess both up- and down-regulation of ELAV 
activity. 
Since ewg is expressed in moderate levels in the nervous system, I attempted to develop 
reporter constructs where the readout would be an amplification of endogenous ewg splicing 
levels. I created an ewg split Gal4 construct where the Gal4 binding domain (BD) replaced 
ewg DNA binding domain and the Gal4 activation domain (AD) was introduced in frame 
downstream of ewg last exon J to produce ewgelav::Gal4. Alternative splicing from exon H to 
J would form a functional Gal4 protein. Alternative usage of the polyA site in intron 6 
potentially could result in a dominant negative form of Gal4. Since ewg isofoms, which lack 
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exon J are not translated, this would likely not be the case. I also created a rescue construct 
where two copies of GFP were cloned in frame downstream of exon J, termed ewgelav::GFP.  
To enhance expression of this construct, I also introduced a deletion of unrequired sequences 
for ELAV regulation (Δ7) which has previously been shown to elevate levels of neuronal 
ewg mRNA isoform (Soller and White, 2003), termed ewgelavΔ7::GFP. Expression of the 
three constructs was restricted to neurons as they were all cloned under the endogenous elav 
promoter.  
Transgenic flies for all three constructs were obtained via PhiC31 transformation and all 
three constructs were inserted at the same cytological chromosomal site- 76A. No GFP from 
UAS-GFP driven by ewgelav::Gal4 was detected (Figure 5.1. A´-A´´) and very low GFP 
levels were observed for ewgelavΔ7::GFP (Figure 5.1. B´´´-B´´´´). Measurable GFP levels 
were only observed for ewg::GFP (Figure 5.1 B´-B´´). Homozygous transgenic flies were 
obtained for ewgelav::GFP and ewgΔ7::GFP, but not for ewgelav::Gal4. When tested for their 
ability to rescue lethality of the null allele ewgΔ, ewgelav::GFP and ewgΔ7::GFP produced 
65% and 70% rescue respectively and ewgelav::Gal4 did not rescue (Table 5.1). This indicated 
that the ewgelav::Gal4 protein was a dominant negative mutant.  
To test if GFP observed from ewgelav::GFP correlated with the amount of protein produced, I 
looked at homozygous and heterozygous ewgelav::GFP eye discs, where two copies of the 
transgene resulted in visually stronger GFP than 1 copy (Figure 5.2A-B). To test if splicing 
of ewgelav::GFP recapitulated endogenous ELAV regulation, I combined ewgelav::GFP with 
elavedr in elave5 null mutant background. elavedr was a previously described elav rescue 
construct which provides full viability but does not express in the eye, resulting in the 
absence of photoreceptor neurons (Koushika et al., 1996). Consistent with ELAV-regulation, 






Figure 5.1 ewg splicing reporters and associated GFP expression  
(A) Schematics of ewgelav::GFP and ewgelav∆7::GFP splicing reporter. The ∆7 deletion in intron 6 
is indicated. (A´-A´´´´) GFP expression in larval central brain and eye imaginal disc visualized as 
average overlay from confocal stack sections. (B) Schematics of ewg::Gal4 splicing reporter. (B´-
B´´) GFP expression in larval central brain and eye imaginal disc visualized as average overlay 
from confocal stack sections taken with identical laser signal settings. 
 
 
Name Rescue (%) Total 
counted 
ewgelav::GFP 65% (210)  533 
ewgelavΔ7::GFP 70% (270)  654 
ewgelav::Gal4 0 (0)  512 
 
 
Table 5.1. Genetic complementation by ewg reporters 
ewgelav::GFP, ewgelavΔ7::GFP and ewgelav::Gal4 were tested for functional complementation 
with ewgΔ null allele. Males +/Y;;Tg/Balancer were crossed to ewgΔ/FM7i females (Tg   








5.2. Splicing of ewgelav::GFP is ELAV dependent.  
(A-B) GFP expression in eye imaginal disc of ewgelav::GFP homozygous and herozygous 
animals. C) GFP expression of ewgelav::GFP in eye imaginal disc in elave5 null mutant 
background. 
GFP expression was visualized as average overlay from confocal stack sections taken with 
identical laser signal settings. 
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5.3. Identification of xenobiotics interfering with ELAV-mediated splicing  
In an initial chemical screen to determine potential interference with ewgelav::GFP splicing, 
three-day old ewgelav::GFP larvae were acutely exposed to various toxic agents in four 
descending concentrations (listed in Table 2.5) and GFP levels were assessed after 24 hours. 
The highest concentration was the stock concentration listed in Table 2.5 and every next one 
was a ten-fold dilution of the previous. In some cases suspensions were applied when 
compounds could not be dissolved in water, as even low DMSO concentrations were shown 
to be toxic to flies (DMSO results were obtained by Saira Karim, a former MSc Toxicology 
student). Despite that chronic exposure of most compounds resulted in a toxic dose response 
and LD50 could be estimated (Table 5.2) none of the drugs at the tested concentrations had 
an effect on GFP levels.  
Considering the importance of rapid detoxification in Drosophila and the neuro-protective 
role of the BBB, lack of changes in GFP expression levels could indicate the following: 
firstly, it was possible that the compounds were never delivered to the brain; and secondly, 
the time of exposure was insufficient to see an effect. Therefore, I performed a chronic 
exposure screen to the 23 compounds in a compromised BBB mutant background where 
moody was downregulated by UAS-moody[M18] in spg glia (as described in Chapter 4). 
Based on chronic exposure alone, one compound, i.e. 5%, enhanced GFP levels and once 
chronic exposure was combined with the compromised BBB background, an additional 2 
compounds either enhanced or decreased GFP levels (Figure 5.3A). Importantly, when 
expressed in the moody mutant background GFP levels from the ewgelav::GFP reporter 
remained unaffected, indicating that this genetic background did not affect splicing regulation 
of ELAV, neither it affected general transcription or translation levels of the reporter (Figure 
5.3B).    
Sodium orthovanadate, quercetin, and β-glycerophosphate were identified as potential 
Table 5.2. Relative LD50 of compounds used to assess changes in GFP levels by 






Ouabain Octahydrate 0.25 mM 
Digitoxin 0.1 mM  
Flunarizine dihydrochloride 0.08 mM  




D-(−)-Quinic acid >10 mM  
Clotrimazole 
(Sensitive to heat) 
1.6 mM 
 
Naringin >2.5 mM  
Aspirin >10 mM 
1- Napthyl phosphate 
monosodium salt monohydrate <0.01 mM 
Barium Chloride 4.75 mM 
β-Glycerophosphate disodium 
salt hydrate >10 mM 
Sodium Orthovanadate 5 mM 
Sodium Flouride 2.6 mM 
Quercetin Dihydrate >10 mM 
Sodium Butyrate 0.02 mM 
Phosphocreatine disodium salt 
hydrate >10 mM 
Phosphocholine chloride 
calcium salt tetrahydrate >10 mM 




Figure 5.3. Compounds can affect GFP levels of ewgelav::GFP in leaky BBB mutant 
background after chronic exposure 
(A) Percentage of compounds that affected GFP levels from ewgelav::GFP in wild type and moody 
background. (B) GFP intensity measured for ewgelav::GFP in wild type and moody background 
(C) Percentage of GFP intensity of ewgelav::GFP  in moody background after chronic exposed to 
sodium orthovanadate (SO), ß-glycerophosphate (BG) and quercetin (QE) at the indicated applied 
concentrations. GFP levels were quantified from whole brain preparations from images taken on a 
Nikon Ti fluorescent microscope and quantification was done with integrated NIS Element 
software.     
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splicing modulators (Figure 5.3C). Sodium orthovanadate was identified in both the wild type 
and BBB mutant background and exhibited an unusual effect on GFP levels, where at 10 µM 
applied concentration it caused twice the increase of GFP compared to that of controls and at 
100 µM and 1 mM the detected GFP levels were similar to that of the control. Two fold GFP 
increase was also observed at 10 and 100 µM of quercetin and a 2.7 fold increase was 
observed at 1 mM of the drug. In contrast, 50% reduction in GFP levels was observed at 100 
µM and 1 mM of applied β-glycerophosphate. 
To test if chronic exposure of sodium orthovanadate, quercetin and β-glycerophosphate at the 
concentrations that produced strongest effect on GFP levels would result in an ELAV mutant 
phenotype, such as vacuolozation in the adult brain, as described in Chapter 3, I examined the 
morphology of the brain of 1-day old adults. In ewgelav::GFP vacuolization was observed 
specifically in the lamina region of the optic lobe at 10 µM (17 out of 17 analyzed heads) but 
not at 100 µM sodium orthovanadate (20 out of 20 heads analyzed) (Figure 5.4A-A´´). In 
ewgelav::GFP exposed to 1mM quercetin no vacuoles were detected (12/12 heads), however, 
once the BBB was compromised, vacuolization was observed in the medulla and lamina 
(12/15 analyzed) and smaller vacuoles in the lamina were also present to a lesser extent in 
control flies (10/10 analyzed) (Figure 5.4B-B´´). Despite reducing GFP levels of the splicing 
reporter, chronic exposure to 1 mM β-glycerophosphate was not associated with the 
formation of vacuoles in wild type background nor increased vacuolization in BBB mutant 
background (12/12 and 9/9 heads analyzed, respectively) (Figure 5.4C-C´). Next, I assessed 
if increased or reduced GFP levels of ewgelav::GFP would correlate to mRNA levels of 
neuronal ewg.  Surprisingly, I observed decreased levels of ewg intron 6 splicing visualized 
by semi-quantitative RT-PCR at 10 µM sodium orthovanadate in the wild type background 
and 1 mM quercetin in the BBB mutant background and no change was observed at 1 mM β-
glycerophosphate in both backgrounds (Figure 5.4D).  
 
 
5.4. Elevated GFP from chronic exposure correspond to vacuolization in adults, but not to 
elevated mRNA levels of ewg 
Representative panels of paraffin sections illustrating brain morphology in 3-day old adults of the 
indicated genotypes exposed to sodium orthovanadate (SO) (A- A´´), quercetin (QE) (B- B´´) and 
ß-glycerophosphate (BG) (C- C´´). Heads were sectioned at 10 µm. (D) Splicing levels of ewg, 
assessed on semi-quantitative RT-PCR using P32 labeled forward primer normalized to control (1-
ewgelav::GFP; 2- ewgelav::GFP in leaky BBB ) Quantification is shown below the panels, c-control. 
RNA was extracted from the brain complex of five 3rd instar larvae from each genotype.   
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5.4. Summary 
The experiments in Chapter 5 aimed to develop a splicing reporter for the assessment of 
interference of xenobiotics with ELAV mediated-splicing in vivo. Out of the three reporters 
developed, only ewgelav::GFP produced sufficient levels of GFP in order to be used  in a 
small-scale drug screen of 25 compounds where changes in GFP could be identified visually. 
This is an important readout, as in vivo qualitative visual assessment decreases screening 
times as specimens are screened without the need for fixation and further antibody staining. 
Validation of positive hits through a quantitative method, such as GFP recording, however, is 
required at a later stage.  
To improve the screening procedures, two points were taken into consideration: 1) drug 
delivery into the brain is facilitated by a compromised BBB; and 2) to show an effect on 
GFP, compounds are to be administered early enough as GFP’s half life is 26 hours (Corish 
and Tyler-Smith, 1999). Taking this into consideration sodium orthovanadate and quercetin 
were found to increase and β-glycerophosphate was found to decrease GFP levels of 
ewgelav::GFP. An increase of GFP related to vacuolization in the lamina for sodium 
orthovanadate and the lamina and central brain for quercetin, whereas, decreased GFP levels 
caused by β-glycerophosphate did not result in any morphological changes.  Possible 
explanations for this are: 1) increased ELAV levels/activity would result in impaired 
development of the nervous system during larval stages and would enhance susceptibility to 
neurodegeneration in the adult brain (as observed for ELAV overexpression in Chapter 3); 
and 2) despite causing a decrease in GFP levels β-glycerophosphate did not effectively 
reduce ELAV levels/activity to a point where neurodegeneration would be observed.    
The fact, that 10 µM sodium orthovanadate and 1 mM quercetin increased GFP levels and 
that was associated with a lower level of ewg intron 6 splicing, was surprising, as the 
opposite was expected. A possible explanations for this result would be that the GFP readout 
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from  ewgelav::GFP does not reflect rapidly enough changes in gene expression as the GFP 
half life is 26 hours and changes in mRNA abundance can occur as early as 1 hour in 
eukaryotes (Shalem et al., 2008). Therefore, the initial effect of sodium orthovandate and 
quercetin could have been an increase of ELAV splicing activity correlated to elevated ewg 
protein and GFP levels. This would argue that the decrease of ewg mRNA observed 96 hours 
post administration is secondary due to the acquired cellular stress, a response to which 
would be a decrease in gene expression and this effect is masked by the relatively long half 




Chapter 6: Discussion 
 
6.1. ELAV/Hu proteins share distinct and overlapping phenotypes 
Based on the longevity, locomotion and adult brain morphology phenotypes for down-
regulated elav, null fne and Rbp9 mutants and the phenotypes observed when the three RNA 
binding proteins were overexpressed in neurons, it is possible to conclude that maintenance 
of their expression levels is crucial for proper neuronal function. 
Despite that reduced longevity and climbing ability as well as formation of vacuoles in the 
central brain of down-regulated and overexpressed elav, fne and Rbp9 mutants aggravated 
with time, it is possible that these phenotypes were a result of pre-defined developmental 
defects which provided a sensitized condition for the manifestation of age-dependent 
neurodegeneration as one-day elave5/elavts1 and elavC155-Gal4;UAS-elav showed reduced 
ability to climb and elave5/elavts1 had clear morphological deformities of the optic lobes. 
Furthermore, altered ELAV, FNE and RBP9 levels resulted in differential vacoulization of 
the adult brain, implying that these proteins are important for the development of specific 
neuronal subsets. Furthermore, differential vacuolization also argues against a general 
neuroprotective role for ELAV, FNE and RBP9, as vacuolization would have occurred 
sporadically, which it did not. Moreover, the lack of photoreceptors in elav, but not in fne 
and Rbp9 transheterozygous mutant females further points to a cell type specific requirement 
for elav, fne and Rbp9 function.  
A surprising result was that transheterozygous elav;Rbp9 mutant females were embryonic 
lethal since viable adult elavts1;Rbp9 males, with an impaired locomotion phenotype, have 
been reported previously (Toba et al., 2010). An explanation for this could be that since in 
Drosophila males, X chromosome dosage compensatory mechanisms double the expression 
of X chromosomal genes, the level of ELAV protein produced in elavts1 males was sufficient 
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for the development of viable animals, whereas, ELAV protein levels in transheterozygous 
elav;Rbp9 mutant females were not and the additive effect from the Rbp9 null mutation 
manifested as embryonic lethality. Similarly, the additive effect of the fne null mutation in 
the elav fne double mutant also manifested in embryonic lethality.  
Neuronal overexpression of ELAV, FNE and RBP9 illustrated that it is the levels of 
cytoplasmic RNA binding proteins (ELAVΔOH, FNE and RBP9) that have a stronger impact 
on neurodegenration. It is possible that excess of these proteins form aggregates which 
results in cytotoxicity. Another explanation for the neurodegenerative phenotype caused by 
ELAVΔOH, FNE and RBP9 could be that these RBPs excessively bind mRNA and 
misregulate mRNA processing. Whether this misregulation is caused through increased 
functionality of the RBPs where an excess of the target proteins results in cytotoxicity, or the 
opposite, where excess RNP binding hinders RNA processing resulting in insufficient 
protein targets made, is a question to be investigated in the future.   
Overexpression of nuclear ELAVNLS demonstrated that ELAV function in splicing cannot be 
increased simply by elevating nuclear levels of the splicing factor and there exists additional 
neuron-specific regulatory control that overwrites ELAV levels and is executed with respect 
to the neuron’s requirement for ELAV targets. It has been suggested that ELAV can 
autoregulate its expression levels by binding to its 3! UTR (Samson, 1998), which could 
potentially involve multiple polyadenylation that vary the length of the 3! UTR and affect 
translation. However, when examined if overexpressed transgenic ELAV would alter 
endogenous ELAV levels, downregulation of the endogenous protein was not observed. 
Therefore, ELAV levels are not determined solely by autoregulation but likely involve 
multifactorial control. Such control could be achieved through a neuron-specific 
phosphorylation state. Overexpression of nuclear phosphomimetic ELAVNLS S472D increased 
splicing levels of nrg in epithelial cells of the developing wing disc but the protein was not 
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detected in neurons, suggesting that constitutively phosphorylated nuclear ELAV is not 
tolerated in the nervous system and overactive nuclear ELAV is rapidly degraded. Activity 
of Hu proteins has been shown to be regulated by phosphorylation and shuttling between the 
nucleus and cytoplasm, suggesting that Drosophila ELAV is under similar control as 
overactive ELAVS472D was detected in higher levels in the cytoplasm in contrast to 
overexpressed ELAV, which remained nuclear.  
Despite sharing high homology in their amino acid sequence, the ability to execute splicing, 
has not been described for FNE and RBP9, and a role in mRNA stability has been suggested 
only for FNE. By assessing GFP levels produced from the ELAV-dependent nrg splicing 
reporter in response to ectopic expression of FNE and RBP9 in epithelial cells, I showed for 
the first time, that alike ELAV, FNE and RBP9 can not only promote splicing but that the 
three RNA binding proteins could bind the same target. In fact, a commonality between 
target sequences was also shown very recently for neuronal human Hu proteins (Ince-Dunn 
et al., 2012). Furthermore, when expressed ectopically in Drosophila HuR, HuB and HuC 
could also promote splicing of nrg, suggesting that ELAV/Hu family of proteins can have 
similar functions and share same binding sites between flies and mammals. However, 
organismal and functional specificity is likely achieved through regulatory mechanisms that 
tailor the proteins’ functionality in response to particular neuronal requirements such as 
neuronal differentiation, maintenance and establishment of neural plasticity as HuR, HuB, 
HuC and HuD expression in all neurons in Drosophila resulted in embryonic lethality, and 
targeted expression in subsets of neurons resulted in differential phenotypes. 
Investigating ELAV family proteins function and ELAV’s regulation led to better 
understanding the potential points of misregulation that could occur from a compound screen 
against xenobiotics interfering with ELAV-mediated splicing. Likely, compounds that alter 
ELAV’s activity though post-translational misregulation, such as kinase and phosphatase 
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inhibitors, would be prime candidates.  
 
6.2. Towards a sensitized Drosophila genetic background for drug testing 
Despite Drosophila being an invaluable tool for genetic studies, toxicity studies in this model 
organism are in their infancy and detailed characterization of the fly’s transporters-mediated 
uptake and excretion systems is mostly elusive. The results obtained in Chapter 4 revealed a 
complicated mode of action for drug transporters in Drosophila, where knockdown of single 
or double mutants did not cause general sensitization and therefor did not provide a suitable 
genetic background for drug screening.  
By testing compounds with different toxicities I showed that Drosophila exhibits a dose 
response to clotrimazole, chlorhexidine, flunarizine, digitoxin and ouabain and that 
mutations in OATP and Mdr/MRP transporters can either desensitize or increase sensitivity 
to these compounds (for summary Table 6.1). Unexpectedly, the Oatp58Db mutant did not 
show sensitization when exposed to ouabain. It has been shown that RNAi knockdown of 
Oatp58Db inhibits excretion of ouabain by 50% at 50 µM concentration in ex vivo 
preparation of Malpighian tubules (Torrie et al., 2004). This data, however, does not relate to 
actual toxicity of ouabain, as it simply points that Oatp58Db can export this compound and 
at 50 µM, the compound is likely not toxic in feeding assays when applied in the food media. 
Furthermore, 50% reduction in transport also indicates that it is not solely Oatp58Db that is 
responsible for ouabain transport but there exist other transporters that mediate ouabain 
excretion. In fact Oatp30B, Oatp33Ea and Mdr50 mutants showed resistance to the drug at 
extraordinary concentration of 2.5 mM and at this point sensitization of the remaining ten 
transporters was not observed, which indicated two things: (1) transporters that demonstrate 
resistance are involved in uptake of compounds into the circulation; and (2) that there could 





Table 6.1. Oatp and Mdr/MRP single and double mutants show differential dose responses in comparison to wild type when exposed to 
clotrimazole, chlorhexidine, flunarizine, digitoxin and ouabain at the indicated concentrations.  
Increased sensitivity is marked in red boxes and resistance is in greed boxes; light blue boxes indicate no change in survival compared to wild 
type. 
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one could be counter-balanced by increased excretion of others which results in a 
resistant/unaffected phenotype for the mutated transporter, indicating that Drosophila 
transporters are redundant in their function and similar observation regarding redundancy has 
also been shown between human transporters (Gong et al., 2011). Through combinations of 
double mutants between transporters expressed in Malpighian tubules, digestive tract and 
BBB, redundancy between Mdr65, Oatp74, Mdr49 and MRP was overcome and a dramatic 
decrease in survival of Mdr65;Oatp74D, Mdr49;Oatp74D and Mdr49;Mrd65 was observed 
when exposed to ouabain at concentrations as low as 2.5 µM which was consistent with 
decreased survival rates of leaky BBB mutants, suggesting that ouabain could be neurotoxic 
to Drosophila. 
To summarize, exposure to chlorhexidine, flunarizine, clotrimazole and digitoxin also 
revealed redundancy between the OATP and Mdr/MRP transporters tested, which was 
overcome in double Mdr65;Oatp74D, Mdr49;Oatp74D and Mdr49;Mdr65 mutants exposed 
to clotrimazole and chlorhexidine and Mdr49;Oatp74D mutant exposed to flunarizine. 
Furthermore, a potential neurotoxic effect also could be attributed to digitoxin and 
chlorhexdine in Drosophila as leaky BBB mutants exposed to these two compounds showed 
decrease in survival rates, whereas clortimazole and flunarizine, likely exhibit general 
toxicity as moody mutants were not sensitive to these two substances.    
An unexpected result was Mdr49;MRP double mutant showing significant level of resistance 
to clotrimazole, chlorhexidine, flunarizine and digitoxin.  A possible explanation for this is 
that since Mdr49 and MRP are highly expressed in Malpighian tubules, knockdown of both 
genes increased efflux from other highly expressed transporters in that tissue such as 
Oatp58Db and Oatp58Dc, which elevated excretion activity compensated for the lack of 
Mdr49 and MRP.  
Despite the screening effort for genetically sensitized background, a knockdown of the same 
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transporters when exposed to different compounds resulted in rather distinct dose-responses 
from which it was difficult to draw a uniform conclusion for the ultimate sensitized mutant 
background.  
Despite that a transporter mutant background for sensitized screening could not be obtained, 
knock down of moody, an essential component of septate junctions, showed that a 
compromised BBB could be a suitable sensitized genetic background to be utilized for 
neurotoxicity screens.  
 
6.3. Compounds interfering with ELAV splicing phenocopy ELAV family mutants  
To assess the effect of elevated and downregulated ELAV levels, viability, negative geotaxis 
and adult brain morphology were examined (Chapter 3). ELAV levels were shown to be 
critical for neuronal development and maintenance and vacoulization in the adult brain was 
observed in both overexpression and downregulation of ELAV. Despite that vacoulization of 
the brain is a phenotypic endpoint for ELAV misregulation, the comparative analysis of 
Drosophila phenotypes produced by a large-scale compound screen would be time 
consuming, labor intensive and subjective (due to differences in phenotype penetrance). 
Thus, a more efficient and specific approach would be to study potential xenobiotic 
interference at the molecular level, where a uniform readout would facilitate the screening 
process. 
I developed such a system by means of a GFP fluorescent reporter based on the regulation of 
ELAV and used it to screen for xenobiotics in a leaky BBB genetic background that could 
interefere with ELAV function. Due to the combinatorial nature of ELAV’s activity 
interference of xenobiotics with ELAV-regulation can occur on several levels: (1) 
compounds can interfere with ELAV’s multimerization and RNA binding activity; (2) can 
interfere with ELAV’s activity through modulation of its post-transcriptional modification, 
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such as phosphorylation; (3) can interfere with ELAV’s interaction with other proteins. 
Despite that the majority of the compounds screened were previously identified to interfere 
with splicing regulation (Table 1.1), only three were identified to modulate GFP levels 
produced by the ewg-based splicing reporter in vivo. A possible explanation to the low 
number of compounds found to affecting ELAV-mediated splicing  from a screen of splicing 
inhibitors could be: 1) inhibition data for these compounds comes from in vitro and none-
neuronal cell culture experiments which would not relate to in vivo neuronal misregulation; 
2) the in vivo screening approach produced a number of false negatives, as early larval 
lethality at higher concentrations from different drugs could have been due to impaired 
ELAV function as GFP levels were only assessed for viable late staged larvae. Sodium 
orthovanadate is a small molecule phosphatase inhibitor that has previously been described to 
promote inclusion of exon 7 of SMN2 in luciferase-reporter assays in cell culture (Zhang et 
al., 2001). Sodium orthovanadate could potentially influence ELAV activity through 
inhibition of dephosphorylation resulting in an overactive phosphorylated ELAV protein, 
which as described in Chapter 3 localized to the cytoplasm and could render ELAV-
associated neurotoxicity. Quercetin is an antioxidant that has been shown to inhibit HuR and 
HuC binding to target mRNA in EMSA in vitro assays (Chae et al., 2009, Kwak et al., 2009). 
Since in Chapter 3 I showed that HuR and HuC can bind the same ELAV target nrg sequence 
to promote splicing of the nrg GFP reporter, it is possible that in vivo quercetin can directly 
inhibit binding of ELAV to its target pre-mRNA. Similarly to sodium orthovanadate, beta-
glycerophosphate is a phosphatase inhibitor that could interfere with ELAV activity through 
modulation of the protein’s posttranslational modifications.  
Vacuolization in adults was observed only for sodium orthovanadate and quercetin which 
application was associated with increased GFP levels from the ewgelav::GFP splicing 
reporter, whereas decreased GFP levels due to beta-glycerophosphate did not relate to the 
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formation of vacuoles. Unexpectedly, when ewg mRNA levels were assessed in response to 
the drugs, reduced levels of the ewg neuronal isoform was detected when GFP levels were 
increased in response to sodium orthovanadate and quercetin and no change in ewg mRNA 
levels were detected when GFP levels were decreased in response to beta-glycerophosphate.  
Overall, further validation by means of in vitro binding assays is required to substantiate 
whether ewg misregulation is due to direct or indirect effects such as inhibition of mRNA 
target binding or an effect from misregulation of ELAV activity.  
 
6.4. Implications 
Little toxicological data for the more than 80,000 chemicals in commercial use today, and the 
approximately 2000 new chemicals introduced each year according to the National 
Toxicology Program, makes the development of sensitive and rapid screening assays for 
neurotoxicity a growing demand (http://ntp.niehs.nih.gov last entered on 12/02/2009). Only 
recently the wide-spread occurrence of alternative splicing has been recognized and even 
more recently has it emerged that interference with this process, be it through genetic defects 
or chemical toxicity, can influence cell survival and disease mechanisms. Based on their 
immense complexity and multi-factorial nature alternative splicing regulatory mechanisms 
have been shown to be susceptible to various conditions: spanning from modes of 
endogenous gene expression regulation to exogenous environmental and chemical factors 
(Table 1.1). Interference of alternative splicing can also, however, be beneficial in relation to 
potential therapeutic use and in the development of a new platform of “forward chemical 
genetics” to study splicing regulation. Exploring those possibilities, however, requires 
elaborate understanding of the mechanisms of gene-specific splicing regulation and the 
precise way in which xenobiotics may interfere with the multiple pattern components that 
regulate the splicing reaction. Based on the high conservation of protein-protein interfaces, 
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the use of alternative systems for high-throughput screening of tissue specific splicing 
modulators is an exciting possibility, in particular the use of invertebrate animal models. In 
recent years, Drosophila has shown great potential in the field of neurotoxicology based on a 
number of established neurodegenerative disease models and a vast amount of genetic tools 
available (Rand, 2010). The development of new model systems for toxicological profiling 
of xenobiotics interfering with alternative splicing, will help to elucidate previously 
unsuspected modes of drug action. However, newly developed systems should be accounted 
for particular characteristics regarding a compound’s delivery and absorption routes. In the 
case of Drosophila, particularly in the study of neurotoxicity, the role of transporter proteins 
and permeability of the Blood Brain Barrier (BBB) are determinants of effective drug 
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